

Volume 28

# Diagnoses of HIV Infection in the United States and Dependent Areas, 2016



The *HIV Surveillance Report* is published annually by the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through June 2017.

The *HIV Surveillance Report* is not copyrighted and may be used and reproduced without permission. Citation of the source is, however, appreciated.

#### **Suggested citation**

Centers for Disease Control and Prevention. *HIV Surveillance Report, 2016*; vol. 28. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2017. Accessed [date].

On the Web: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html

#### Confidential information, referrals, and educational material on HIV infection

**CDC-INFO** 

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

http://wwwn.cdc.gov/dcs/ContactUs/Form

#### Acknowledgments

Publication of this report would not have been possible without the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

This report was prepared by the following CDC staff and contractors: Kristen Hess, Anna Satcher Johnson, Xiaohong Hu, Jianmin Li, Baohua Wu, Chenchen Yu, Hong Zhu, Chan Jin, Mi Chen, John Gerstle, Marie Morgan, Michael Friend, Azfar Siddiqi, Angela Hernandez, the HIV Incidence and Case Surveillance Branch, and the Data Management Team of the Quantitative Sciences and Data Management Branch.

### **Contents**

Con	nmentary	5
Гес	hnical Notes	11
Γab	les	
	Section 1 Diagnoses of HIV Infection and Diagnoses of Infection Classified as Stage 3 (AIDS)	
	Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2011–2016—United States Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2011–2016—United States and	17 18
	6 dependent areas	
	Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2011–2016 and cumulative—United States Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2011–2016 and cumulative—United States	19 20
	and 6 dependent areas	
	Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2016—United States Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2016—United States and 6	21 22
30	dependent areas	22
4a	Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States	23
4b	Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas	24
5a	Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and	25
<i>5</i> 1.	injection drug use, by selected characteristics, 2011–2016—United States	29
30	Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas	29
62	Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—	33
0a	United States	33
6h	Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—United	37
	States and 6 dependent areas	5,
7a	Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—	41
-1	United States	
/b	Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6 dependent areas	45
8a	Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact <i>and</i> injection drug	49
	use, by selected characteristics, 2011–2016—United States	
8b	Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug	53
00	use, by selected characteristics, 2011–2016—United States and 6 dependent areas Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States	57
	Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States  Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States and 6	61
90	dependent areas	01
10a	Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States	65
	Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6	69
	dependent areas	
l 1a	Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2011–2016—United States	73
11b	Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United	73
	States and 6 dependent areas	7.4
	Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2011–2016 and cumulative—United States	74
120	Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2011–2016 and cumulative—United States and 6 dependent areas	74
13	Stage 3 (AIDS) among children aged <13 years, by year of diagnosis, 1992–2016—United States and	75
	6 dependent areas	
14	Diagnoses of HIV infection among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2016—United States and 6 dependent areas	76
15	Stage 3 (AIDS) among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2016—United States and 6 dependent areas	77
	-	

	Section 2 Deaths and Survival after a Diagnosis of HIV Infection or Stage 3 (AIDS) Classification	
16a	Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2011–2015— United States	78
16b	Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2011–2015— United States and 6 dependent areas	80
17a	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2011–2015 and cumulative—United States	82
17b	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2011–2015 and cumulative—United States and 6 dependent areas	84
18a	Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2015—United States	86
18b	Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2015— United States and 6 dependent areas	88
19a	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2015—United States	90
19b	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2015—United States and 6 dependent areas	92
	Section 3 Persons Living with Diagnosed HIV Infection or with Infection Ever Classified as Stage 3 (AIDS) (Prevalence)	
200	Persons living with diagnosed HIV infection, by year and selected characteristics, 2011–2015—United States	94
	Persons living with diagnosed HIV infection, by year and selected characteristics, 2011–2015—United States and 6 dependent areas	9 <del>4</del> 96
21a	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected	98
	characteristics, 2011–2015—United States	, ,
21b	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2011–2015—United States and 6 dependent areas	100
22a	Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2015— United States	102
22b	Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2015— United States and 6 dependent areas	104
23a	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2015—United States	106
23b	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2015—United States and 6 dependent areas	108
	Section 4 Data by Area of Residence	
24	Diagnoses of HIV infection, by area of residence, 2015 and 2016—United States and 6 dependent areas	110
25	Stage 3 (AIDS), by area of residence, 2015, 2016, and cumulative—United States and 6 dependent areas	111
26	Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2015—United States and 6 dependent areas	
27	Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2015—United States and 6 dependent areas	115
28	Diagnoses of HIV infection, 2016, and persons living with diagnosed HIV infection (prevalence), year-end 2015, by metropolitan statistical area of residence—United States and Puerto Rico	117
29	Stage 3 (AIDS), 2016 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2015, by metropolitan statistical area of residence—United States and Puerto Rico	120
Web	Addresses for Reports of State and Local HIV Surveillance	125

HIV Surveillance Report 4 Vol. 28

#### Commentary

The Centers for Disease Control and Prevention (CDC) collects, analyzes, and disseminates surveillance data on HIV infection; these data are one of the nation's primary sources of information on HIV in the United States. The annual surveillance report, published by the Division of HIV/AIDS Prevention, summarizes information about diagnosed HIV infection in the United States and dependent areas. HIV surveillance data are used by CDC's public health partners in other federal agencies, health departments, nonprofit organizations, academic institutions, and the general public to help focus prevention efforts; plan services; allocate resources; develop policy; detect, monitor, and intervene in HIV clusters; and monitor trends in HIV infection.

Numbers and rates of diagnoses of HIV infection during 2011–2015 and preliminary numbers for 2016 are based on data from all 50 states, the District of Columbia, and 6 U.S. dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands).

During 2011–2015, the annual number and rate of diagnoses of HIV infection in the United States decreased. Numbers and rates of diagnoses of HIV infection increased in some subgroups and decreased in others. Variations in trends among groups are expected and may be due to differences in testing behaviors, targeted HIV testing initiatives, or changes in the numbers of HIV infections (incidence) in some subgroups. (For slide sets of trends among selected populations [2010–2015], see Additional Resources.)

#### REPORT CHANGES

In response to requests from our partners for expanded data, the 2016 report includes tables that provide stratifications by transmission category and race/ethnicity for multiple years (2011–2016).

• Tables 5a/b and 8a/b display data on diagnoses of HIV infection and stage 3 (AIDS) classifications, respectively, for infections attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by year and selected characteristics for each racial/ethnic group.

• Data on diagnoses of HIV infection and stage 3 (AIDS) classifications, by year and selected characteristics for each racial/ethnic group, are also presented for infections attributed to injection drug use (Tables 6a/b and 9a/b) and heterosexual contact (Tables 7a/b and 10a/b).

Data on survival after a diagnosis of HIV or stage 3 (AIDS) classification are not presented in this report (for survival data, see *HIV Supplemental Surveillance Report*, Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 Dependent Areas [Suggested Readings]).

#### **DEFINITIONS AND DATA SPECIFICATIONS**

The term diagnosis of HIV infection is defined as a diagnosis of HIV infection regardless of the stage of disease (stage 0, 1, 2, 3 [AIDS], or unknown) and refers to all persons with a diagnosis of HIV infection. The term HIV infection, stage 3 (AIDS) and its condensed version—stage 3 (AIDS)—refer specifically to persons with diagnosed HIV whose infection was classified as stage 3 (AIDS) during a given year (for diagnoses) or whose infection has ever been classified as stage 3 (AIDS) (for prevalence and deaths). The 2008 surveillance case definition for HIV infection was used to classify cases diagnosed through 2013. The 2014 revised surveillance case definition was used to classify cases diagnosed after 2013. For more information on HIV surveillance case definitions and the stages of HIV infection, please review the Technical Notes.

The data on diagnoses of HIV infection reflect the date of diagnosis (diagnosed by December 31, 2016; reported to CDC as of June 30, 2017), not the date of report to CDC. Similarly, the data specific to stage 3 (AIDS) reflect the first date the criteria for stage 3 (AIDS) were met. HIV diagnoses do not necessarily reflect when a person became infected. HIV surveillance data may not be representative of all persons infected with HIV because not all infected persons have been (1) tested, (2) tested at a time when their infection could be detected and diagnosed, or (3) reported to the surveillance system (e.g., home-

based testing). Because of reporting delays, the number of cases diagnosed in a given year may be lower than the numbers presented in later reports; however, fluctuations in the number of diagnoses for a calendar year typically subside after 2 to 3 years of reporting.

#### HIGHLIGHTS OF ANALYSES

All rates are per 100,000 population. The standard used for reporting trends in numbers and rates is an increase or a decrease of 5% or more during the specified time frame (e.g., when comparing 2011 and 2015). Exceptions to this standard were made where numbers were small or rates were based on small numbers. The HIV diagnosis and stage 3 (AIDS) classification data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay and therefore should not be included when assessing trends.

Please read all table titles and footnotes carefully to ensure a complete understanding of the displayed data.

### Diagnoses of HIV Infection and Diagnoses of Infection Classified as Stage 3 (AIDS)

#### **Diagnoses of HIV infection**

From 2011 through 2015, the annual number and the rate of diagnoses of HIV infection in the United States decreased (Table 1a). In 2016, the rate was 12.3.

- Age group: From 2011 through 2015, the rate for persons aged 25–29 years increased. The rates for children (aged less than 13 years) and persons aged 13–14, 15–19, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64 years, and 65 years and older decreased. The rates for persons aged 20–24 and 30–34 years remained stable. In 2016, the highest rate was for persons aged 25–29 years (34.8), followed by the rate for persons aged 20–24 years (30.3).
- Race/ethnicity: From 2011 through 2015, the rates for American Indians/Alaska Natives, Asians, and Native Hawaiians/other Pacific Islanders increased. The rates for blacks/African Americans, whites, and persons of multiple races decreased. The rates for Hispanics/Latinos remained stable. In 2016, the highest rate was 43.6 for blacks/African Americans, followed by 17.0 for Hispanics/Latinos, 12.9 for persons of multiple races, 10.2 for American Indians/Alaska

- Natives, 8.5 for Native Hawaiians/other Pacific Islanders, 5.5 for Asians, and 5.2 for whites.
- Sex: From 2011 through 2015, the rates for male and female adults and adolescents decreased. In 2016, males accounted for 81% of all diagnoses of HIV infection among adults and adolescents. The 2016 rate for male adults and adolescents was 24.3; the 2016 rate for females was 5.4.
- Transmission category: From 2011 through 2015, among male adults and adolescents, the annual number of diagnosed HIV infections attributed to injection drug use, to male-to-male sexual contact and injection drug use, or to heterosexual contact decreased. The number of infections attributed to male-to-male sexual contact remained stable. Among female adults and adolescents, the number of infections attributed to injection drug use or to heterosexual contact decreased. In 2016, among all adults and adolescents, the diagnosed infections attributed to maleto-male sexual contact (70%, including male-tomale sexual contact and injection drug use) and those attributed to heterosexual contact (24%) accounted for approximately 94% of diagnosed HIV infections in the United States.
- **Region**: From 2011 through 2015, the rates of diagnoses of HIV infection in the Northeast and the South decreased. The rates in the Midwest and the West remained stable. In 2016, rates were 16.8 in the South, 11.2 in the Northeast, 10.2 in the West, and 7.5 in the Midwest.

#### Stage 3 (AIDS)

From 2011 through 2015, the annual number and the rate of infections classified as stage 3 (AIDS) in the United States decreased (Table 2a). In 2016, the rate of infections classified as stage 3 (AIDS) was 5.6.

- Age group: Because of the change in case definition in 2014, the trend among children (aged less than 13 years) was not assessed. From 2011 through 2015, the rates for all other age groups decreased. In 2016, the highest rate was for persons aged 35–39 years (11.1), followed by the rate for persons aged 30–34 years (10.9). Please use caution when interpreting data for children (aged less than 13 years): the numbers are small.
- Race/ethnicity: From 2011 through 2015, the rates for all race/ethnicity groups decreased. In

2016, the highest rate was 21.1 for blacks/African Americans, followed by 9.7 for persons of multiple races, 7.2 for Hispanics/Latinos, 4.3 for American Indians/Alaska Natives, 2.6 for Native Hawaiians/other Pacific Islanders, 2.2 for whites, and 1.9 for Asians.

- Sex: From 2011 through 2015, the rates for male and female adults and adolescents decreased. In 2016, males accounted for 76% of all infections classified as stage 3 (AIDS) among adults and adolescents. The 2016 rate for males was 10.5; the 2016 rate for females was 3.1.
- Transmission category: From 2011 through 2015, the annual number of infections classified as stage 3 (AIDS) among male adults and adolescents with HIV infection attributed to male-to-male sexual contact, to injection drug use, to male-to-male sexual contact and injection drug use, or to heterosexual contact decreased. The number of infections classified as stage 3 (AIDS) among female adults and adolescents with HIV infection attributed to injection drug use or to heterosexual contact decreased. Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
- **Region**: From 2011 through 2015, the rates of infections classified as stage 3 (AIDS) in the 4 regions of the United States decreased. In 2016, rates were 7.8 in the South, 5.5 in the Northeast, 4.1 in the West, and 3.5 in the Midwest.

#### **Deaths**

### Deaths of persons with diagnosed HIV infection

From 2011 through 2015 in the United States, the annual number and rate of deaths of persons with diagnosed HIV infection decreased (Table 16a). In 2015, the rate of deaths of persons with diagnosed HIV infection was 4.8. Deaths of persons with diagnosed HIV infection may be due to any cause (i.e., may or may not be related to HIV infection).

• **Age group**: From 2011 through 2015, the rates of deaths for persons aged 60–64 and 65 years and older increased. The rates of deaths for persons aged 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, and 50–54 years decreased. The rate for persons

- aged 55–59 years remained stable. Please use caution when interpreting data for children (aged less than 13 years at death) and persons aged 13–14 and 15–19 years: the numbers are small.
- Race/ethnicity: From 2011 through 2015, the rates of deaths for persons of multiple races increased. The rates of deaths for Asians, blacks/ African Americans, and Hispanics/Latinos decreased. The rates for American Indians/Alaska Natives and whites remained stable. In 2015, the highest rate of deaths was for blacks/African Americans: 17.5. Please use caution when interpreting data for Native Hawaiians/other Pacific Islanders: the numbers are small.
- Sex and transmission category: From 2011 through 2015, the rates of deaths for male and female adults and adolescents decreased. The number of deaths among males with diagnosed HIV infection attributed to injection drug use, to heterosexual contact, or to perinatal transmission decreased. The numbers of deaths among males attributed to male-to-male sexual contact or maleto-male sexual contact and injection drug use remained stable. The number of deaths among females with infection attributed to injection drug use or to heterosexual contact decreased. The number of deaths among female adults and adolescents with infection attributed to perinatal transmission remained stable. Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
- Region: From 2011 through 2015, the rates of deaths in the Northeast, the Midwest, and the South decreased. The rates of deaths in the West remained stable. In 2015, rates were 6.4 in the Northeast, 6.3 in the South, 3.3 in the West, and 2.6 in the Midwest.

### Deaths of persons with infection ever classified as stage 3 (AIDS)

From 2011 through 2015 in the United States, the annual number and rate of deaths of persons with infection ever classified as stage 3 (AIDS) decreased (Table 17a). In 2015, the rate of deaths of persons with stage 3 (AIDS) was 3.9. Deaths of persons with stage 3 (AIDS) may be due to any cause.

- Age group: From 2011 through 2015, the rates of deaths among persons aged 60–64 and 65 years and older increased. Rates of deaths among persons aged 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, and 50–54 years decreased. Rates among persons aged 55–59 years remained stable. Please use caution when interpreting data for children (aged less than 13 years) and persons aged 13–14 and 15–19 years: the numbers are small.
- Race/ethnicity: From 2011 through 2015, the rates of deaths for Asians, blacks/African Americans, and Hispanics/Latinos decreased. The rates of deaths for American Indians/Alaska Natives, whites, and persons of multiple races remained stable. In 2015, the highest death rate was for blacks/African Americans: 14.0. Please use caution when interpreting data for Native Hawaiians/other Pacific Islanders: the numbers are small.
- Sex and transmission category: From 2011 through 2015, the rates of deaths for male and female adults and adolescents decreased. The numbers of deaths among males with infection attributed to injection drug use, to heterosexual contact, or to perinatal transmission decreased. The numbers of deaths among males attributed to male-to-male sexual contact or male-to-male sexual contact and injection drug use remained stable. Among female adults and adolescents with infection attributed to injection drug use or to heterosexual contact, the number of deaths decreased. The number of deaths among females with infection attributed to perinatal transmission remained stable. Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
- **Region**: From 2011 through 2015, the rates of deaths in the Northeast, the Midwest, and the South decreased; the rate in the West remained stable. In 2015, rates were 5.1 in the Northeast, 5.1 in the South, 2.8 in the West, and 2.0 in the Midwest.

## Prevalence: Persons Living with Diagnosed HIV Infection and Persons Living with Infection Ever Classified as Stage 3 (AIDS)

#### Prevalence of diagnosed HIV infection

From 2011 through 2015, the number and rate of persons in the United States living with diagnosed HIV infection increased (Table 20a). At year-end 2015, 973,846 persons in the United States were living with diagnosed HIV infection. The prevalence of diagnosed HIV infection was 303.5.

- Age group: At year-end 2015, persons aged 50–54 years made up the largest percentage of persons living with diagnosed HIV (18%). The highest rate (767.9) was among persons aged 50–54 years, followed by those aged 45–49 (703.6) and those aged 55–59 (603.8). From 2011 through 2015, the largest percentage increase in rates (57%) was among persons aged 65 years and older (from 94.2 in 2011 to 148.0 in 2015).
- Race/ethnicity: At year-end 2015, the highest rate (1,017.8) and the largest percentage (42%) were those for blacks/African Americans. Among the remaining race/ethnicity groups, the rates were 577.3 for persons of multiple races, 379.4 for Hispanics/Latinos, 160.3 for Native Hawaiians/other Pacific Islanders, 150.9 for whites, 122.6 for American Indians/Alaska Natives, and 74.8 for Asians.
- Sex and transmission category: At year-end 2015, the rates were 563.9 for male adults and adolescents, 169.7 for female adults and adolescents, and 4.4 for children (aged less than 13 years at year-end 2015). Among a total of 738,832 males (aged 13 years and older at year-end 2015), 71% of infections were attributed to male-to-male sexual contact, 10% to injection drug use, 10% to heterosexual contact, 7% to male-to-male sexual contact and injection drug use, and 1% to perinatal transmission. Among a total of 232,692 females (aged 13 years and older at year-end 2015), 75% of infections were attributed to heterosexual contact, 22% to injection drug use, and 2% to perinatal transmission. Among a total of 2,322 children aged less than 13 years at year-end 2015, 81% of infections were attributed to perinatal transmission.

• **Region**: At year-end 2015, the rate was highest in the Northeast at 417.8, followed by 359.3 in the South, 248.6 in the West, and 170.6 in the Midwest.

#### Prevalence of stage 3 (AIDS)

From 2011 through 2015, the number of persons living with infection ever classified as stage 3 (AIDS) increased; the rate remained stable (Table 21a). At year-end 2015, 522,283 persons in the United States were living with infection ever classified as stage 3 (AIDS). The prevalence of infections classified as stage 3 (AIDS) was 162.8.

- Age group: At year-end 2015, the highest rate (479.0) and the largest percentage (20%) were those for persons aged 50–54 years, followed by persons aged 45–49 (407.4 and 16%, respectively). From 2011 through 2015, the largest percentage increase in rates (55%) was among persons aged 65 years and older (from 63.2 in 2011 to 98.1 in 2015).
- Race/ethnicity: At year-end 2015, the highest rate (539.2) and the largest percentage (41%) were those for blacks/African Americans. Among the remaining race/ethnicity groups, the rates were 339.9 for persons of multiple races, 214.4 for Hispanics/Latinos, 81.3 for Native Hawaiians/other Pacific Islanders, 78.8 for whites, 63.0 for American Indians/Alaska Natives, and 36.1 for Asians.
- Sex and transmission category: At year-end 2015, the rates were 304.0 for male adults and adolescents, 90.2 for female adults and adolescents, and 0.5 for children (aged less than 13 years at year-end 2015). Among a total of 398,300 males (aged 13 years and older at yearend 2015), 66% of infections were attributed to male-to-male sexual contact, 13% to injection drug use, 12% to heterosexual contact, 8% to male-to-male sexual contact and injection drug use, and 1% to perinatal transmission. Among a total of 123,707 females (aged 13 years and older at year-end 2015), 72% of infections were attributed to heterosexual contact, 25% to injection drug use, and 2% to perinatal transmission. Among a total of 276 children aged less than 13 years at year-end 2015, 88% of infections were attributed to perinatal transmission.

• **Region**: At year-end 2015, the rate was highest in the Northeast at 238.2, followed by 187.1 in the South, 136.3 in the West, and 86.5 in the Midwest.

#### ADDITIONAL RESOURCES

The following were prepared by using HIV surveillance data:

- MMWR articles (selected): http://www.cdc.gov/ hiv/library/reports/mmwr.html
- Other surveillance reports: http://www.cdc.gov/ hiv/library/reports/hiv-surveillance.html
- Public-use slides updated annually: http://www .cdc.gov/hiv/library/slidesets/
- NCHHSTP AtlasPlus [interactive tool for accessing HIV/AIDS, STD, TB, and hepatitis data]: http://www.cdc.gov/nchhstp/atlas/

#### SUGGESTED READINGS

- CDC. Establishing a holistic framework to reduce inequities in HIV, viral hepatitis, STDs, and tuberculosis in the United States. http://stacks.cdc.gov/view/cdc/11585. Published October 2010. Accessed October 27, 2017.
- CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2015. *HIV Surveillance Supplemental Report* 2017;22(No. 2). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published July 2017. Accessed October 27, 2017.
- CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case definition for HIV infection—United States, 2014. MMWR 2014;63(RR-03):1–10. http://www.cdc
  .gov/mmwr/indrr\_2014.html. Accessed October 27, 2017.
- CDC. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR 2008;57(RR-10):1–12. http://www.cdc.gov/mmwr/indrr\_2008.html. Accessed October 27, 2017.

- CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. http://www.cdc.gov/mmwr/index2015.html. Accessed October 27, 2017.
- CDC. Vital Signs: HIV infection, testing, and risk behaviors among youths—United States. *MMWR* 2012;61(47):971–976. http://www.cdc.gov/mmwr/index2012.html. Accessed October 27, 2017.
- CDC. Vital Signs: HIV testing and diagnosis among adults—United States. *MMWR* 2010;59(47): 1550–1555. http://www.cdc.gov/mmwr/index2010.html. Accessed October 27, 2017.
- Cohen SM, Gray KM, Ocfemia MC, Johnson AS, Hall HI. The status of the National HIV Surveillance System, United States, 2013. *Public Health Rep* 2014;129(4):335–341. doi:10.1177/003335491412900408.
- Frieden TR, Foti KE, Mermin J. Applying public health principles to the HIV epidemic—how are we doing? *N Engl J Med* 2015;373:2281–2287. doi:10.1056/NEJMms1513641.
- Hall HI, Song R, Tang T, et al. HIV trends in the United States: diagnoses and estimated incidence. *JMIR Public Health Surveill* 2017;3(1):e8. doi.10.2196/publichealth.7051.
- Satcher Johnson A, Song R, Hall HI. Estimated HIV incidence, prevalence, and undiagnosed infections in US states and Washington, DC, 2010–2014. *J Acquir Immune Defic Syndr* 2017;76(2):116–122. doi:10.1097/QAI.0000000000001495.
- Song R, Hall HI, Green TA, Szwarcwald CL, Pantazis N. Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections in the United States. *J Acquir Immune Defic Syndr* 2017;74(1):3–9. doi:10.1097/QAI.000000000001151.

#### SURVEILLANCE OF HIV INFECTION

This report includes case report data from 50 states, the District of Columbia, and 6 U.S. dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands) in which laws or regulations require confidential reporting to the jurisdiction (not to CDC), by name, for adults, adolescents, and children with confirmed diagnoses of HIV infection. After the removal of personally identifiable information, data from these reports were submitted to CDC. Although AIDS cases have been reported to CDC since 1981, the date of implementation of HIV infection reporting has differed from jurisdiction to jurisdiction. All states, the District of Columbia, and 6 U.S. dependent areas had fully implemented name-based HIV infection reporting by April 2008.

Please use caution when interpreting data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested, (2) tested at a time when the infection could be detected and diagnosed, or (3) reported to the surveillance system (e.g., home-based testing). Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential name-based HIV registries of state and local health departments. In addition, testing patterns are influenced by many factors, including the extent to which testing is routinely offered to specific groups and the availability of, and access to, medical care and testing services. The data presented in this report provide minimum counts of persons for whom HIV infection has been diagnosed and reported to the surveillance system. Finally, although all jurisdictions use a uniform case report form, surveillance practices in data collection and updating of case records may differ among jurisdictions.

The completeness of reporting of HIV infection is estimated to be at least 80% in all but 5 jurisdictions [1].

#### STAGES OF HIV INFECTION

Both the 2008 and 2014 HIV case definitions were used to classify HIV infection among adults and adolescents and among children [2, 3]. In the following lists, some bulleted items are paraphrases, not quotations from the published surveillance case definitions. The intention is to emphasize the differences between the 2008 and 2014 case definitions.

The 2008 case definition was used to classify cases diagnosed through 2013. For adults and adolescents, this definition incorporates an HIV infection staging system that includes AIDS (HIV infection, stage 3). The 2008 stages of HIV infection are defined as follows:

- HIV infection, stage 1: No AIDS-defining opportunistic illness (OI) and either CD4+ T-lymphocyte (CD4 lymphocyte) count of ≥500 cells/µL or CD4 percentage of total lymphocytes of ≥29.
- HIV infection, stage 2: No AIDS-defining OI and either CD4 lymphocyte count of 200–499 cells/µL or CD4 percentage of total lymphocytes of 14–28.
- HIV infection, stage 3 (AIDS): Documentation of an AIDS-defining OI or either a CD4 lymphocyte count of <200 cells/μL or CD4 percentage of total lymphocytes of <14. Documentation of an AIDS-defining OI supersedes a CD4 lymphocyte count or percentage that would not, by itself, be the basis for a stage 3 (AIDS) classification.
- HIV infection, stage unknown: No reported information on AIDS-defining OIs and no information available on CD4 lymphocyte count or percentage.

The 2014 case definition was used to classify cases diagnosed after 2013. It is similar to the 2008 case definition except for the following: (1) inclusion of criteria for stage 0, (2) the inclusion of CD4 lymphocyte testing criteria for stage 3 in children, and (3) changes in the cutoffs for CD4 percentage of total lymphocytes used for classification of stages 1 and 2 in persons aged 6 years and older [3]. The stages of HIV infection in the 2014 case definition are based on age-

specific CD4 lymphocyte counts or percentages of total lymphocytes and are defined as follows:

- HIV infection, stage 0: Negative (nonreactive) or indeterminate HIV-1 test result within 6 months before the first positive (reactive) HIV-1 test result, or a negative or an indeterminate HIV-1 antibody test result within 6 months before or after the first HIV-1 nucleic acid test result (if the latter was not the first positive HIV test). The stage remains stage 0 until 6 months after the first positive test result. After 6 months, the stage may be reclassified as 1, 2, 3, or unknown if based on a CD4 lymphocyte test result or the diagnosis of an OI. The diagnosis of an AIDS-defining OI or a low CD4 lymphocyte test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
- HIV infection, stages 1, 2, and 3: Documentation of an AIDS-defining OI (excluding stage 0 as described above) is stage 3. Otherwise, the stage is determined by the lowest CD4 lymphocyte test result [3, p 7].
- **HIV infection, stage unknown**: No reported information on AIDS-defining OIs and no information available on CD4 lymphocyte count or percentage.

The transition to CD4 lymphocyte-based criteria for stage 3 (AIDS) among children has resulted in an increase in the number of annual stage 3 (AIDS) classifications among pediatric cases diagnosed after 2013. Before implementation of the 2014 revised case definition, an OI diagnosis was required for a pediatric case to meet the criteria for stage 3 classification.

In this report, the term *diagnosis of HIV infection* is defined as a diagnosis of HIV infection regardless of the stage of disease (stage 0, 1, 2, 3 [AIDS], or unknown) and refers to all persons with a diagnosis of HIV infection. The term HIV infection, *stage 3 (AIDS)* and its condensed version—*stage 3 (AIDS)*—refer specifically to persons with diagnosed HIV whose infection was classified as stage 3 (AIDS) during a given year (for diagnoses) or whose infection has ever been classified as stage 3 (AIDS) (for prevalence and deaths).

#### **TABULATION AND PRESENTATION OF DATA**

The data in this report include information received by CDC through June 30, 2017. The data are organized into 4 sections.

- Section 1 (Tables 1a/b-15): numbers and rates of diagnoses of HIV infection (any stage) and diagnoses of infection classified as stage 3 (AIDS)
- Section 2 (Tables 16a/b–19a/b): numbers and rates of deaths among persons with diagnosed HIV infection (any stage) and persons with infection ever classified as stage 3 (AIDS)
- Section 3 (Tables 20a/b–23a/b): numbers and rates of persons living with diagnosed HIV infection (any stage) and persons living with infection ever classified as stage 3 (AIDS) (i.e., prevalence)
- Section 4 (Tables 24–29): numbers and rates of diagnoses and prevalence of HIV infection (any stage) and diagnoses and prevalence of infection classified as stage 3 (AIDS), presented by state and metropolitan statistical area (MSA)

Many tables in the 2016 report present data in 2 formats. Tables in the first format—labeled "a"—exclude data from the dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands). Tables in the second format—labeled "b"—include data from the dependent areas.

Please use caution when interpreting numbers less than 12, and rates and trends based on these numbers.

Numbers of diagnoses for the most recent year (2016) are preliminary (subject to change). Please use caution when interpreting these numbers, and do not include them when assessing trends.

### Diagnoses of HIV Infection and of Infection Classified as Stage 3 (AIDS)

This report is based on diagnoses of HIV infection that the 50 states, the District of Columbia, and 6 U.S. dependent areas reported to CDC as of June 30, 2017. Data from all areas are included in tables displaying numbers and rates of diagnoses of HIV infection and of diagnoses of infection classified as stage 3 (AIDS), by selected characteristics, area of residence, and MSA (Tables 1a/b–15, 24, 25, 28, and 29). For tables presenting diagnosis data, region or area of residence reflects the address at the time of

diagnosis of HIV infection or at the time of stage 3 (AIDS) classification.

#### **Deaths**

Persons reported to the National HIV Surveillance System are assumed alive unless their deaths have been reported to CDC. Death data include deaths of persons with diagnosed HIV infection (Tables 16a/b and 18a/b) or with infection ever classified as stage 3 (AIDS) (Tables 17a/b and 19a/b) regardless of the cause of death. Because of delays in the reporting of deaths, only 5 years (2011–2015) of death data are displayed. The exclusion of data from the most recent year allowed at least 18 months for deaths to be reported to CDC. For the death tables, region or area of residence is based on residence at death. When information on residence at death is not available, the state where a person's death occurred is used.

#### Prevalence: Persons Living with Diagnosed HIV Infection and Persons Living with Infection Ever Classified as Stage 3 (AIDS)

Because of delays in the reporting of deaths, only 5 years of prevalence data are displayed. The data reflect persons living with diagnosed HIV infection, regardless of stage of disease, (Tables 20a/b, 22a/b, 26, and 28) and persons living with infection ever classified as stage 3 (AIDS) (Tables 21a/b, 23a/b, 27, and 29) at the end of a given year during 2011–2015. The exclusion of data from the most recent year allowed at least 18 months for deaths to be reported and for these deaths to be factored into calculations of prevalence. For tables presenting prevalence data, region or area of residence is based on most recent known address as of the end of the specified year.

#### Age

The designation "adults and adolescents" refers to persons aged 13 years and older; the designation "children" refers to persons aged less than 13 years. For presentations of data on persons living with diagnosed HIV infection (Tables 20a/b, 22a/b, and 26) and presentations of data on persons living with infection classified as stage 3 (AIDS) (Tables 21a/b, 23a/b, and 27), the age-group assignment (e.g., 20–24 years) or the age designation (e.g., "adults and adolescents") is based on the person's age as of December 31 of the

specified year. For presentations of data on deaths of persons with diagnosed HIV infection (Tables 16a/b and 18a/b) and deaths of persons with infection classified as stage 3 (AIDS) (Tables 17a/b and 19a/b), agegroup assignment is determined by the person's age at the time of death. For all other tables, the age designation or the specific age-group assignment is based on the person's age at the time of diagnosis (HIV infection or infection classified as stage 3 [AIDS]).

Age-group designations for transmission categories in tables displaying data on prevalence and on deaths are based on a person's age at the end of the specified year or age at death, respectively. The transmission categories among "adults and adolescents" in these tables include persons who were children at the time of diagnosis but who were aged 13 years and older during the specified year or at death.

#### Sex

Sex designations in this report are based on a person's sex at birth. Transgender is an umbrella term that is used to identify persons whose sex assigned at birth does not match current gender identity or expression. Data for transgender persons are not presented in this report because information on gender identity (a person's internal understanding of his or her gender or the gender with which a person identifies) is not consistently collected or documented in the data sources used by HIV reporting jurisdictions. HIV surveillance personnel collect data on gender identity, when available, from sources such as case report forms submitted by health care or HIV testing providers and medical records, or by matching with other health department databases (e.g., Ryan White program data). In May 2012, CDC issued guidance to state and local programs on methods for collecting data on transgender persons and working with transgender-specific data. However, characterization of HIV infection among transgender persons may require supplemental data from special studies.

#### **Race and Ethnicity**

In the Federal Register [4] for October 30, 1997, the Office of Management and Budget (OMB) announced the Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity. Implementation by January 1, 2003, was mandated. At a minimum, data on the following race categories should be collected:

- · American Indian or Alaska Native
- Asian
- · black or African American
- Native Hawaiian or other Pacific Islander
- · white

Additionally, systems must be able to retain information when multiple race categories are reported. In addition to data on race, data on 2 categories of ethnicity should be collected:

- Hispanic or Latino
- not Hispanic or Latino

The Asian or Pacific Islander category displayed in annual surveillance reports published prior to the 2007 surveillance report was split into 2 categories: (1) Asian and (2) Native Hawaiian or other Pacific Islander. The Asian category (in tables where footnoted) includes the cases in Asians/Pacific Islanders (referred to as legacy cases) that were reported before the implementation of the new race categories in 2003 (e.g., cases of HIV infection that were diagnosed and reported to CDC before 2003 but that were classified as stage 3 [AIDS] after 2003) and a small percentage of cases that were reported after 2003 but that were reported according to the old race category (Asian/ Pacific Islander). In tables of diagnoses of HIV infection during 2011-2016, the Asian category does not include Asian/Pacific Islander cases because these cases were diagnosed after 2003 and were reported to CDC in accordance with OMB's Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity [4].

This report also presents data for persons for whom multiple race categories are reported. In this report, persons categorized by race were not Hispanic or Latino. The number of persons reported in each race category may, however, include persons whose ethnicity was not reported.

#### **Geographic Designations**

Data by region or area of residence reflect the address at the time of diagnosis of HIV infection or at the time of stage 3 (AIDS) classification for tables that present number of diagnoses (Tables 1a/b–15a/b, 24, 25, 28, 29). For tables presenting prevalence data (20a/b–23a/b, 26–29), region or area of residence is based on most recent known address as of the end of

the specified year. For the death tables (16a/b–19a/b), region or area of residence is based on residence at death. When information on residence at death is not available, the state where a person's death occurred is used.

The 4 regions of residence used in this report are defined by the U.S. Census Bureau as follows:

**Northeast**: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont

**Midwest**: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin

**South**: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia

**West**: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming

U.S. dependent areas: American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands

#### **Metropolitan Statistical Areas**

In the *Federal Register* for June 28, 2010, OMB published revised standards for defining MSAs in federal statistical activities [5]. These standards, which provided for the identification of MSAs in the United States and Puerto Rico, replaced the 2000 standards. The adoption of the new standards was effective as of June 28, 2010. On February 28, 2013, OMB announced new MSA delineations based on the new standards and Census 2010 data [6]. Tables 28 (data on diagnosed HIV infection) and 29 (data on stage 3 [AIDS]) present numbers and rates of diagnoses and prevalence, by MSA, for areas with populations of 500,000 or more. The MSAs listed in these tables were defined according to OMB's most recent update (February 2013) of statistical areas [6].

#### **Transmission Categories**

Transmission category is the term for the classification of cases that summarizes a person's possible HIV risk factors; the summary classification results from selecting, from the presumed hierarchical order of probability, the 1 (single) risk factor most likely to have been responsible for transmission. For surveillance purposes, a diagnosis of HIV infection is counted only once in the hierarchy of transmission categories. Persons with more than 1 reported risk factor for HIV infection are classified in the transmission category listed first in the hierarchy. The exception is men who had sexual contact with other men and injected drugs; this group makes up a separate transmission category.

Persons whose transmission category is classified as male-to-male sexual contact include men who have ever had sexual contact with other men (i.e., homosexual contact) and men who have ever had sexual contact with both men and women (i.e., bisexual contact). Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

Tables of prevalence data and tables of death data include a separate transmission category of adults and adolescents with HIV infection attributed to perinatal transmission. The category includes persons infected through perinatal transmission but aged 13 years and older during the specified year or at death.

Cases of HIV infection reported without a risk factor listed in the hierarchy of transmission categories are classified as "no identified risk (NIR)." Cases classified as NIR include cases that are being followed up by local health department staff; cases in persons whose risk-factor information is missing because they died, declined to be interviewed, or were lost to follow-up; and cases in persons who were interviewed or for whom other follow-up information was available but for whom no risk factor was identified.

Because a substantial proportion of cases of HIV infection are reported to CDC without an identified risk factor, multiple imputation is used to assign a transmission category [7]. Multiple imputation is a statistical approach in which each missing transmission category is replaced with a set of plausible values that represent the uncertainty about the true, but missing, value [8]. Each resulting data set containing the plausible values is analyzed by using standard procedures, and the results from these analyses are then combined to produce the final results. In tables displaying transmission categories, multiple imputation was used for

adults and adolescents, but not for children (because the number of cases in children is small, missing transmission categories were not imputed).

#### Rates

Rates per 100,000 population were calculated for (1) the numbers of diagnoses of HIV infection and the numbers of infections classified as stage 3 (AIDS), (2) the numbers of deaths of persons with diagnosed HIV infection and deaths of persons with infection ever classified as stage 3 (AIDS), and (3) the numbers of persons living with diagnosed HIV infection and persons living with infection ever classified as stage 3 (AIDS).

The population denominators used to compute the rates for the 50 states, the District of Columbia, and Puerto Rico were based on the Vintage 2016 postcensal estimates file (for years 2011–2016) from the U.S. Census Bureau [9]. The population denominators for American Samoa, Guam, the Northern Mariana Islands, the Republic of Palau, and the U.S. Virgin Islands were based on estimates and projections from the U.S. Census Bureau's International Data Base [10]. Each rate was calculated by dividing the total number of diagnoses (or deaths or prevalence) for the calendar year by the population for that calendar year and then multiplying the result by 100,000. The denominators used for calculating the rates specific to age, sex, and race/ethnicity were computed by applying the appropriate vintage estimates for age, sex, and race/ethnicity for the 50 states and the District of Columbia [9]. The same method was used to calculate the denominators for Puerto Rico, with the exception of race/ethnicity estimates; these data are not available for Puerto Rico (see next paragraph). For the other 5 U.S. dependent areas, estimates from the U.S. Census Bureau's International Data Base were used for ageand sex-specific population denominators [10].

CDC currently does not provide subpopulation rates by race/ethnicity for the 6 U.S. dependent areas because the U.S. Census Bureau does not collect information from all dependent areas. Rates for transmission categories are not provided in this report because of the absence of denominator data from the U.S. Census Bureau, the source of data used for calculating all rates in this report.

#### **REFERENCES**

- Karch DL, Chen M, Tang T. Evaluation of the National Human Immunodeficiency Virus Surveillance System for the 2011 diagnosis year. *J Public Health Manag Pract* 2014;20(6):598–607. doi: 10.1097/ PHH.0000000000000033.
- 2. CDC. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR 2008;57(RR-10):1–12.
- 3. CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case definition for HIV infection—United States, 2014. *MMWR* 2014;63(RR-03):1–10.
- 4. Office of Management and Budget. Revisions to the standards for the classification of federal data on race and ethnicity. *Federal Register* 1997;62:58782–58790. http://go.usa.gov/vSdR. Accessed October 27, 2017.
- Office of Management and Budget. 2010 Standards for delineating metropolitan and micropolitan statistical areas. Federal Register 2010;75(123):37246–39052. https://go.usa.gov/xn43u. Accessed October 27, 2017.
- 6. Office of Management and Budget. Revised delineations of metropolitan statistical areas, new definitions of micropolitan statistical areas and combined statistical areas, and guidance on uses of the delineations of these areas. OMB Bulletin 13-01. https://go.usa.gov/xn43h. Published February 28, 2013. Accessed October 27, 2017.
- 7. Harrison KM, Kajese T, Hall HI, Song R. Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach. *Public Health Rep* 2008;123(5):618–627.
- 8. Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. New York: John Wiley & Sons Inc; 1987.
- 9. U.S. Census Bureau. Population and Housing Unit Estimates Datasets. https://go.usa.gov/xn4cc Accessed October 27, 2017.
- 10. U.S. Census Bureau. International Data Base. http://go.usa.gov/vSUj. Updated August 2017. Accessed October 27, 2017.

Table 1a. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2011-2016—United States

_	20	11	20	12	20	13	20	14	20	15	20	16
•	No.	Rate	No.	Rate <sup>a</sup>	No.	Rate <sup>a</sup>	No.	Rate <sup>a</sup>	No.	Rate <sup>a</sup>	No.	Rate <sup>a</sup>
Age at diagnosis (yr)												
<13	198	0.4	240	0.5	186	0.4	180	0.3	135	0.3	122	0.2
13–14	42	0.5	47	0.6	41	0.5	35	0.4	26	0.3	23	0.3
15–19	1,999	9.2	1,882	8.8	1,692	8.0	1,731	8.2	1,721	8.2	1,652	7.8
20–24	7,072	31.9	7,141	31.6	7,058	30.9	7,349	32.1	7,228	31.9	6,776	30.3
25–29	6,364	29.9	6,469	30.2	6,661	30.9	7,188	32.7	7,600	33.9	7,964	34.8
30–34	5,251	25.6	5,468	26.1	5,214	24.5	5,460	25.4	5,461	25.3	5,701	26.2
35–39	4,463	22.8	4,158	21.3	3,985	20.3	4,266	21.5	4,253	20.9	4,242	20.4
40–44	4,791	22.8	4,449	21.1	3,945	18.9	3,789	18.4	3,416	16.9	3,334	16.9
45–49	4,573	20.6	4,302	19.8	3,934	18.5	3,627	17.4	3,319	16.0	3,156	15.1
50–54	3,350	14.8	3,199	14.2	2,982	13.2	2,907	12.9	2,987	13.4	2,959	13.5
55–59	1,990	9.8	1,928	9.3	2,902	9.5	1,938	9.0	1,886	8.7	1,923	8.7
			•				•				•	
60–64	1,068	6.0	1,059	5.9	1,074	5.9	975	5.3	997	5.2	1,089	5.6
≥65	823	2.0	826	1.9	858	1.9	831	1.8	847	1.8	841	1.7
Race/ethnicity												
American Indian/Alaska Native	143	6.2	176	7.6	154	6.6	187	8.0	197	8.3	243	10.2
Asian	744	4.9	784	5.0	810	5.0	938	5.6	947	5.5	977	5.5
Black/African American	18,992	49.5	18,258	47.1	17,470	44.6	17,530	44.4	17,432	43.7	17,528	43.6
Hispanic/Latino <sup>b</sup>	9,292	17.9	9,291	17.5	9,097	16.8	9,710	17.6	9,695	17.2	9,766	17.0
Native Hawaiian/Other Pacific Islander	55	10.8	54	10.4	49	9.2	44	8.1	80	14.4	48	8.5
White	11,146	5.6	11,039	5.6	10,636	5.4	10,618	5.4	10,465	5.3	10,345	5.2
Multiple races	1,612	27.7	1,566	26.1	1,436	23.2	1,249	19.6	1,060	16.1	875	12.9
Transmission category <sup>c</sup>												
Male adult or adolescent												
Male-to-male sexual contact	26,052	_	26,254	_	25,719	_	26,642	_	26,459	_	26,570	_
Injection drug use	1,666	_	1,489	_	1,396	_	1,297	_	1,343	_	1,285	_
Male-to-male sexual contact and	1,455	_	1,407	_	1,288	_	1,271	_	1,270	_	1,201	_
injection drug use	1,100		1,101		1,200		1,211		1,210		1,201	
Heterosexual contact <sup>d</sup>	3,745	_	3,461	_	3,323	_	3,223	_	3,187	_	3,037	_
Other <sup>e</sup>	46	_	59	_	46		44	_	46	_	38	_
Subtotal	32,964	26.1	32,671	25.6	31,772	24.7	32,476	25.0	32,306	24.7	32,131	24.3
	02,004	20.1	02,071	20.0	01,772	24.1	02,470	20.0	02,000	27.1	02,101	24.0
Female adult or adolescent	4 000		4 4 4 7		4 000		000		4.004		000	
Injection drug use	1,262	_	1,147	_	1,002	_	933	_	1,004	_	939	_
Heterosexual contact <sup>d</sup>	7,517	_	7,071	_	6,640	_	6,653	_	6,401	_	6,541	_
Other <sup>e</sup>	43	_	40	_	52	_	35	_	30	_	49	_
Subtotal	8,822	6.7	8,257	6.2	7,694	5.7	7,620	5.6	7,435	5.4	7,529	5.4
Child (<13 yrs at diagnosis)												
Perinatal	146	_	173	_	122	_	137	_	100	_	99	_
Other <sup>f</sup>	52	_	67	_	64	_	43	_	35	_	23	_
Subtotal	198	0.4	240	0.5	186	0.4	180	0.3	135	0.3	122	0.2
Region of residence <sup>g</sup>												
Northeast	7,755	13.9	7,551	13.5	7,013	12.5	6,994	12.5	6,502	11.6	6,309	11.2
Midwest	5,391	8.0	5,484	8.1	5,327	7.9	5,106	7.5	5,224	7.7	5,068	7.5
South	21,291	18.3	20,493	17.5	20,020	16.9	20,345	17.0	20,442	16.9	20,588	16.8
West	7,547	10.3	7,640	10.4	7,292	9.8	7,831	10.4	7,708	10.3	7,817	10.0
Total	41,984	13.5	41,168	13.1	39,652	12.5	40,276	12.6	39,876	12.4	39,782	12.3

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends.

<sup>&</sup>lt;sup>a</sup> Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

b Hispanics/Latinos can be of any race.

C Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

 $<sup>\</sup>ensuremath{^{\text{d}}}$  Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

 $<sup>\</sup>ensuremath{\text{g}}$  Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2011-2016—United States and 6 dependent areas

	20	11	20	12	20	13	20	14	20	15	20	16
	No.	Rate <sup>a</sup>	No.	Rate <sup>a</sup>	No.	Rate <sup>a</sup>	No.	Ratea	No.	Rate <sup>a</sup>	No.	Ratea
Age at diagnosis (yr)												
<13	200	0.4	240	0.4	186	0.3	180	0.3	135	0.3	122	0.2
13–14	43	0.5	48	0.6	42	0.5	35	0.4	26	0.3	23	0.3
15–19	2,020	9.2	1,900	8.8	1,712	8.0	1,757	8.2	1,728	8.1	1,665	7.8
20–24	7,155	31.9	7,245	31.6	7,148	30.9	7,459	32.2	7,310	31.8	6,848	30.2
25–29	6,460	30.0	6,568	30.3	6,742	30.9	7,280	32.8	7,692	34.0	8,030	34.7
30–34	5,340	25.7	5,566	26.3	5,302	24.6	5,524	25.4	5,521	25.3	5,766	26.2
35–39	4,551	22.9	4,226	21.4	4,050	20.4	4,341	21.6	4,318	21.0	4,312	20.5
40–44	4,895	23.0	4,544	21.3	4,010	19.0	3,866	18.6	3,475	17.0	3,391	17.0
45–49	4,683	20.9	4,402	20.0	4,017	18.7	3,686	17.5	3,384	16.1	3,214	15.2
50–54	3,435	15.0	3,269	14.3	3,055	13.4	2,955	13.0	3,041	13.5	3,009	13.6
55–59	2,038	9.9	1,966	9.3	2,065	9.6	1,984	9.1	1,921	8.7	1,971	8.9
60–64	1,095	6.1	1,082	6.0	1,109	6.0	1,004	5.3	1,013	5.3	1,114	5.7
≥65	846	2.0	867	2.0	886	2.0	856	1.8	878	1.8	859	1.7
	040	2.0	001	2.0	000	2.0	030	1.0	070	1.0	003	1.7
Race/ethnicity			4-0								0.10	
American Indian/Alaska Native	143	_	176	_	154	_	187	_	197	_	243	_
Asian	745	_	784	_	810	_	939	_	952	_	978	_
Black/African American	19,008	_	18,262	_	17,487	_	17,546	_	17,441	_	17,533	_
Hispanic/Latino <sup>b</sup>	10,049	_	10,039	_	9,748	_	10,336	_	10,241	_	10,292	_
Native Hawaiian/Other Pacific Islander	55	_	55	_	50	_	46	_	83	_	54	_
White	11,148	_	11,040	_	10,639	_	10,623	_	10,467	_	10,349	_
Multiple races	1,613	_	1,567	_	1,436	_	1,250	_	1,061	_	875	_
Transmission category <sup>c</sup>												
Male adult or adolescent												
Male-to-male sexual contact	26,332	_	26,556	_	26,009	_	26,962	_	26,753	_	26,844	_
Injection drug use	1,778	_	1,579	_	1,478	_	1,364	_	1,403	_	1,333	_
Male-to-male sexual contact and	1,476	_	1,434	_	1,306	_	1,280	_	1,288	_	1,210	_
injection drug use	,		, -		,		,		,		, -	
Heterosexual contact <sup>d</sup>	3,894	_	3,598	_	3,439	_	3,334	_	3,274	_	3,138	_
Other <sup>e</sup>	47	_	59	_	46	_	44	_	47	_	38	_
Subtotal	33,527	26.2	33,226	25.7	32,278	24.8	32,983	25.1	32,765	24.7	32,563	24.4
	00,021	20.2	00,220	20.1	02,210	21.0	02,000	20.1	02,700	21	02,000	21.1
Female adult or adolescent	4.000		4 400		4.000		047		1 000		050	
Injection drug use	1,296	_	1,169	_	1,028	_	947	_	1,009	_	952	_
Heterosexual contact <sup>d</sup>	7,696	_	7,248	_	6,781	_	6,782	_	6,502	_	6,638	_
Other <sup>e</sup>	43	_	40	_	52	_	35	_	30	_	49	_
Subtotal	9,034	6.7	8,457	6.2	7,860	5.8	7,764	5.6	7,542	5.4	7,639	5.5
Child (<13 yrs at diagnosis)												
Perinatal	147	_	173	_	122	_	137	_	100	_	99	_
Other <sup>f</sup>	53	_	67	_	64	_	43	_	35	_	23	_
Subtotal	200	0.4	240	0.4	186	0.3	180	0.3	135	0.3	122	0.2
Region of residence <sup>g</sup>												
Northeast	7,755	13.9	7,551	13.5	7,013	12.5	6,994	12.5	6,502	11.6	6,309	11.2
Midwest	5,391	8.0	5,484	8.1	5,327	7.9	5,106	7.5	5,224	7.7	5,068	7.5
South	21,291	18.3	20,493	17.5	20,020	16.9	20,345	17.0	20,442	16.9	20,588	16.8
West	7,547	10.4	7,640	10.4	7,292	9.8	7,831	10.4	7,708	10.3	7,817	10.0
U.S. dependent areas	7,5 <del>4</del> 7	19.1	7,040 755	18.7	672	16.9	651	16.6	7,708 566	14.6	7,617 542	14.2
Total	42,761	13.5	41,923	13.2	40,324	12.6	40,927	12.7	40,442	12.5	40,324	12.3

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends.

a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

b Hispanics/Latinos can be of any race.

C Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

g Data are based on residence at time of diagnosis of HIV infection.

Table 2a. Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2011-2016 and cumulative—United States

	20	11	20	12	20	13	20	14	20	15	20	16	Cumulative <sup>2</sup>
	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.
Age at diagnosis (yr)													
<13 <sup>c</sup>	18	0.0	11	0.0	9	0.0	71	0.1	40	0.1	38	0.1	9,573
13–14	41	0.5	28	0.3	28	0.3	15	0.2	9	0.1	12	0.1	1,478
15–19	434	2.0	356	1.7	401	1.9	188	0.9	191	0.9	209	1.0	9,298
20–24	1,986	9.0	1,914	8.5	2,009	8.8	1,351	5.9	1,295	5.7	1,252	5.6	53,874
25–29	2,799	13.1	2,776	13.0	2,788	12.9	2,341	10.7	2,370	10.6	2,426	10.6	145,223
30–34	3,164	15.4	3,258	15.6	2,927	13.8	2,407	11.2	2,412	11.2	2,384	10.9	228,528
35–39	3,226	16.5	2,961	15.2	2,826	14.4	2,404	12.1	2,241	11.0	2,308	11.1	246,794
40–44	3,810	18.1	3,478	16.5	3,086	14.8	2,482	12.1	2,209	11.0	2,049	10.4	207,611
45–49	3,987	18.0	3,686	17.0	3,324	15.7	2,677	12.8	2,411	11.6	2,152	10.3	143,912
50–54	2,905	12.9	2,906	12.9	2,780	12.3	2,300	10.2	2,263	10.2	2,132	9.9	87,792
											,		
55–59	1,814	9.0	1,786	8.6	1,786	8.4	1,585	7.4	1,480	6.8	1,499	6.8	49,416
60–64	915	5.1	1,011	5.7	1,031	5.7	850	4.6	837	4.4	913	4.7	26,487
≥65	730	1.8	729	1.7	763	1.7	738	1.6	722	1.5	753	1.5	22,360
Race/ethnicity													
American Indian/Alaska Native	99	4.3	91	3.9	85	3.6	86	3.7	93	3.9	102	4.3	3,580
Asian <sup>d</sup>	348	2.3	355	2.3	345	2.1	322	1.9	320	1.9	335	1.9	10,067
Black/African American	12,269	32.0	11,965	30.9	11,214	28.7	9,071	23.0	8,623	21.6	8,501	21.1	508,711
Hispanic/Latino <sup>e</sup>	5,483	10.6	5,247	9.9	5,102	9.4	4,228	7.7	4,061	7.2	4,111	7.2	231,473
Native Hawaiian/	30	5.9	24	4.6	22	4.1	17	3.1	24	4.3	15	2.6	837
Other Pacific Islander	00	0.0		1.0			.,	0.1		1.0	10	2.0	001
White	6,379	3.2	6,092	3.1	5,858	3.0	4,826	2.4	4,629	2.3	4,442	2.2	439,998
Multiple races	1,221	21.0	1,126	18.7	1,132	18.3	859	13.5	730	11.1	654	9.7	37,588
· .	1,221	21.0	1,120	10.7	1,102	10.5	003	13.3	730	11.1	054	3.1	37,300
Transmission category <sup>†</sup>													
Male adult or adolescent													
Male-to-male sexual contact	13,493	_	13,212	_	12,997	_	10,413	_	10,067	_	10,075	_	599,230
Injection drug use	1,657	_	1,557	_	1,348	_	1,159	_	1,010	_	952	_	185,414
Male-to-male sexual contact	1,256	_	1,185	_	1,006	_	782	_	786	_	751	_	87,872
and injection drug use													
Heterosexual contact <sup>g</sup>	2,822	_	2,666	_	2,550	_	2,157	_	1,989	_	1,992	_	86,911
Other <sup>h</sup>	123	_	109	_	127	_	80	_	99	_	80	_	11,694
Subtotal	19,350	15.3	18,729	14.7	18,028	14.0	14,591	11.2	13,951	10.6	13,851	10.5	971,120
Female adult or adolescent	•		,		•		,		•		,		•
Injection drug use	1,285	_	1,176	_	1,023	_	840	_	786		728	_	91,021
Heterosexual contact <sup>g</sup>	5,049	_	4,882		4,560		3,820	_	3,625	_	3,434	_	154,584
Other <sup>h</sup>				_		_							
	127	_	103	<u> </u>	139	_	87	2.5	78	_	109	_	6,048
Subtotal	6,461	4.9	6,160	4.6	5,721	4.2	4,747	3.5	4,489	3.3	4,271	3.1	251,653
Child (<13 yrs at diagnosis)													
Perinatal	14	_	9	_	8	_	61	_	31	_	31	_	8,697
Other <sup>i</sup>	4	_	2	_	1	_	10	_	9	_	7	_	876
Subtotal	18	0.0	11	0.0	9	0.0	71	0.1	40	0.1	38	0.1	9,573
Region of residence													•
Northeast	5,106	9.2	4,744	8.5	4,329	7.7	3,508	6.3	3,303	5.9	3,088	5.5	354,229
Midwest	3,250	4.8	3,115	4.6	2,957	4.4	2,476	3.7	2,329	3.4	2,359	3.5	132,116
South	13,163	11.3	12,847	11.0	12,544	10.6	10,134	8.5	9,742	8.0	9,584	7.8	501,523
West	4,310	5.9	4,194	5.7	3,928	5.3	3,291	4.4	3,106	4.1	3,129	4.1	244,478
Total <sup>k</sup>	25,829	8.3	24,900	7.9	23,758	7.5	19,409	6.1	18,480	5.8	18,160	5.6	1,232,346

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> From the beginning of the epidemic through 2016.

b Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>&</sup>lt;sup>C</sup> The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

d Includes Asian/Pacific Islander legacy cases (see Technical Notes).

e Hispanics/Latinos can be of any race.

f Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>9</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

h Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

i Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

j Data are based on residence at time of stage 3 (AIDS) classification.

k Cumulative total includes 92 persons whose race/ethnicity is unknown.

Table 2b. Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2011–2016 and cumulative—United States and 6 dependent areas

	20	11	20	12	20	13	20	14	20	15	20	16	Cumulativea
	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.
Age at diagnosis (yr)													
<13 <sup>c</sup>	19	0.0	11	0.0	9	0.0	71	0.1	40	0.1	39	0.1	10,000
13–14	43	0.5	29	0.3	29	0.3	15	0.2	9	0.1	12	0.1	1,538
15–19	442	2.0	357	1.6	406	1.9	193	0.9	191	0.9	212	1.0	9,542
20–24	2,002	8.9	1,933	8.4	2,031	8.8	1,371	5.9	1,307	5.7	1,266	5.6	55,326
25–29	2,833	13.1	2,809	13.0	2,816	12.9	2,360	10.6	2,392	10.6	2,438	10.5	149,471
30–34	3,210	15.4	3,299	15.6	2,973	13.8	2,446	11.2	2,437	11.2	2,405	10.9	235,471
35–39	3,298	16.6	3,017	15.3	2,878	14.5	2,453	12.2	2,273	11.1	2,347	11.2	254,080
40–44	3,881	18.2	3,551	16.7	3,144	14.9	2,538	12.2	2,243	11.0	2,077	10.4	213,477
45–49	4,081	18.2	3,767	17.1	3,395	15.8	2,730	12.9	2,450	11.6	2,194	10.4	147,932
50–54	2,985	13.1	2,965	13.0	2,846	12.5	2,347	10.3	2,308	10.2	2,197	9.9	90,220
55–59	1,846	9.0	1,825	8.7	1,834	8.6	1,623	7.5	1,503	6.8	1,529	6.9	50,882
60–64	932	5.2	1,032	5.7	1,057	5.8	872	4.6	845	4.4	926	4.7	27,308
≥65	761	1.8	760	1.7	785	1.7	754	1.6	740	1.5	767	1.5	23,348
	701	1.0	700	1.7	700	1.7	754	1.0	140	1.5	101	1.0	20,040
Race/ethnicity	00		04		0.5		00		00		400		2 504
American Indian/Alaska Native	99	_	91	_	85	_	86	_	93	_	102	_	3,581
Asian <sup>d</sup>	350	_	355	_	345	_	323	_	321	_	336	_	10,124
Black/African American	12,275	_	11,975	_	11,219	_	9,079	_	8,632	_	8,504	_	509,200
Hispanic/Latino <sup>e</sup>	5,976	_	5,689	_	5,541	_	4,581	_	4,305	_	4,350	_	267,013
Native Hawaiian/	31	_	25	_	22	_	17	_	26	_	20	_	864
Other Pacific Islander	0.070		0.004		5.050		4 000		4.004		4 4 4 4 0		440 447
White	6,379	_	6,094	_	5,859	_	4,828	_	4,631	_	4,443	_	440,117
Multiple races	1,223	_	1,126	_	1,132	_	859	_	730	_	654	_	37,604
Transmission category <sup>†</sup> Male adult or adolescent													
Male-to-male sexual contact	13,612	_	13,332	_	13,134	_	10,513	_	10,155	_	10,157	_	605,555
Injection drug use	1,759	_	1,652	_	1,424	_	1,229	_	1,057	_	993	_	198,978
Male-to-male sexual contact and injection drug use	1,279	_	1,206	_	1,018	_	791	_	800	_	769	_	90,494
Heterosexual contact <sup>g</sup>	2,928	_	2,743	_	2,638	_	2,232	_	2,038	_	2,045	_	91,070
Other <sup>h</sup>	126	_	112	_	129	_	81	_	101	_	82	_	11,900
Subtotal	19,704	15.4	19,045	14.8	18,344	14.1	14,845	11.3	14,150	10.7	14,047	10.5	997,997
Female adult or adolescent			.0,0.0		.0,0		,		,		, •		001,001
Injection drug use	1,311	_	1,200	_	1,051	_	869	_	794	_	736	_	94,118
Heterosexual contact <sup>g</sup>	5,168	_	4,994	_	4,659	_	3,896	_	3,675	_	3,478	_	160,285
Other <sup>h</sup>	131	_	105	_	141	_	92	_	79	_	109	_	6,195
Subtotal	6,610	4.9	6,299	4.7	5,850	4.3	4,857	3.5	4,548	3.3	4,323	3.1	260,598
Child (<13 yrs at diagnosis)	-,		-,		-,		.,		.,		.,		,
Perinatal	15	_	9	_	8	_	61	_	31	_	32	_	9,099
Other <sup>i</sup>	4	_	2	_	1	_	10	_	9	_	7	_	901
Subtotal	19	0.0	11	0.0	9	0.0	71	0.1	40	0.1	39	0.1	10,000
Region of residence					-			• • • • • • • • • • • • • • • • • • • •		***		•	,
Northeast	5,106	9.2	4,744	8.5	4,329	7.7	3,508	6.3	3,303	5.9	3,088	5.5	354,229
Midwest	3,250	4.8	3,115	4.6	2,957	4.4	2,476	3.7	2,329	3.4	2,359	3.5	132,116
South	13,163	11.3	12,847	11.0	12,544	10.6	10,134	8.5	9,742	8.0	9,584	7.8	501,523
West	4,310	5.9	4,194	5.7	3,928	5.3	3,291	4.4	3,106	4.1	3,129	4.1	244,478
U.S. dependent areas	504	12.4	455	11.3	445	11.2	364	9.3	258	6.7	249	6.5	36,249
<u>Total<sup>k</sup></u>	26,333	8.3	25,355	8.0	24,203	7.6	19,773	6.1	18,738	5.8	18,409	5.6	1,268,595

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> From the beginning of the epidemic through 2016.

b Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>&</sup>lt;sup>C</sup> The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

d Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>e</sup> Hispanics/Latinos can be of any race.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>9</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

h Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

Data are based on residence at time of stage 3 (AIDS) classification.

k Cumulative total includes 92 persons whose race/ethnicity is unknown.

Table 3a. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2016—United States

	Inc	erican lian/ a Native	Δα	sian	Black//	African		anic/	Haw Other	itive raiian/ Pacific	Wh	iita	Multin	e races	To	tal
	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb	No.	Rateb
Ago et diagnosis (ur)	110.	Nuto	110.	itato	110.	Nuto	110.	itato	110.	Nutc	110.	Nuto	110.	Nutc	110.	Nutc
Age at diagnosis (yr) <13	0	0.0	8	0.3	78	1.1	16	0.1	0	0.0	16	0.1	4	0.2	122	0.2
13–14	0	0.0	3	0.3	15	1.3	3	0.1	0	0.0	0	0.0	2	0.2	23	0.2
15–19	3	1.6	19	1.8	1,029	34.5	334	7.0	2	4.9	222	2.0	43	6.1	1,652	7.8
20–24	36	18.6	128	10.1	3,584	108.7	1,623	33.8	3	6.7	1,213	10.0	189	30.5	6,776	30.3
25–29	61	32.0	197	13.0	3,661	112.4	2,085	45.2	10	19.2	1,773	13.9	177	35.9	7,964	34.8
30–34	42	25.5	175	11.4	2,201	78.6	1,689	37.9	9	18.1	1,465	11.8	120	30.5	5,701	26.2
35–39	24	15.9	129	9.0	1,680	63.0	1,205	28.1	8	18.3	1,108	9.4	88	26.0	4,242	20.4
40–44	28	19.9	113	8.0	1,264	50.8	896	22.6	5	13.3	967	8.5	61	21.7	3,334	16.9
45–49	17	11.6	80	6.2	1,180	45.5	722	20.2	2	5.6	1,085	8.3	70	27.1	3,156	15.1
50–54	12	7.6	50	4.3	1,135	42.3	590	19.0	6	17.2	1,116	7.7	50	20.9	2,959	13.5
55–59	9	5.8	34	3.3	832	32.2	300	11.8	0	0.0	709	4.6	39	17.4	1,923	8.7
60–64	7	5.4	20	2.2	506	23.8	164	8.5	0	0.0	374	2.6	18	10.0	1,089	5.6
≥65	4	1.5	21	1.0	363	8.3	139	3.5	3	6.1	297	0.8	14	3.9	841	1.7
Transmission category <sup>c</sup>																
Male adult or adolescent																
Male-to-male sexual contact	152	_	739	_	10,223	_	7,425	_	31	_	7,390	_	610	_	26,569	_
Injection drug use	17	_	17	_	471	_	299	_	0	_	458	_	23	_	1,285	_
Male-to-male sexual contact and injection drug use	21	_	9	-	254	_	270	_	5	_	597	_	46	_	1,201	_
Heterosexual contact <sup>d</sup>	8	_	56	_	1,926	_	581	_	3	_	424	_	40	_	3,037	_
Other <sup>e</sup>	1	_	3	_	16	_	7	_	0	_	10	_	0	_	38	_
Subtotal	198	20.9	824	11.6	12,890	82.8	8,582	38.8	39	16.8	8,879	10.6	719	33.8	32,131	24.3
Female adult or adolescent	t															
Injection drug use	14	_	7	_	338	_	139	_	2	_	411	_	29	_	939	_
Heterosexual contact <sup>d</sup>	31	_	136	_	4,189	_	1,025	_	7	_	1,032	_	121	_	6,541	_
Other <sup>e</sup>	0	_	2	_	33	_	4	_	0	_	8	_	3	_	49	_
Subtotal	45	4.5	145	1.8	4,560	26.2	1,168	5.3	9	3.9	1,450	1.7	152	6.7	7,529	5.4
Child (<13 yrs at diagnosis	)															
Perinatal	0	_	3	_	64	_	15	_	0	_	13	_	4	_	99	_
Other <sup>f</sup>	0	_	5	_	14	_	1	_	0	_	3	_	0	_	23	_
Subtotal	0	0.0	8	0.3	78	1.1	16	0.1	0	0.0	16	0.1	4	0.2	122	0.2
Region of residence <sup>g</sup>																
Northeast	9	7.1	201	5.4	2,479	39.0	1,935	24.1	5	23.5	1,475	4.0	205	22.1	6,309	11.2
Midwest	20	4.9	103	4.7	2,511	35.6	591	11.2	4	12.4	1,718	3.3	121	9.4	5,068	7.5
South	66	8.3	233	5.6	11,062	47.4	4,194	19.6	9	10.3	4,634	6.6	390	17.5	20,588	
West	148	13.9	440	5.7	1,476	42.3	3,046	13.4	30	7.0	2,518	6.5	159	6.9	7,817	
Total	243	10.2	977	5.5	17,528		9,766	17.0	48	8.5	10,345	5.2	875	12.9	39,782	

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Hispanics/Latinos can be of any race.

b Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>&</sup>lt;sup>C</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

 $<sup>^{\</sup>mathbf{e}}$  Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>&</sup>lt;sup>9</sup> Data are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian	Black/African American	Hispanic/ Latino <sup>a</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Age at diagnosis (yr)								
<13	0	8	78	16	0	16	4	122
13–14	0	3	15	3	0	0	2	23
15–19	3	19	1,029	347	2	222	43	1,665
20–24	36	128	3,585	1,690	5	1,215	189	6,848
25–29	61	197	3,661	2,150	11	1,773	177	8,030
30–34	42	175	2,202	1,751	11	1,465	120	5,766
35–39	24	130	1,680	1,274	8	1,108	88	4,312
40–44	28	113	1,265	952	5	967	61	3,391
45–49	17	80	1,181	778	2	1,086	70	3,214
50–54	12	50	1,135	640	6	1,116	50	3,009
55–59	9	34	832	346	1	710	39	1,971
60–64	7	20	507	188	0	374	18	1,114
≥65	4	21	363	157	3	297	14	859
Transmission category <sup>b</sup>								
Male adult or adolescent								
Male-to-male sexual contact	152	740	10,226	7,689	35	7,392	610	26,844
Injection drug use	17	17	471	345	1	459	23	1,333
Male-to-male sexual contact and injection drug use	21	9	254	278	6	597	46	1,210
Heterosexual contact <sup>c</sup>	8	56	1,927	680	3	424	40	3,138
Other <sup>d</sup>	1	3	16	7	0	10	0	38
Subtotal	198	825	12,895	8,999	45	8,882	719	32,563
Female adult or adolescen	t							
Injection drug use	14	7	338	152	2	411	29	952
Heterosexual contact <sup>c</sup>	31	136	4,189	1,121	7	1,033	121	6,638
Other <sup>d</sup>	0	2	33	4	0	8	3	49
Subtotal	45	145	4,560	1,277	9	1,451	152	7,639
Child (<13 yrs at diagnosis	s)							
Perinatal	0	3	64	15	0	13	4	99
Other <sup>e</sup>	0	5	14	1	0	3	0	23
Subtotal	0	8	78	16	0	16	4	122
Region of residence <sup>f</sup>								
Northeast	9	201	2,479	1,935	5	1,475	205	6,309
Midwest	20	103	2,511	591	4	1,718	121	5,068
South	66	233	11,062	4,194	9	4,634	390	20,588
West	148	440	1,476	3,046	30	2,518	159	7,817
U.S. dependent areas	0	1	5	526	6	4	0	542
Total	243	978	17,533	10,292	54	10,349	875	40,324

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12 should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Hispanics/Latinos can be of any race.

b Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

C Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

e Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

f Data are based on residence at time of diagnosis of HIV infection.

Table 4a. Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States

	Inc	erican lian/ a Native	As	ian <sup>a</sup>		African rican		anic/ ino <sup>b</sup>	Haw Other	tive raiian/ Pacific	Wł	nite	Multip	le races	To	otal
	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>
Age at diagnosis (yr)																
<13	1	0.2	1	0.0	25	0.3	2	0.0	0	0.0	5	0.0	4	0.2	38	0.1
13–14	0	0.0	0	0.0	6	0.5	6	0.3	0	0.0	0	0.0	0	0.0	12	
15–19	0	0.0	3	0.3	148	5.0	34	0.7	0	0.0	15	0.1	9	1.3	209	1.0
20–24	7	3.6	21	1.7	738	22.4	300	6.2	1	2.2	141	1.2	44	7.1	1,252	5.6
25–29	17	8.9	51	3.4	1,309	40.2	582	12.6	2	3.8	374	2.9	91	18.5	2,426	
30–34	16	9.7	53	3.5	1,083	38.7	653	14.7	3	6.0	485	3.9	91	23.2	2,384	
35–39	17	11.2	52	3.6	1,039	39.0	648	15.1	7	16.0	473	4.0	72	21.2	2,308	
40–44	16	11.4	47	3.3	926	37.2	480	12.1	0	0.0	523	4.6	57	20.3	2,049	
45–49	12	8.2	39	3.0	890	34.3	478	13.4	1	2.8	647	5.0	85	32.9	2,152	
50–54	4	2.5	28	2.4	884	33.0	415	13.3	1	2.9	741	5.1	92	38.4	2,165	9.9
55–59	8	5.1	21	2.0	670	25.9	245	9.7	0	0.0	504	3.3	51	22.7	1,499	
60–64	1	0.8	8	0.9	445	20.9	127	6.6	0	0.0	299	2.1	33	18.3	913	
≥65	3	1.2	11	0.5	338	7.7	141	3.6	0	0.0	235	0.6	25	6.9	753	
Transmission category <sup>d</sup>																
Male adult or adolescent																
Male-to-male sexual contact	57	_	232	_	3,922	_	2,613	_	8	_	2,910	_	333	_	10,075	
Injection drug use	6	_	12	_	406	_	248	_	1	_	240	_	39	_	952	_
Male-to-male sexual contact and injection drug use	8	_	3	_	217	_	156	_	1	_	314	_	53	_	751	_
Heterosexual contacte	6	_	25	_	1,293	_	383	_	2	_	239	_	44	_	1,992	_
Other <sup>f</sup>	0	_	2	_	40	_	18	_	0	_	11	_	9	_	81	_
Subtotal	77	8.1	273	3.8	5,879	37.8	3,419	15.4	12	5.2	3,713	4.4	478	22.5	13,851	10.5
Female adult or adolescent	t															
Injection drug use	8	_	3	_	326	_	114	_	0	_	235	_	42	_	728	_
Heterosexual contact <sup>e</sup>	16	_	56	_	2,202	_	555	_	3	_	479	_	123	_	3,434	_
Other <sup>f</sup>	0	_	2	_	69	_	22	_	0	_	10	_	8	_	109	_
Subtotal	24	2.4	61	0.8	2,597	14.9	690	3.2	3	1.3	724	8.0	172	7.6	4,271	3.1
Child (<13 yrs at diagnosis	)															
Perinatal	1	_	1	_	20	_	2	_	0	_	4	_	3	_	31	_
Other <sup>g</sup>	0	_	0	_	5	_	0	_	0	_	1	_	1	_	7	_
Subtotal	1	0.2	1	0.0	25	0.3	2	0.0	0	0.0	5	0.0	4	0.2	38	0.1
Region of residenceh																
Northeast	5	4.0	66	1.8	1,236	19.5	968	12.1	2	9.4	634	1.7	177	19.1	3,088	5.5
Midwest	18	4.4	39	1.8	1,173	16.6	277	5.3	1	3.1	770	1.5	81	6.3	2,359	
South	23	2.9	83	2.0	5,504	23.6	1,712	8.0	1	1.1	1,966	2.8	295	13.2	9,584	
West	56	5.3	147	1.9	588	16.9	1,154	5.1	11	2.6	1,072	2.8	101	4.4	3,129	
Total	102	4.3	335	1.9	8,501	21.1	4,111	7.2	15	2.6	4,442	2.2	654	9.7	18,160	5.6

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

b Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

 $<sup>^{\</sup>mbox{\scriptsize e}}$  Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

<sup>&</sup>lt;sup>9</sup> Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>&</sup>lt;sup>h</sup> Data are based on residence at time of stage 3 (AIDS) classification.

Table 4b. Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas

	American Indian/ Alaska Native	<b>As</b> ian <sup>a</sup>	Black/African American	Hispanic/ Latino <sup>b</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Age at diagnosis (yr)								
<13	1	1	26	2	0	5	4	39
13–14	0	0	6	6	0	0	0	12
15–19	0	3	148	37	0	15	9	212
20–24	7	21	738	312	2	142	44	1,266
25–29	17	51	1,309	594	2	374	91	2,438
30–34	16	53	1,083	672	5	485	91	2,405
35–39	17	53	1,039	686	7	473	72	2,347
40–44	16	47	926	507	1	523	57	2,077
45–49	12	39	891	519	1	647	85	2,194
50–54	4	28	884	447	1	741	92	2,197
55–59	8	21	671	273	1	504	51	1,529
60–64	1	8	445	140	0	299	33	926
≥65	3	11	338	155	0	235	25	767
Transmission category <sup>c</sup>								
Male adult or adolescent								
Male-to-male sexual contact	57	232	3,922	2,692	11	2,910	333	10,157
Injection drug use	6	13	406	288	1	240	39	993
Male-to-male sexual contact and injection drug use	8	3	217	174	1	314	53	769
Heterosexual contact <sup>d</sup>	6	25	1,294	435	2	239	44	2,045
Other <sup>e</sup>	0	2	40	20	0	11	9	83
Subtotal	77	274	5,880	3,609	16	3,713	478	14,047
Female adult or adolescen	t							
Injection drug use	8	3	326	121	0	235	42	736
Heterosexual contact <sup>d</sup>	16	56	2,203	596	4	480	123	3,478
Other <sup>e</sup>	0	2	69	22	0	10	8	109
Subtotal	24	61	2,598	739	4	725	172	4,323
Child (<13 yrs at diagnosis	s)							
Perinatal	1	1	21	2	0	4	3	32
Other <sup>f</sup>	0	0	5	0	0	1	1	7
Subtotal	1	1	26	2	0	5	4	39
Region of residence <sup>g</sup>								
Northeast	5	66	1,236	968	2	634	177	3,088
Midwest	18	39	1,173	277	1	770	81	2,359
South	23	83	5,504	1,712	1	1,966	295	9,584
West	56	147	588	1,154	11	1,072	101	3,129
U.S. dependent areas	0	1	3	239	5	1	0	249
Total	102	336	8,504	4,350	20	4,443	654	18,409

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12 should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

b Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

 $<sup>{\</sup>bf g}$  Data are based on residence at time of stage 3 (AIDS) classification.

Table 5a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States

		Ma	ale-to-male	sexual cont	act		Ma	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ι	ıse
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Am	erican India	ın/Alaska Na	ative				
Age at diagnosis (	yr)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	6	4	1	4	6	3	0	1	0	0	1	0
20–24	13	21	17	32	31	27	4	1	1	1	4	4
25–29	14	15	23	28	24	42	1	5	1	1	1	8
30–34	7	15	13	18	17	31	1	3	2	0	0	4
35–39	14	10	7	6	14	12	0	3	1	0	4	2
40–44	6	14	8	12	6	15	1	1	0	1	0	0
45–49	9	11	7	10	8	10	2	1	1	2	0	0
50–54	2	6	7	8	5	6	0	1	1	2	0	1
55–59	2	1	0	2	4	3	1	0	0	0	0	1
60–64	2	0	1	0	0	4	0	0	0	0	0	0
≥65	1	0	2	1	0	1	0	0	0	0	0	0
Region of residence	c <b>e</b> a											
Northeast	0	5	1	4	3	6	0	1	0	0	0	0
Midwest	6	6	6	10	10	14	2	2	1	3	1	2
South	22	30	22	30	36	42	0	2	1	0	3	8
West	46	55	56	77	65	89	8	11	5	4	7	12
Total	74	96	85	121	114	151	10	16	7	7	11	22
10141	• • • • • • • • • • • • • • • • • • • •						sian		•	•		
Age at diagnosis (	ur)					AS	oiaii					
13–14	(יי <b>ע</b> 0	0	0	1	1	0	0	0	0	0	0	0
15–14	12	11	8	15	22	19	0	0	0	1	0	0
20–24	85	77	100	127	127	108	4	0	1	3	4	3
25–29	94	127	110	143	173	172	1	2	3	3	2	3 1
30–34	9 <del>4</del> 86	85	99	143	108	131	3	5	3 1	2	2	1
35–39	92	96	99 81					1		3	3	1
				99	75	85	5	•	2			2
40–44	70	70	89 55	77 60	83	89 50	4	5	2	5	3	0
45–49	51	51	55	62	64	58	2	1	1	1	2	1
50–54	23	25	20	33	38	33	1	0	0	1	1	1
55–59	10	9	12	10	14	20	1	0	0	0	0	0
60–64	8	7	6	6	4	13	0	0	0	0	0	0
≥65	2	6	4	8	6	12	0	0	0	0	0	0
Region of residence		400		46.	400	4.40	•	_			•	
Northeast	93	103	92	124	108	146	3	5	4	1	3	1
Midwest	42	39	49	53	85	70	0	2	0	6	2	3
South	128	111	140	146	164	160	4	2	1	3	6	0
West	269	311	302	377	358	363	15	7	6	10	8	5
Total	532	564	583	700	715	739	22	16	11	20	19	9

Table 5a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States (cont)

	\$ 9												
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016	
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	
						Black/Africa	ın America	n					
Age at diagnosis	(yr)												
13–14	5	9	11	5	8	4	0	1	0	0	0	0	
15–19	896	880	811	803	866	801	17	14	14	15	12	16	
20–24	2,992	3,018	3,075	3,185	3,023	2,914	82	53	68	53	57	47	
25-29	1,857	1,904	2,080	2,340	2,529	2,700	62	40	57	51	41	59	
30-34	1,044	1,020	1,078	1,204	1,244	1,293	35	44	37	40	36	40	
35–39	682	690	671	693	751		42	32	20	24	35	30	
40–44	738	686		530	493	513	32	23	26	22	18	14	
45–49												15	
50–54												14	
55–59												7	
60–64												8	
≥65												4	
Region of resider	nce <sup>a</sup>												
Northeast	1,327	1,270	1,236	1,275	1,236	1,190	50	50	42	42	27	30	
Midwest							62	51			37	52	
South							222	151	170	141	144	134	
West												38	
Total	9,719	9,608	9,619	10,009	10,130	10,223	375	290	299	269	248	254	
						Hispanio	:/I atinob						
Age at diagnosis	(yr)					· ···opa····o	, <u></u>						
13–14		2	2	5	1	1	0	1	0	0	0	0	
15–19					284	285		13				11	
20–24												46	
25–29												55	
30–34						•						58	
35–39												39	
40–44												28	
45–49												8	
50–54												14	
55–59												6	
60–64												4	
oo=o4 ≥65												2	
Region of resider			•	•	•	<b>~</b> _	_	•	•	_	-	_	
Northeast	1,335	1,372	1,362	1,420	1,353	1,256	76	81	71	51	46	39	
Midwest	434	502	481	501	477	456	24	26	24	15	25	23	
South	2,446	2,548	2,573	2,802	3,025	3,223	113	104	90	102	99	94	
West	2,161	2,255	2,373	2,423	2,409	2,491	142	139	114	122	119	113	
Total	6,376	6,677	6,567	7,146	7,264	7,426	355	350	299	290	289	269	

Table 5a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States (cont)

		Ma	ale-to-male	sexual cont	act		Ma	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ı	ıse
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	Hawaiian/Ot	her Pacific	Islander				
Age at diagnosis ()	yr)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	1	1	1	2	2	1	0	0	0	1	0
20–24	10	12	3	6	11	2	1	0	0	0	0	0
25–29	9	4	9	3	12	8	0	1	2	0	0	2
30-34	6	11	10	6	12	5	0	2	0	1	0	2
35–39	9	4	3	7	6	5	0	0	0	0	1	0
40–44	5	1	3	3	3	5	0	0	0	0	0	0
45-49	0	3	4	3	6	1	0	1	0	0	0	0
50–54	1	3	2	1	5	2	0	0	0	0	0	0
55–59	1	3	0	0	3	0	0	0	0	0	0	0
60–64	0	1	0	1	0	0	0	0	0	0	0	0
≥65	0	0	0	1	0	2	0	0	0	0	0	1
Region of residence	e <sup>a</sup>											
Northeast	2	3	2	0	2	4	0	0	0	0	0	1
Midwest	0	1	2	1	1	3	0	1	0	0	0	0
South	8	7	3	7	19	5	0	0	1	0	1	0
West	32	31	28	24	38	19	2	3	1	1	1	4
Total	42	42	35	32	60	31	2	4	2	1	2	5
						WI	nite					
Age at diagnosis (y	yr)											
13–14	1	2	1	3	0	0	0	0	0	0	0	0
15–19	182	144	137	143	154	165	8	10	11	10	15	11
20–24	983	983	981	992	988	929	88	86	98	71	92	79
25–29	1,141	1,192	1,133	1,292	1,309	1,305	117	108	123	142	141	124
30–34	1,035	1,122	1,043	1,026	1,044	1,035	89	113	96	111	114	113
35–39	894	835	794	841	766	745	89	85	71	75	91	76
40–44	1,141	1,055	932	819	716	669	68	77	74	74	47	60
45–49	1,152	1,150	1,044	954	776	786	66	78	48	59	47	52
50-54	809	838	775	830	814	811	47	48	36	46	58	38
55–59	473	472	509	462	428	489	15	25	23	20	30	26
60–64	250	232	298	237	257	249	13	8	13	10	10	11
≥65	183	203	230	204	195	208	7	6	8	3	4	8
Region of residence	:e <sup>a</sup>											
Northeast	1,295	1,265	1,164	1,155	1,036	1,028	73	80	69	59	71	64
Midwest	1,424	1,413	1,383	1,322	1,276	1,224	99	104	77	99	112	107
South	3,430	3,451	3,380	3,364	3,176	3,303	201	212	240	243	242	222
West	2,095	2,100	1,952	1,961	1,959	1,835	235	247	215	218	225	203
Total	8,244	8,229	7,879	7,802	7,447	7,390	608	643	601	619	650	596

Table 5a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States (cont)

		Ma	ale-to-male	sexual cont	act		Ma	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ι	ıse
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multipl	e races					
Age at diagnosis (y	r)					-						
13–14	1	2	0	0	0	0	0	0	0	0	0	0
15–19	77	70	62	62	41	33	0	3	6	3	2	3
20-24	263	285	264	207	187	155	19	19	18	18	10	9
25-29	191	197	198	177	187	145	18	10	11	14	12	10
30-34	128	133	121	108	92	90	12	17	12	5	18	7
35-39	96	97	91	80	68	48	5	10	7	6	2	7
40–44	108	90	62	65	43	39	10	7	3	10	4	2
45–49	95	70	70	58	40	36	10	9	5	6	2	4
50-54	49	49	35	42	38	26	6	3	5	2	0	3
55–59	27	29	27	23	16	22	4	6	1	2	1	2
60–64	20	8	15	5	11	11	1	4	0	0	1	1
≥65	11	10	10	7	8	5	0	0	1	0	0	0
Region of residence												
Northeast	, 189	214	248	175	172	147	19	13	10	12	12	7
Midwest	179	183	126	116	104	72	11	15	13	10	10	10
South	516	476	409	385	307	265	29	33	29	22	15	20
West	179	165	409 170	363 157	30 <i>7</i> 147	203 127	29 27	33 27	29 17	22	16	9
Total	1,063	1,038	953	833	730	611	86	88	69	66	53	46
						То	tal					
Age at diagnosis (y	-											
13–14	12	15	14	14	10	5	1	2	0	0	0	0
15–19	1,463	1,412	1,282	1,315	1,375	1,308	42	41	40	46	43	40
20–24	5,528	5,727	5,723	6,006	5,846	5,535	258	225	242	185	223	188
25–29	4,567	4,784	4,950	5,491	5,808	6,143	275	231	266	266	265	259
30–34	3,335	3,558	3,470	3,700	3,717	3,908	213	254	202	220	226	225
35–39	2,588	2,485	2,413	2,615	2,609	2,580	184	174	141	150	170	155
40–44	2,803	2,603	2,352	2,171	1,957	1,943	148	156	137	140	99	103
45–49	2,469	2,421	2,233	2,122	1,907	1,790	143	150	100	107	86	80
50-54	1,649	1,620	1,526	1,553	1,614	1,634	102	91	76	82	79	70
55-59	883	858	909	872	849	913	55	46	46	45	51	42
60-64	426	438	487	429	420	464	23	28	23	22	17	25
≥65	332	334	361	354	347	347	12	10	15	7	10	14
Region of residence	, <sup>a</sup>											
Northeast	4,241	4,232	4,105	4,154	3,910	3,776	221	230	196	165	158	143
Midwest	3,620	3,764	3,664	3,622	3,533	3,466	197	201	160	175	186	196
South	12,600	12,578	12,527	13,038	13,186	13,477	568	503	533	511	509	478
West	5,591	5,680	5,422	5,828	5,830	5,851	469	473	399	420	416	385
Total	26,052	26,254	25,719	26,642	26,459	26,570	1,455	1,407	1,288	1,271	1,270	1,201

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

 $<sup>^{\</sup>mathrm{a}}$  Data are based on residence at time of diagnosis of HIV infection.

 $<sup>^{\</sup>mbox{\scriptsize b}}$  Hispanics/Latinos can be of any race.

Table 5b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas

<u>-</u>		Ma	ale-to-male	sexual cont	act		M	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ı	ıse
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Amer	ican Indian	Alaska Nati	ive				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	6	4	1	4	6	3	0	1	0	0	1	0
20–24	13	21	17	32	31	27	4	1	1	1	4	4
25–29	14	15	23	28	24	42	1	5	1	1	1	8
30-34	7	15	13	18	17	31	1	3	2	0	0	4
35–39	14	10	7	6	14	12	0	3	1	0	4	2
40-44	6	14	8	12	6	15	1	1	0	1	0	0
45-49	9	11	7	10	8	10	2	1	1	2	0	0
50-54	2	6	7	8	5	6	0	1	1	2	0	1
55–59	2	1	0	2	4	3	1	0	0	0	0	1
60–64	2	0	1	0	0	4	0	0	0	0	0	0
≥65	1	0	2	1	0	1	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	0	5	1	4	3	6	0	1	0	0	0	0
Midwest	6	6	6	10	10	14	2	2	1	3	1	2
South	22	30	22	30	36	42	0	2	1	0	3	8
West	46	55	56	77	65	89	8	11	5	4	7	12
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	74	96	85	121	114	151	10	16	7	7	11	22
						As	ian					
Age at diagnosis (yr)												
13–14	0	0	0	1	1	0	0	0	0	0	0	0
15–19	12	11	8	15	22	19	0	0	0	1	0	0
20–24	85	77	100	127	127	108	4	0	1	3	4	3
25–29	94	127	110	143	175	172	1	2	3	3	2	1
30–34	86	85	99	119	109	131	3	5	1	2	2	1
35–39	92	96	81	99	76	86	5	1	2	3	3	2
40–44	70	70	89	77	83	89	4	5	2	5	3	0
45–49	51	51	55	62	64	58	2	1	1	1	2	1
50–54	23	25	20	34	38	33	1	0	0	1	1	1
55–59	10	9	12	10	14	20	1	0	0	0	0	0
60–64	8	7	6	6	4	13	0	0	0	0	0	0
≥65	2	6	4	8	6	12	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	93	103	92	124	108	146	3	5	4	1	3	1
Midwest	42	39	49	53	85	70	0	2	0	6	2	3
South	128	111	140	146	164	160	4	2	1	3	6	0
West	269	311	302	377	358	363	15	7	6	10	8	5
U.S. dependent areas	0	0	0	1	4	1	0	0	0	0	0	0
Total	532	564	583	701	719	740	22	16	11	20	19	9
ı olai	JJZ	JU4	555	701	119	7-10	22	10	• • •	20	19	J

Table 5b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

<u>.</u>		Ma	ale-to-male	sexual cont	act		Ma	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ı	use
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	ın America	n				
Age at diagnosis (yr)												
13–14	5	9	11	5	8	4	0	1	0	0	0	0
15–19	896	880	811	803	866	801	17	14	14	15	12	16
20–24	2,993	3,018	3,076	3,185	3,024	2,915	82	53	68	53	57	47
25–29	1,858	1,904	2,081	2,340	2,530	2,700	62	40	57	51	41	59
30–34	1,044	1,020	1,078	1,205	1,244	1,294	35	44	37	40	36	40
35–39	683	690	672	694	751	777	42	32	20	24	35	30
40–44	738	687	607	530	494	514	32	23	26	22	18	14
45-49	639	596	537	484	472	420	34	33	28	16	17	15
50-54	464	407	381	346	360	388	37	25	21	21	10	14
55–59	238	215	200	236	215	231	25	10	15	15	14	7
60–64	90	116	103	105	89	114	8	13	8	10	4	8
≥65	76	67	66	80	82	68	3	3	4	3	4	4
Region of residence <sup>a</sup>												
Northeast	1,327	1,270	1,236	1,275	1,236	1,190	50	50	42	42	27	30
Midwest	1,535	1,620	1,619	1,620	1,581	1,627	62	51	46	42	37	52
South	6,049	5,955	6,000	6,304	6,460	6,478	222	151	170	141	144	134
West	808	763	764	810	853	928	41	38	41	44	40	38
U.S. dependent areas	4	1	4	4	5	3	1	0	0	0	0	0
Total	9,723	9,609	9,623	10,013	10,135	10,226	376	290	299	269	248	254
						Hispanio	:/Latino <sup>b</sup>					
Age at diagnosis (yr)												
13–14	7	2	2	5	1	1	0	1	0	0	0	0
15–19	297	314	276	305	287	293	18	13	9	17	11	11
20–24	1,234	1,406	1,348	1,541	1,535	1,457	64	69	56	43	59	46
25–29	1,313	1,409	1,452	1,573	1,640	1,817	77	70	70	57	71	57
30-34	1,065	1,216	1,157	1,251	1,233	1,364	72	76	59	61	57	60
35–39	835	773	788	923	962	943	49	48	41	45	38	40
40–44	761	714	682	697	642	635	34	44	36	29	30	29
45–49	554	567	532	570	570	494	34	28	18	24	19	10
50–54	319	307	321	305	367	391	11	19	17	11	10	14
55–59	145	135	164	147	178	163	9	6	7	8	6	6
60–64	62	80	74	80	66	78	4	4	2	2	2	4
≥65	63	53	54	58	65	52	2	0	3	3	4	2
Region of residence <sup>a</sup>												
Northeast	1,335	1,372	1,362	1,420	1,353	1,256	76	81	71	51	46	39
Midwest	434	502	481	501	477	456	24	26	24	15	25	23
South	2,446	2,548	2,573	2,802	3,025	3,223	113	104	90	102	99	94
West	2,161	2,255	2,151	2,423	2,409	2,491	142	139	114	122	119	113
U.S. dependent areas	275	298	284	309	281	264	19	26	17	9	18	8
Total	6,651	6,975	6,851	7,455	7,545	7,690	374	376	316	299	307	277
ıvıaı	0,031	0,313	0,031	1,433	1,343	1,050	314	310	310	233	JU 1	211

Table 5b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

-		IVI	ale-to-male	sexual cont	act	Male-to-male sexual contact and injection drug use						
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	lawaiian/Ot	her Pacific	Islander				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	1	1	1	2	2	1	0	0	0	1	0
20–24	10	12	3	6	12	4	1	0	0	0	0	0
25–29	9	4	9	3	13	8	0	1	2	0	0	3
30–34	6	12	11	7	12	7	0	2	0	1	0	2
35–39	9	4	3	7	6	5	0	0	0	0	1	0
40–44	5	1	3	4	3	5	0	0	0	0	0	0
45–49	0	3	4	3	6	1	0	1	0	0	0	0
50–54	1	3	2	1	5	2	0	0	0	0	0	0
55–59	1	3	0	0	3	1	0	0	0	0	0	0
60–64	0	1	0	1	0	0	0	0	0	0	0	0
≥65	0	0	0	1	0	2	0	0	0	0	0	1
Region of residence <sup>a</sup>												
Northeast	2	3	2	0	2	4	0	0	0	0	0	1
Midwest	0	1	2	1	1	3	0	1	0	0	0	0
South	8	7	3	7	19	5	0	0	1	0	1	0
West	32	31	28	24	38	19	2	3	1	1	1	4
U.S. dependent areas	0	1	1	2	3	5	0	0	0	0	0	1
Total	42	43	36	34	63	36	2	4	2	1	2	6
						Wł	nite					
Age at diagnosis (yr)												
13–14	1	2	1	3	0	0	0	0	0	0	0	0
15–19	182	144	137	143	154	165	8	10	11	10	15	11
20–24	983	983	981	993	988	930	88	86	98	71	92	79
25–29	1,141	1,192	1,133	1,293	1,309	1,305	117	108	123	142	141	124
30–34	1,035	1,122	1,044	1,027	1,044	1,035	89	113	96	111	114	113
35–39	894	835	794	841	766	745	89	85	71	75	91	76
40–44	1,141	1,056	932	819	716	669	68	77	74	74	47	60
45–49	1,152	1,150	1,044	954	776	787	66	78	48	59	47	52
50–54	809	838	775	830	815	811	47	48	36	46	58	38
55–59	473	472	509	463	428	489	15	25	23	20	30	26
60–64	250	232	298	237	257	249	13	8	13	10	10	11
≥65	183	203	230	204	195	208	7	6	8	3	4	8
Region of residence <sup>a</sup>												
Northeast	1,295	1,265	1,164	1,155	1,036	1,028	73	80	69	59	71	64
Midwest	1,424	1,413	1,383	1,322	1,276	1,224	99	104	77	99	112	107
South	3,430	3,451	3,380	3,364	3,176	3,303	201	212	240	243	242	222
West	2,095	2,100	1,952	1,961	1,959	1,835	235	247	215	218	225	203
U.S. dependent areas	0	1	1	4	1	2	0	0	0	0	0	0
Total	8,244	8,230	7,880	7,806	7,448	7,392	608	643	601	619	650	596

Table 5b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

		Ma	ale-to-male	sexual cont	act		Ma	ale-to-male	sexual cont	act and inje	ction drug ı	ıse
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multipl	e races					
Age at diagnosis (yr)												
13–14	1	2	0	0	0	0	0	0	0	0	0	0
15–19	77	70	62	63	41	33	0	3	6	3	2	3
20–24	263	285	264	207	187	155	19	19	18	18	10	9
25–29	191	197	198	177	187	145	18	10	11	14	12	10
30–34	128	134	121	108	92	90	12	17	12	5	18	7
35–39	96	97	91	80	68	48	5	10	7	6	2	7
40–44	108	90	62	65	43	39	10	7	3	10	4	2
45-49	95	70	70	58	40	36	10	9	5	6	2	4
50-54	49	49	35	42	38	26	6	3	5	2	0	3
55–59	27	29	27	23	16	22	4	6	1	2	1	2
60–64	20	8	15	5	11	11	1	4	0	0	1	1
≥65	11	10	10	7	8	5	0	0	1	0	0	0
Region of residence <sup>a</sup>												
Northeast	189	214	248	175	172	147	19	13	10	12	12	7
Midwest	179	183	126	116	104	72	11	15	13	10	10	10
South	516	476	409	385	307	265	29	33	29	22	15	20
West	179	165	170	157	147	127	27	27	17	22	16	9
U.S. dependent areas	0	1	0	1	0	0	0	0	0	0	0	0
Total	1,063	1,039	953	834	730	611	86	88	69	66	53	46
						To	tal					
Age at diagnosis (yr)												
13–14	13	15	14	14	10	5	1	2	0	0	0	0
15–19	1,471	1,423	1,297	1,333	1,378	1,316	44	41	40	46	43	40
20–24	5,581	5,800	5,788	6,091	5,905	5,595	261	228	243	187	226	188
25–29	4,618	4,848	5,007	5,557	5,877	6,190	277	236	267	267	267	262
30–34	3,370	3,604	3,522	3,734	3,750	3,951	213	259	207	220	228	227
35–39	2,622	2,505	2,435	2,650	2,643	2,616	189	179	141	152	175	156
40–44	2,828	2,633	2,383	2,205	1,987	1,965	149	157	141	141	102	104
45–49	2,499	2,448	2,250	2,141	1,934	1,805	147	151	102	107	87	82
50–54	1,667	1,635	1,541	1,565	1,628	1,657	103	96	80	83	80	71
55–59	896	864	912	881	857	929	55	47	46	45	51	42
60–64	431	443	496	433	428	468	25	28	23	22	17	25
≥65	336	339	365	359	355	347	12	10	15	8	12	14
Region of residence <sup>a</sup>										-		
Northeast	4,241	4,232	4,105	4,154	3,910	3,776	221	230	196	165	158	143
Midwest	3,620	3,764	3,664	3,622	3,533	3,466	197	201	160	175	186	196
South	12,600	12,578	12,527	13,038	13,186	13,477	568	503	533	511	509	478
West	5,591	5,680	5,422	5,828	5,830	5,851	469	473	399	420	416	385
	280	302	5, <del>4</del> 22 290		293	274		473 26		420 9		303 9
U.S. dependent areas				320			20		18		18	
Total	26,332	26,556	26,009	26,962	26,753	26,844	1,476	1,434	1,306	1,280	1,288	1,210

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

 $<sup>^{\</sup>mbox{\scriptsize a}}$  Data are based on residence at time of diagnosis of HIV infection.

<sup>&</sup>lt;sup>b</sup> Hispanics/Latinos can be of any race.

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—United States

			Ma	ale					Fen	nale		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Amo	erican India	n/Alaska Na	ative				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	2	2	1	0	3	1	1	1	0	2	1
25–29	2	2	1	2	2	4	2	0	0	1	2	2
30–34	0	1	2	0	2	0	5	4	2	2	2	2
35–39	3	0	1	0	1	1	4	2	0	2	1	2
40-44	0	5	3	3	0	2	0	2	3	2	2	2
45-49	2	0	3	2	0	2	0	3	1	1	2	1
50–54	1	0	1	3	1	0	1	0	2	0	0	4
55–59	2	2	1	0	1	3	1	1	0	0	1	0
60-64	0	0	0	0	0	1	0	0	1	1	1	0
≥65	0	0	1	0	0	0	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	0	1	0	1	0	0	0	0	1	0	0	0
Midwest	0	2	1	1	0	1	5	3	3	2	0	1
South	2	1	4	4	2	4	4	1	2	4	4	1
West	8	10	10	5	5	13	7	8	6	5	9	11
Total	10	14	15	11	7	18	16	12	12	11	13	13
						As	ian					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	1	0	0	1	0	0	0	0	0
20–24	0	0	2	0	0	0	1	1	0	0	1	2
25–29	0	1	2	0	0	2	1	3	0	1	0	1
30–34	3	2	3	3	6	2	0	0	1	0	1	1
35–39	4	6	3	5	1	4	2	2	0	2	0	2
40–44	3	5	5	3	3	1	1	0	1	1	1	0
45–49	3	1	2	1	1	3	0	0	2	1	0	1
50–54	1	1	1	2	2	2	1	0	1	1	0	1
55–59	1	1	2	0	1	1	0	0	3	1	0	0
60–64	1	1	1	1	1	1	0	0	0	1	1	0
≥65	0	1	0	1	1	1	0	0	0	0	0	0
Region of residence <sup>a</sup>	-	•	-	•	•	•	-	-	-	-	-	-
Northeast	7	5	7	6	7	6	2	2	1	2	1	2
Midwest	2	0	2	1	0	1	1	1	1	2	1	0
South	2	4	6	7	3	3	1	1	2	0	2	2
West	4	9	7	4	8	3 7	3	3	4	3	2	2
Total	15	18	22	18	18	17	7	7	8	7	6	6

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—United States (cont)

			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Afric	an Americai	า				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	1	0	0	2	0
15–19	9	8	7	6	5	6	15	14	10	9	6	10
20–24	28	35	30	37	35	29	41	46	31	30	25	25
25–29	39	43	43	42	43	46	51	42	32	40	44	36
30–34	54	56	48	41	44	38	52	57	45	36	33	39
35–39	64	53	50	39	41	55	59	56	37	42	33	36
40–44	100	70	52	48	47	48	78	66	48	45	35	32
45–49	131	99	102	70	49	53	108	73	61	50	44	30
50–54	126	122	92	65	70	68	83	89	59	48	45	52
55–59	115	91	88	79	62	55	62	54	59	45	33	39
60–64	54	52	47	44	37	42	23	29	25	19	24	25
≥65	40	40	31	41	32	32	16	20	13	17	15	14
Region of residence <sup>a</sup>												
Northeast	231	203	186	162	129	132	151	145	93	103	86	77
Midwest	79	70	63	48	50	49	82	67	59	45	50	49
South	401	349	293	273	239	238	312	293	237	197	169	174
West	49	47	48	30	47	51	45	41	31	37	34	37
Total	760	669	590	513	465	470	590	546	420	382	339	337
						Hispani	c/Latino <sup>b</sup>					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	3	3	2	1	2	7	5	5	5	4	2
20–24	25	12	20	16	26	18	13	18	14	17	22	11
25–29	47	35	37	32	35	34	24	19	23	15	14	28
30–34	63	57	51	45	49	47	32	28	21	23	17	18
35–39	55	58	42	36	46	37	25	24	15	19	16	15
40–44	68	55	44	50	41	31	25	19	22	27	15	16
45–49	75	52	60	50	37	31	38	24	19	16	17	13
50–54	46	51	35	36	39	41	17	17	18	17	16	16
55–59	36	27	37	28	30	26	9	12	10	14	8	11
60–64	12	23	11	12	11	13	6	6	6	7	4	5
≥65	14	18	13	9	14	18	5	3	6	6	6	5
Region of residence <sup>a</sup>												
Northeast	187	170	145	108	120	100	83	87	72	69	53	48
Midwest	34	21	20	11	19	11	11	9	11	11	6	8
South	123	119	95	95	101	94	66	43	41	44	46	45
West	98	84	91	102	90	93	43	36	33	42	34	38
		394	351	316	330	298	203	175	157			

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—United States (cont)

			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	Hawaiian/O	ther Pacific	Islander				
Age at diagnosis (yr	·)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	1	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	1	0	0	0	1	0	0	0	0	0	0	0
40–44	0	0	0	0	1	0	0	0	0	0	0	0
45–49	1	0	1	0	0	0	0	0	0	0	0	0
50–54	0	0	0	0	0	0	0	0	0	0	0	2
55–59	0	0	0	0	1	0	0	0	0	0	1	0
60–64	1	0	0	1	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence	a											
Northeast	0	0	0	1	1	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	1	0	0	0	0	0	0	0
West	3	0	1	0	1	0	0	0	0	0	2	2
Total	3	0	1	1	3	0	0	0	0	0	2	2
		-				W	hite					
Age at diagnosis (yr	.)											
13–14	0	0	0	0	0	0	0	0	0	0	1	0
15–19	2	7	2	3	2	4	6	9	9	11	9	4
20–24	21	31	28	29	- 47	32	34	28	37	37	48	35
25–29	32	38	36	37	82	77	60	50	50	52	86	83
30–34	45	47	48	55	75	65	52	51	57	60	84	71
35–39	42	26	37	47	51	69	47	40	36	45	54	54
40–44	59	46	47	62	52	49	51	46	49	34	65	41
45–49	62	56	60	52	67	50	56	45	48	36	45	42
50–54	58	57	50	55	52	49	54	37	41	27	42	38
55–59	35	24	38	31	34	33	25	29	22	19	24	22
60–64	21	13	17	21	18	16	6	11	12	6	12	13
≥65	10	7	13	11	10	13	6	4	5	5	6	7
。 Region of residence		•	10				Ü		ŭ	ŭ	ŭ	•
Northeast	77	66	64	67	73	84	85	73	73	56	69	75
Midwest	41	45	52	52	139	86	50	45	61	38	131	79
South	135	137	152	153	156	161	169	163	161	162	194	179
West	131	105	107	129	124	127	90	69	72	76	82	78
Total	384	353	375	401	492	458	394	350	367	332	476	411

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—United States (cont)

			M	ale					Fen	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multip	le races					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	1	0	1	3	1	2	1	0
20–24	2	4	0	1	1	2	5	3	3	2	1	2
25–29	7	2	4	8	6	2	5	7	5	2	2	2
30-34	3	3	6	7	4	1	12	6	4	6	8	2
35–39	6	4	2	4	0	4	5	7	4	5	3	6
40-44	5	4	8	2	2	4	5	9	6	5	2	3
45-49	6	5	5	3	2	2	8	10	4	5	3	6
50-54	6	8	8	4	5	5	5	5	6	6	4	4
55–59	11	3	3	4	3	2	5	5	3	2	5	3
60–64	3	5	4	2	1	1	1	2	3	1	2	1
≥65	3	2	2	2	3	1	1	1	1	1	1	0
Region of residence <sup>a</sup>												
Northeast	17	15	9	9	7	6	18	21	12	11	7	6
Midwest	5	5	1	7	6	3	5	6	7	1	5	4
South	22	10	21	10	11	10	25	26	17	18	13	13
West	6	10	10	10	5	5	4	4	5	7	6	6
Total	50	40	41	36	29	24	5 <b>2</b>	57	41	37	31	29
Total		70	71	- 30				- 37	71	- 51	- 31	23
Age at diagnosis (yr)						10	otal					
13–14	0	0	0	0	0	0	1	1	1	0	3	1
15–14	13	20	12	11	9	13	30	32	26	28	19	16
20–24	75	84	82	84	109	84	95	97	86	86	100	75
25–29	126	122	123	122	168	164	144	120	111	112	149	153
30–34	168	166	158	152	181	154	153	145	130	127	144	133
35–39	175	148	135	130	141	170	141	130	93	114	108	114
40–44	235	184	160	168	147	136	160	141	128	113	119	93
45–49	233 278	213	233	178	157	140	210	155	134	109	112	93
50–54	239	213	186	165	170	165	160	149	126	97	106	116
55–59	200	149	168	142	132	119	100	100	96	81	72	75
60–64	91	94	80	81	68	73	38	49	47	35	43	75 44
≥65	67	68	61	64	60	75 65	28	28	25	30	28	27
Region of residence <sup>a</sup>	01	00	01	04	00	00	20	20	20	00	20	21
Northeast	520	460	412	352	337	328	340	328	251	241	216	208
Midwest	162	143	140	121	213	152	153	130	141	99	192	141
South	685	621	571	542	513	509	577	528	461	425	427	415
West	300	265	274	281	280	296	192	160	150	168	169	175
Total	1,666	1,489	1,396	1,297	1,343	1,285	1,262	1,147	1,002	933	1,004	939

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

 $<sup>^{\</sup>mathrm{a}}$  Data are based on residence at time of diagnosis of HIV infection.

<sup>&</sup>lt;sup>b</sup> Hispanics/Latinos can be of any race.

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas

_			Ma	ale					Fer	nale		
<u>-</u>	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Amo	erican India	n/Alaska Na	ative				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	2	2	1	0	3	1	1	1	0	2	1
25–29	2	2	1	2	2	4	2	0	0	1	2	2
30-34	0	1	2	0	2	0	5	4	2	2	2	2
35–39	3	0	1	0	1	1	4	2	0	2	1	2
40–44	0	5	3	3	0	2	0	2	3	2	2	2
45–49	2	0	3	2	0	2	0	3	1	1	2	1
50–54	1	0	1	3	1	0	1	0	2	0	0	4
55–59	2	2	1	0	1	3	1	1	0	0	1	0
60–64	0	0	0	0	0	3 1	0	0	1	1	1	0
60–64 ≥65	0	0	1	0	0	0	0	0	0	0	0	•
	U	U	I	U	U	U	U	U	U	U	U	0
Region of residence <sup>a</sup>												
Northeast	0	1	0	1	0	0	0	0	1	0	0	0
Midwest	0	2	1	1	0	1	5	3	3	2	0	1
South	2	1	4	4	2	4	4	1	2	4	4	1
West	8	10	10	5	5	13	7	8	6	5	9	11
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	10	14	15	11	7	18	16	12	12	11	13	13
						As	ian					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	1	0	0	1	0	0	0	0	0
20–24	0	0	2	0	0	0	1	1	0	0	1	2
25–29	0	1	2	0	0	2	1	3	0	1	0	1
30–34	3	2	3	3	6	2	0	0	1	0	1	1
35–39	4	6	3	5	2	4	2	2	0	2	0	2
40–44	3	5	5	3	3	1	1	0	1	1	1	0
45–49	3	1	2	1	1	3	0	0	2	1	0	1
50–54	1	1	1	2	2	2	1	0	1	1	0	1
55–59	1	1	2	0	1	1	0	0	'	1	0	0
		1			•	•			3	1		
60–64 ≥65	1 0	1 1	1 0	1 1	1 1	1 1	0 0	0 0	0 0	1 0	1 0	0 0
Region of residence <sup>a</sup>	U	ı	U	1	Į.	I	U	U	U	U	U	U
Northeast	7	<b>E</b>	7	6	7	6	2	2	1	n	1	2
	7	5		6	7	6	2	2	1	2		2
Midwest	2	0	2	1	0	1	1	1	1	2	1	0
South	2	4	6	7	3	3	1	1	2	0	2	2
West	4	9	7	4	8	7	3	3	4	3	2	2
U.S. dependent areas	0	0	0	0	1	0	0	0	0	0	0	0
Total	15	18	22	18	19	17	7	7	8	7	6	6

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

<u>.</u>			Ma	ale					Fer	nale		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	an Americaı	า				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	1	0	0	2	0
15–19	9	8	7	6	5	6	15	14	10	9	6	10
20–24	28	35	30	37	35	29	41	46	31	30	25	25
25–29	39	43	43	42	43	46	51	42	32	40	44	36
30–34	54	56	48	41	44	38	52	57	45	36	33	39
35–39	64	53	51	39	41	55	60	56	37	43	33	36
40–44	100	70	52	49	47	48	78	66	48	45	35	32
45–49	131	99	102	70	49	53	108	73	61	50	44	30
50–54	127	122	92	66	70	68	83	89	59	48	45	52
55–59	115	91	88	79	62	55	62	54	59	45	33	39
60–64	54	52	47	46	37	42	23	29	25	19	24	25
<sup>00–04</sup> ≥65	40	40	31	41	32	32	16	20	13	17	15	14
Region of residence	10	10	01		OL.	0L	10	20	10		10	• • • • • • • • • • • • • • • • • • • •
Northeast	231	203	186	162	129	132	151	145	93	103	86	77
Midwest	79	70	63	48	50	49	82	67	59	45	50	49
South	401	349	293	273	239	238	312	293	237	197	169	174
West	49	47	48	30	47	51	45	41	31	37	34	37
U.S. dependent areas	1	1	1	2	0	0	0	0	1	0	0	0
Total	761	670	591	515	465	470	<b>590</b>	546	421	382	339	337
Total	701	070	331	313	403			J40	421	302	333	331
						Hispani	c/Latino <sup>b</sup>					
Age at diagnosis (yr) 13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–14	4	4	3	2	2	4	7	5	5	6	4	3
20–24	31	18	23	20	29	21	15	22	14	18	22	12
25–29	54	43	41	41	38	36	28	20	25	15	14	29
30–34	79	69	58	50	58	49	37	31	23	25	18	20
35–39	73	66	53	43	51	45	32	27	21	22	18	17
40–44	86	72	51	55	48	39	33	20	24	30	16	17
45–49	92	69	74	62	44	36	41	28	24	17	17	15
50–54	64	59	46	41	48	44	19	19	21	18	17	17
55–59	43	34	49	39	39	32	11	14	11	15	8	11
60–64	15	25	15	17	15	17	7	8	8	7	4	6
≥65	14	24	17	12	16	23	5	3	8	7	6	5
Region of residence <sup>a</sup>												
Northeast	187	170	145	108	120	100	83	87	72	69	53	48
Midwest	34	21	20	11	19	11	11	9	11	11	6	8
South	123	119	95	95	101	94	66	43	41	44	46	45
West	98	84	91	102	90	93	43	36	33	42	34	38
U.S. dependent areas	110	89	80	65	58	46	33	23	25	14	6	13
Total	552	483	431	381	388	344	236	198	182	180	145	152

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

<u>-</u>			Ma	ale					Fer	nale		
<u>-</u>	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native	Hawaiian/O	ther Pacific	Islander				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	1	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	1	0	0	0	1	0	0	0	0	0	0	0
40–44	0	0	0	0	1	0	0	0	0	0	0	0
45–49	1	0	1	0	0	0	0	0	0	0	0	0
50-54	0	0	0	0	0	0	0	0	0	0	0	2
55–59	0	0	0	0	1	0	0	0	0	0	1	0
60–64	1	0	0	1	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	0	0	0	1	1	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	1	0	0	0	0	0	0	0
West	3	0	1	0	1	0	0	0	0	0	2	2
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	3	0	1	1	3	0	0	0	0	0	2	2
						W	hite					
Age at diagnosis (yr)						•••						
13–14	0	0	0	0	0	0	0	0	0	0	1	0
15–19	2	7	2	3	2	4	6	9	9	11	9	4
20–24	21	31	28	29	47	32	34	28	37	37	48	35
25–29	32	38	36	37	82	77	60	50	50	52	86	83
30–34	45	47	48	55	75	65	52	51	57	60	84	71
35–39	42	26	37	47	51	69	47	40	36	45	54	54
40–44	59	46	47	62	52	49	51	46	49	34	65	41
45–49	62	56	60	52	67	50	56	45	48	36	45	42
50–54	58	57	50	55	53	49	54	37	41	27	42	38
55–59	35	24	38	31	34	33	25	29	22	19	24	22
60–64	21	13	36 17	21	18	33 16	6	11	12	6	12	13
60–64 ≥65	10	7	13	11	10	13	6	4	5	5	6	7
Region of residence <sup>a</sup>		•	10		10	10	v	•	J	v	J	,
Northeast	77	66	64	67	73	84	85	73	73	56	69	75
Midwest	41	45	52	52	139	86	50	45	61	38	131	79
South	135	137	152	153	156	161	169	163	161	162	194	179
West	131	105	107	129	124	127	90	69	72	76	82	78
U.S. dependent areas	1	0	0	0	0	127	0	09	0	0	0	0
Total	385	353	375	401	492	459	394	350	367	332	476	411

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multipl	e races					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	1	0	1	3	1	2	1	0
20–24	2	4	0	1	1	2	5	3	3	2	1	2
25–29	7	2	4	8	6	2	5	7	5	2	2	2
30-34	3	3	6	7	4	1	12	6	4	6	8	2
35–39	6	4	2	4	0	4	5	7	4	5	3	6
40–44	5	4	8	2	2	4	5	9	6	5	2	3
45-49	6	5	5	3	2	2	8	10	4	5	3	6
50–54	6	8	8	4	5	5	5	5	6	6	4	4
55–59	11	3	3	4	3	2	5	5	3	2	5	3
60–64	3	5	4	2	1	1	1	2	3	1	2	1
≥65	3	2	2	2	3	1	1	1	1	1	1	0
Region of residence <sup>a</sup>												
Northeast	17	15	9	9	7	6	18	21	12	11	7	6
Midwest	5	5	1	7	6	3	5	6	7	1	5	4
South	22	10	21	10	11	10	25	26	17	18	13	13
West	6	10	10	10	5	5	4	4	5	7	6	6
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	50	40	41	36	29	24	52	57	41	37	31	29
						To	otal					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	1	1	0	3	1
15–19	15	21	12	12	10	15	30	32	26	29	19	17
20–24	81	90	85	88	111	88	97	101	86	87	100	76
25–29	133	130	127	130	171	165	148	121	113	112	149	154
30–34	184	178	165	156	189	156	158	148	132	130	145	135
35–39	192	155	146	137	148	178	148	133	99	118	110	116
40–44	253	201	167	173	154	144	168	143	130	116	120	94
45–49	297	230	247	190	164	146	213	159	139	110	112	95
50–54	257	248	198	171	179	168	162	151	129	98	107	117
55–59	207	156	181	152	141	126	104	102	97	82	72	76
60–64	93	96	84	87	72	77	38	51	49	35	44	45
≥65	67	74	65	67	62	70	28	28	27	31	28	27
Region of residence <sup>a</sup>	•			•	-	. •				•		
Northeast	520	460	412	352	337	328	340	328	251	241	216	208
Midwest	162	143	140	121	213	152	153	130	141	99	192	141
South	685	621	571	542	513	509	577	528	461	425	427	415
West	300	265	274	281	280	296	192	160	150	168	169	175
U.S. dependent areas	112	90	82	67	60	48	33	23	25	14	6	13
S.S. dopondont drods	114	50	02	01	00	70	00	20	20	17	U	10

 $<sup>^{\</sup>mbox{\scriptsize a}}$  Data are based on residence at time of diagnosis of HIV infection.

<sup>&</sup>lt;sup>b</sup> Hispanics/Latinos can be of any race.

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United States

			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Am	erican India	n/Alaska Na	ative				
Age at diagnosis (	yr)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	1	0	0	0	0	2	0	1	3	2	0
20–24	2	1	1	0	1	0	1	3	3	1	2	1
25–29	0	0	2	0	0	0	2	2	1	7	7	5
30–34	1	2	3	3	1	1	4	6	2	2	8	3
35–39	1	0	1	1	1	1	2	3	4	2	5	6
40–44	3	0	0	1	0	2	3	4	2	2	6	8
45–49	0	4	4	3	3	1	4	4	2	1	3	3
50–54	1	0	1	0	2	0	2	1	6	5	4	1
55–59	0	1	0	1	1	0	3	1	1	3	4	2
60–64	0	2	0	0	0	0	0	3	0	0	0	2
≥65	0	0	0	0	0	2	0	1	2	0	1	1
Region of residen	ce <sup>a</sup>											
Northeast	0	1	3	2	2	0	0	2	0	0	1	3
Midwest	0	2	5	1	1	1	1	7	5	3	8	1
South	1	2	1	0	2	2	7	6	6	8	18	10
West	8	7	3	6	4	5	14	12	11	13	13	18
Total	9	12	12	9	9	8	22	27	22	24	40	32
	-						ian					
Age at diagnosis (	vr)					As	nan					
13–14	0	0	0	0	0	0	0	0	1	0	0	1
15–19	0	0	0	1	0	0	6	6	2	1	3	0
20–24	0	0	1	1	0	4	7	10	8	10	13	11
25–29	2	3	7	7	6	3	23	24	20	20	19	18
30–34	6	7	6	13	3	10	13	20	22	20	21	30
35–39	8	7	5	8	19	11	19	22	24	23	18	25
40–44	10	9	9	6	9	6	12	14	15	18	16	16
45–49	7	6	10	6	7	7	7	7	11	9	9	11
43–49 50–54	5	7	5	7	5		9	7			7	
	3	, 1	5 4	2	5 4	5 3		4	6 7	8 8	4	8 9
55 <b>–</b> 59	l -	'	•	_		-	5	·	•	-	•	·
60–64	5	5	2	1	0	4	6	7	2	5	7	3
≥65	4	2	1	6	4	4	2	0	3	1	5	3
Region of residen												
Northeast	7	12	10	15	10	10	19	20	21	22	19	35
Midwest	8	7	6	10	8	10	20	8	19	13	16	12
South	16	13	16	15	23	22	30	33	37	37	45	44
West	18	14	18	16	18	14	39	56	44	52	41	46
Total	49	46	50	56	59	56	108	117	121	124	121	137

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United States (cont)

-												
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	an Americar	1				
Age at diagnosis (yr)												
13–14	0	0	1	1	1	0	7	13	6	5	8	6
15–19	34	36	35	29	34	33	258	213	189	186	144	146
20–24	151	166	141	158	161	145	616	491	463	476	473	414
25–29	198	175	194	197	249	232	605	604	565	565	531	583
30–34	236	234	217	209	207	216	634	648	566	541	530	573
35–39	277	233	223	211	215	216	609	552	518	553	543	565
40–44	355	305	234	256	248	215	555	549	489	476	437	440
45–49	395	350	296	251	244	223	586	564	497	436	404	439
50–54	341	295	267	252	255	221	466	442	424	366	394	390
55–59	206	212	200	193	208	179	297	309	323	326	298	319
60–64	136	123	126	114	122	128	182	173	143	152	180	188
≥65	120	127	126	126	104	117	116	109	122	126	132	126
Region of residence <sup>a</sup>	0		0	0								0
Northeast	487	469	415	420	365	326	867	864	694	761	705	710
Midwest	204	197	215	172	187	189	558	564	537	485	498	508
South	1,680	1,528	1,338	1,311	1,398	1,315	3,248	2,984	2,845	2,714	2,612	2,658
West	78	63	91	94	98	96	258	254	231	248	260	313
Total	2,449	2,257	2,059	1,997	2,048	1,926	4,931	4,666	4,307	4,208	4,075	4,189
Total	2,443	2,231	2,000	1,337	2,040	-		4,000	4,301	4,200	4,073	7,103
						Hispani	c/Latino <sup>b</sup>					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	5	0	2	1	0	2
15–19	9	6	7	3	6	5	58	45	43	45	36	26
20–24	36	41	37	39	32	50	132	108	91	124	120	96
25–29	74	53	79	62	53	63	145	144	150	136	137	132
30–34	111	99	113	97	85	81	177	136	138	162	137	159
35–39	114	81	98	105	97	77	152	137	133	161	149	128
40–44	100	91	83	101	81	82	146	130	126	126	127	124
45–49	85	79	74	86	74	82	143	123	122	116	111	107
50–54	63	65	60	71	63	52	100	88	115	93	110	99
55–59	41	42	53	43	44	38	64	64	62	77	62	72
60–64	30	26	22	22	25	25	40	35	39	40	37	42
≥65	30	29	21	21	36	24	30	44	29	29	28	38
Region of residence <sup>a</sup>												
Northeast	217	190	176	172	159	149	419	362	353	347	316	338
Midwest	51	37	39	35	39	36	86	62	63	69	49	52
South	337	291	324	335	307	297	471	398	407	424	463	432
West	87	94	107	107	90	99	213	232	227	271	224	203
Total	692	612	646	649	595	581	1,189	1,054	1,050	1,111	1,052	1,025

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United States (cont)

			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	-lawaiian/O	ther Pacific	slander				
Age at diagnosis (y	r)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	1	1	0
20–24	0	0	0	0	0	0	0	0	4	1	2	1
25–29	0	0	0	0	1	0	1	1	0	0	0	0
30–34	0	0	0	0	0	0	0	3	1	1	1	2
35–39	1	0	0	0	2	1	1	1	0	1	0	2
40–44	0	0	0	1	0	0	1	0	1	1	1	0
45–49	0	0	0	0	1	1	2	0	1	0	0	0
50–54	0	0	0	0	1	0	0	1	3	1	1	2
55–59	0	0	0	0	1	0	2	0	0	1	1	0
60–64	0	0	0	0	0	0	0	0	1	1	0	0
≥65	0	1	0	0	0	0	0	0	0	0	0	0
Region of residence	e <sup>a</sup>											
Northeast	0	0	0	1	0	0	0	1	0	1	0	0
Midwest	0	0	0	0	0	1	0	0	0	0	2	0
South	0	0	0	0	1	2	1	1	5	1	2	2
West	1	2	0	0	4	0	6	4	6	6	3	5
Total	1	2	0	1	5	3	7	6	11	8	7	7
						W	hite					
Age at diagnosis (y	r)											
13–14	0	0	0	0	0	0	3	2	3	3	0	0
15–19	2	2	3	3	3	3	40	34	20	30	23	32
20–24	- 17	19	13	16	13	29	105	113	106	119	99	106
25–29	38	41	38	40	41	36	130	124	108	127	127	146
30–34	28	36	31	42	38	38	127	112	116	134	124	143
35–39	33	38	47	29	37	42	121	104	111	120	107	122
40–44	66	70	75	57	50	44	142	142	96	112	106	104
45–49	71	70	64	61	61	45	125	118	111	105	116	109
50–54	66	63	56	74	39	74	108	99	93	110	111	106
55–59	48	42	54	41	47	50	55	69	71	82	90	88
60–64	40	26	32	29	35	28	38	30	53	30	32	55
≥65	39	30	43	38	44	35	19	22	26	15	27	23
Region of residence					• •							_3
Northeast	109	89	90	93	74	74	148	141	146	148	132	148
Midwest	64	70	64	55	52	45	183	163	154	156	163	165
South	214	201	221	202	221	235	536	498	459	513	519	519
West	60	77	81	80	60	70	147	168	154	171	148	200
Total	447	437	456	430	407	424	1,014	970	913	988	962	1,032

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United States (cont)

			M	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multip	le races					
Age at diagnosis (	yr)											
13–14	0	0	0	0	0	0	0	1	0	0	0	1
15–19	1	2	2	1	0	0	18	14	15	10	7	6
20–24	8	7	8	4	9	4	31	35	27	27	13	16
25–29	8	9	11	7	10	6	25	23	28	24	19	12
30–34	11	9	11	8	8	2	31	31	27	25	25	19
35–39	10	16	9	16	8	6	26	24	27	23	21	17
40–44	19	16	14	9	3	5	31	28	19	29	8	9
45–49	14	11	14	17	4	6	31	25	24	16	16	17
50-54	12	8	11	4	7	3	22	15	18	14	16	9
55–59	8	8	8	9	5	4	17	16	15	9	12	6
60-64	3	7	7	2	1	3	8	11	10	9	5	3
≥65	5	2	5	4	8	1	8	8	7	4	3	7
Region of residence	ce <sup>a</sup>											
Northeast	39	35	37	26	17	15	73	67	64	45	42	25
Midwest	7	13	8	8	7	5	27	27	33	22	15	26
South	48	38	47	35	31	17	129	120	104	105	75	61
West	3	10	7	12	7	3	19	18	16	17	14	8
Total	97	96	99	81	62	40	248	232	217	189	146	120
						To	otal					
Age at diagnosis (	yr)											
13–14	0	0	1	1	1	0	14	16	12	8	8	10
15–19	47	47	48	36	43	42	381	311	269	276	216	210
20-24	214	235	201	218	217	232	892	759	702	757	720	645
25-29	319	280	330	313	360	340	930	923	872	878	839	895
30-34	393	386	381	373	342	348	987	954	871	884	847	929
35-39	444	376	383	371	379	355	929	844	815	884	842	865
40-44	553	492	415	429	391	355	889	867	749	765	700	700
45–49	571	519	462	424	394	364	897	841	769	684	658	685
50-54	489	439	399	408	373	354	707	652	664	598	642	616
55-59	303	307	319	288	309	274	442	463	479	505	471	495
60-64	213	188	188	168	183	188	272	258	247	238	262	292
≥65	198	192	196	195	196	184	176	183	189	174	196	198
Region of residence	c <b>e</b> <sup>a</sup>											
Northeast	859	797	731	729	627	574	1,527	1,457	1,278	1,324	1,214	1,258
Midwest	334	326	337	280	295	288	875	831	811	749	751	764
South	2,296	2,072	1,946	1,899	1,984	1,888	4,420	4,039	3,863	3,803	3,734	3,727
West	255	267	307	315	282	287	695	744	688	777	703	792
Total	3,745	3,461	3,323	3,223	3,187	3,037	7,517	7,071	6,640	6,653	6,401	6,541

 $<sup>\</sup>overset{\textbf{a}}{\underset{\cdot}{\text{}}}$  Data are based on residence at time of diagnosis of HIV infection.

b Hispanics/Latinos can be of any race.

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6 dependent areas

_			Ma	ale					Fer	nale		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Am	erican India	n/Alaska Na	ative				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	1	0	0	0	0	2	0	1	3	2	0
20–24	2	1	1	0	1	0	1	3	3	1	2	1
25–29	0	0	2	0	0	0	2	2	1	7	7	5
30–34	1	2	3	3	1	1	4	6	2	2	8	3
35–39	1	0	1	1	1	1	2	3	4	2	5	6
40–44	3	0	0	1	0	2	3	4	2	2	6	8
45–49	0	4	4	3	3	1	4	4	2	1	3	3
50–54	1	0	1	0	2	0	2	1	6	5	4	1
55–59	0	1	0	1	1	0	3	1	1	3	4	2
55–59 60–64	0	1	0	0	-		0	3	0			2
	•	2			0	0				0	0	
≥65	0	0	0	0	0	2	0	1	2	0	1	1
Region of residence <sup>a</sup>	•			•	•		•	•	•	•		
Northeast	0	1	3	2	2	0	0	2	0	0	1	3
Midwest	0	2	5	1	1	1	1	7	5	3	8	1
South	1	2	1	0	2	2	7	6	6	8	18	10
West	8	7	3	6	4	5	14	12	11	13	13	18
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	9	12	12	9	9	8	22	27	22	24	40	32
						As	ian					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	1	0	0	1
15–19	0	0	0	1	0	0	6	6	2	1	3	0
20–24	0	0	1	1	0	4	7	10	8	10	13	11
25–29	2	3	7	7	6	3	23	24	20	20	19	18
30–34	6	7	6	13	3	10	14	20	22	20	21	30
35–39	8	7	5	8	19	11	19	22	24	23	18	25
40–44	10	9	9	6	9	6	12	14	15	18	16	16
45–49	7	6	10	6	7	7	7	7	11	9	9	11
50–54	5	7	5	7	5	5	9	7	6	8	7	8
55–59	1	•		2	4	3	5		7	8	=	
		1	4	1				4 7			4	9
60–64 ≥65	5 4	5 2	2 1	6	0 4	4 4	6 2	0	2 3	5 1	7 5	3
	7	۷	1	J	7	7	۷.	U	3	1	3	3
Region of residence <sup>a</sup> Northeast	7	12	10	15	10	10	19	20	21	22	19	35
Midwest	8	7	6	10	8	10	20	8	19	13	16	12
South	16	13	16	15	23	22	30	33	37	37	45	44
West	18	14	18	16	18	14	39	56	44	52	41	46
U.S. dependent areas	0	0	0	0	0	0	1	0	0	0	0	0
Total	49	46	50	56	59	56	109	117	121	124	121	137

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

<u>-</u>			M	ale					Fer	nale		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	an Americar	า				
Age at diagnosis (yr)												
13–14	0	0	1	1	1	0	7	13	6	5	8	6
15–19	34	36	35	29	34	33	258	213	189	186	144	146
20–24	152	166	141	158	161	145	616	491	464	476	473	414
25–29	198	175	195	197	249	232	605	604	566	565	533	583
30–34	236	234	217	209	207	216	634	649	566	542	530	573
35–39	278	233	223	211	215	216	612	552	518	554	543	565
40–44	355	305	234	256	248	215	556	550	489	476	437	440
45-49	395	350	296	251	244	224	587	564	499	437	404	439
50-54	341	295	269	255	255	221	466	442	424	367	394	390
55–59	206	212	200	193	208	179	297	309	325	327	298	319
60–64	138	123	127	115	122	128	182	173	144	152	180	188
≥65	120	127	126	127	104	117	116	109	123	126	134	126
Region of residence <sup>a</sup>												
Northeast	487	469	415	420	365	326	867	864	694	761	705	710
Midwest	204	197	215	172	187	189	558	564	537	485	498	508
South	1,680	1,528	1,338	1,311	1,398	1,315	3,248	2,984	2,845	2,714	2,612	2,658
West	78	63	91	94	98	96	258	254	231	248	260	313
U.S. dependent areas	5	1	4	5	0	2	5	2	7	5	4	0
Total	2,454	2,258	2,063	2,002	2,048	1,928	4,936	4,668	4,314	4,213	4,079	4,189
						Hispani	c/Latino <sup>b</sup>					
Age at diagnosis (yr)						mopani	5/ <b>L</b> utill 10					
13–14	0	0	0	0	0	0	5	1	3	1	0	2
15–19	10	7	9	3	6	5	65	50	46	53	39	29
20–24	41	45	44	46	39	52	145	122	103	134	129	100
25–29	88	61	85	73	59	73	162	157	159	143	146	138
30–34	122	113	122	105	96	89	198	152	150	176	143	167
35–39	122	94	108	113	105	85	163	157	149	180	158	143
40–44	123	114	91	113	87	95	173	152	140	147	140	137
45–49	111	103	96	98	89	100	169	150	142	131	126	122
50–54	87	84	75	84	77	65	121	110	137	104	120	109
55–59			62			47	76	75	77	88	74	87
	55 40	53		56 36	50							
60–64 >65	40 38	32 44	32 34	36 29	28 46	34 35	45 41	43 60	44 33	44 34	38 35	49 40
≥65	30	44	34	29	40	ან	41	υU	აა	3 <del>4</del>	33	40
Region of residence <sup>a</sup>	047	100	176	170	150	140	440	260	252	247	246	220
Northeast	217	190	176	172	159	149	419	362	353	347	316	338
Midwest	51	37	39	35	39	36	86	62	63	69	49	52
South	337	291	324	335	307	297	471	398	407	424	463	432
West	87	94	107	107	90	99	213	232	227	271	224	203
U.S. dependent areas	144	136	112	106	86	99	172	175	132	124	97	96
Total	836	748	758	755	681	680	1,361	1,229	1,182	1,235	1,149	1,121

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

_	2011	2012										
		2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	Hawaiian/Ot	ther Pacific I	slander				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	1	1	0
20–24	0	0	0	0	0	0	0	0	4	1	2	1
25–29	0	0	0	0	1	0	1	1	0	0	0	0
30–34	0	0	0	0	0	0	0	3	1	1	1	2
35–39	1	0	0	0	2	1	1	1	0	1	0	2
40–44	0	0	0	1	0	0	1	0	1	1	1	0
45–49	0	0	0	0	1	1	2	0	1	0	0	0
50–54	0	0	0	0	2	0	0	1	3	1	1	2
55–59	0	0	0	0	1	0	2	0	0	1	1	0
60–64	0	0	0	0	0	0	0	0	1	1	0	0
≥65	0	1	0	0	0	0	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	0	0	0	1	0	0	0	1	0	1	0	0
Midwest	0	0	0	0	0	1	0	0	0	0	2	0
South	0	0	0	0	1	2	1	1	5	1	2	2
West	1	2	0	0	4	0	6	4	6	6	3	5
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
•												
Total	1	2	0	1	5	3	7	6	11	8	7	7
						W	hite					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	3	2	3	3	0	0
15–19	2	2	3	3	3	3	40	34	20	30	23	32
20–24	17	19	13	16	13	29	105	113	106	119	99	107
25–29	38	41	38	40	41	36	130	124	108	127	127	146
30–34	28	36	31	42	38	38	127	112	116	134	124	143
35–39	33	38	47	29	37	42	121	104	111	120	107	122
40–44	67	70	75	57	50	44	142	142	96	112	106	104
45–49	71	70	64	61	61	45	125	118	111	105	116	109
50–54	66	63	56	74	39	74	108	99	93	110	111	106
55–59	48	42	54	41	47	50	55	69	71	82	90	88
60–64	40	26	32	29	35	28	38	30	54	30	32	55
≥65	39	30	43	38	44	35	19	22	26	16	27	23
Region of residence <sup>a</sup>												
Northeast	109	89	90	93	74	74	148	141	146	148	132	148
Midwest	64	70	64	55	52	45	183	163	154	156	163	165
South	214	201	221	202	221	235	536	498	459	513	519	519
West	60	77	81	80	60	70	147	168	154	171	148	200
U.S. dependent areas	1	0	0	0	0	0	0	0	1	1	0	1
Total	448	437	456	430	407	424	1,014	970	914	989	962	1,033

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

<u>-</u>			Ma	ale					Fer	nale		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multip	le races					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	1	0	0	0	1
15–19	1	2	2	1	0	0	18	14	15	10	7	6
20-24	8	7	8	4	9	4	31	35	27	27	14	16
25-29	8	9	11	7	10	6	25	23	28	24	19	12
30-34	11	9	11	8	8	2	31	31	27	25	25	19
35-39	10	16	9	16	8	6	27	24	27	23	21	17
40-44	19	16	14	9	3	5	31	28	19	29	8	9
45-49	14	11	14	17	4	6	31	25	24	16	16	17
50-54	12	8	11	4	7	3	22	15	18	14	16	9
55–59	8	8	8	9	5	4	17	16	15	9	12	6
60–64	3	7	7	2	1	3	8	11	10	9	5	3
≥65	5	2	5	4	8	1	8	8	7	4	3	7
Region of residence <sup>a</sup>												
Northeast	39	35	37	26	17	15	73	67	64	45	42	25
Midwest	7	13	8	8	7	5	27	27	33	22	15	26
South	48	38	47	35	31	17	129	120	104	105	75	61
West	3	10	7	12	7	3	19	18	16	17	14	8
U.S. dependent areas	0	0	0	0	0	0	1	0	0	0	1	0
Total	97	96	99	81	62	40	249	232	217	189	147	120
						To	otal					
Age at diagnosis (yr)												
13–14	0	0	1	1	1	0	14	17	13	8	8	10
15–19	48	48	50	36	43	42	388	316	272	284	219	213
20–24	220	239	209	225	224	234	905	773	714	767	730	650
25–29	333	289	337	323	367	350	947	936	882	885	850	901
30–34	404	400	390	381	353	356	1,009	972	883	899	853	937
35–39	453	388	393	378	388	363	944	864	831	904	851	880
40–44	577	515	422	442	397	368	918	890	763	786	713	713
45–49	598	543	484	436	409	384	924	867	791	700	673	700
50–54	513	457	416	424	388	367	728	674	686	610	655	626
55–59	318	318	328	302	314	284	454	474	496	517	483	510
60–64	224	194	199	182	187	197	278	266	254	242	263	299
≥65	206	206	210	204	206	194	187	199	194	180	205	200
Region of residence <sup>a</sup>												
Northeast	859	797	731	729	627	574	1,527	1,457	1,278	1,324	1,214	1,258
Midwest	334	326	337	280	295	288	875	831	811	749	751	764
South	2,296	2,072	1,946	1,899	1,984	1,888	4,420	4,039	3,863	3,803	3,734	3,727
West	255	267	307	315	282	287	695	744	688	777	703	792
U.S. dependent areas	150	137	117	111	87	101	178	177	140	130	101	97
Total	3,894	3,598	3,439									

 $<sup>^{\</sup>mathrm{a}}$  Data are based on residence at time of diagnosis of HIV infection.

<sup>&</sup>lt;sup>b</sup> Hispanics/Latinos can be of any race.

Table 8a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States

	2011 No.	2012	2013								00:-	
	Ne		2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	NO.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Am	erican India	n/Alaska N	ative				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	1	0	0	0	0	0	1	0
20–24	3	3	3	3	6	3	1	2	1	0	2	3
25–29	4	6	5	5	5	12	1	2	0	0	1	2
30–34	8	14	9	8	6	11	1	2	2	1	0	0
35–39	9	2	3	5	5	9	0	1	0	0	0	1
40–44	9	9	10	9	4	8	3	1	0	0	0	1
45–49	6	3	3	6	3	6	2	1	0	2	1	0
50–54	2	6	7	6	4	3	2	0	1	2	0	0
55–59	1	1	0	2	2	3	1	0	2	0	0	0
60–64	2	0	0	0	0	1	0	0	0	0	0	0
<sup>00–04</sup> ≥65	0	1	1	1	1	2	0	0	0	0	0	0
Region of residence <sup>a</sup>	Ü	'		•	•	_	Ū	Ü	v	v	v	v
Northeast	2	3	1	1	0	3	0	0	1	0	0	0
Midwest	3	2	3	4	3	8	2	1	0	2	0	1
South	10	14	9	9	15	16	0	1	0	1	2	2
West	30	26	29	30	18	30	10	9	5	3	4	4
Total	45	45	42	44	36	57	12	11	6	6	6	7
Total	43	45	42	44	30			11	0	0		
						As	ian <sup>b</sup>					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	2	1	0	2	2	0	0	0	0	0	0
20–24	11	9	21	16	14	18	0	1	0	0	0	0
25–29	33	30	34	26	36	46	1	2	1	3	0	0
30–34	35	31	39	32	32	38	1	0	1	0	1	1
35–39	46	45	32	39	25	24	4	2	1	2	0	0
40–44	42	41	51	37	41	37	1	4	4	6	2	0
45–49	26	39	35	39	28	29	2	0	0	0	1	0
50–54	12	20	20	13	30	19	0	1	0	0	1	1
55–59	9	11	8	4	12	11	0	0	0	0	0	0
60–64	6	6	4	3	1	3	0	1	0	0	0	0
≥65	3	4	4	5	3	6	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	33	35	35	40	46	38	0	1	2	0	1	0
Midwest	22	16	23	25	29	23	0	1	2	3	3	0
South	52	49	51	48	32	56	1	2	1	1	0	0
West	114	138	139	101	118	115	8	6	2	7	3	2
Total	221	238	248	214	225	232	9	10	7	11	7	2

Table 8a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States (cont)

		Ma	ale-to-male	sexual cont	act		M	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ı	use
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	an America	n				
Age at diagnosis (y	/r)											
13–14	3	3	2	1	0	0	0	0	0	0	0	0
15–19	163	148	155	85	84	88	2	4	2	3	1	2
20–24	896	852	924	593	560	537	27	20	22	13	10	9
25-29	866	924	997	855	861	950	35	28	33	21	27	21
30-34	708	742	704	580	625	617	37	47	30	26	18	30
35–39	523	527	495	413	413	439	44	35	29	14	26	26
40–44	586	564	475	383	347	335	45	40	40	26	24	21
45–49	550	528	482	370	358	316	66	69	49	34	31	27
50–54	389	350	372	292	307	300	54	61	41	28	29	29
55–59	198	212	197	187	163	181	47	22	37	28	18	19
60–64	66	95	104	91	75	95	14	17	17	12	15	24
≥65	61	66	61	59	70	64	7	6	4	7	9	8
Region of residence							•	-	•	•		-
Northeast	683	637	655	486	471	466	58	59	39	24	28	24
Midwest	788	784	798	624	582	642	54	54	50	36	31	32
South	3,144	3,167	3,143	2,487	2,520	2,485	229	193	179	121	129	133
West	394	423	372	310	290	329	39	42	35	31	19	27
Total	5,009	5,011	4,968	3,907	3,863	3,922	380	348	303	212	207	216
10141	0,000	0,011	4,300	0,501	0,000	· · · · · · · · · · · · · · · · · · ·		040		LIL	201	210
						Hispanio	c/Latino <sup>c</sup>					
Age at diagnosis (y	-	•		•	•		•		•	•	•	•
13–14	1	0	1	0	0	1	0	1	0	0	0	0
15–19	46	42	51	17	15	19	3	2	3	0	1	1
20–24	298	350	293	234	213	219	26	20	13	9	9	12
25–29	536	519	516	428	414	460	37	22	29	24	32	16
30–34	484	579	520	453	447	472	54	39	34	33	28	26
35–39	517	432	492	432	407	428	44	43	42	20	26	30
40–44	488	428	424	334	317	292	41	43	29	21	22	23
45–49	398	390	391	320	295	278	37	44	29	17	26	19
50-54	234	216	239	183	206	226	22	28	25	14	17	20
55–59	114	120	112	104	111	111	15	8	9	12	12	4
60–64	55	60	51	54	50	55	4	5	5	7	5	4
≥65	51	39	46	41	34	50	2	1	3	3	2	1
Region of residence												
Northeast	663	615	624	498	493	446	94	70	46	30	30	28
Midwest	243	237	231	200	200	191	16	18	19	11	12	10
South	1,243	1,192	1,217	1,017	1,016	1,115	71	73	79	58	63	58
West	1,073	1,132	1,064	885	800	861	102	94	77	60	74	61
Total	3,222	3,176	3,136	2,600	2,509	2,613	283	255	221	159	179	157

Table 8a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States (cont)

		Ma	ale-to-male	sexual cont	act		M	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ι	use
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	Hawaiian/Ot	her Pacific	Islander				
Age at diagnosis (	yr)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	4	2	0	0	3	1	1	0	0	0	1	0
25-29	4	3	5	0	3	1	0	0	0	0	0	1
30-34	3	3	2	3	1	2	0	0	0	1	0	0
35–39	3	3	2	3	2	4	0	0	0	0	0	0
40–44	3	1	2	1	1	0	0	0	0	0	0	0
45–49	2	3	2	2	3	0	0	1	0	0	0	0
50–54	1	3	2	1	4	0	0	0	0	0	0	0
55–59	1	1	0	0	0	0	0	0	0	0	0	0
60–64	0	1	0	1	0	0	0	0	0	0	0	0
≥65	1	0	0	0	0	0	0	0	0	0	0	0
Region of residence												
Northeast	2	1	0	0	2	0	0	0	0	0	0	1
Midwest	0	2	0	1	0	0	0	0	0	0	0	0
South	1	2	0	2	3	0	0	0	0	0	0	0
West	19	14	15	8	12	8	1	1	0	1	1	0
Total	22	19	15	11	17	8	1	1	0	1	1	1
10101				•••	···		nite	•		•	<u> </u>	-
Age at diagnosis (	vr)					VVI	iite					
13–14	۰۰ <i>ر</i> 1	0	0	0	0	0	0	0	0	0	0	0
15–19	29	22	18	6	12	10	1	1	0	1	2	1
20–24	177	160	177	113	107	91	19	17	15	18	12	13
25–29	318	368	334	264	276	249	45	40	36	30	28	28
30–34	449	462	401	337	328	317	66	61	53	37	46	44
35–39	473	418	425	330	318	288	70	63	49	36	51	45
40–44	763	619	585	400	351	324	70 77	82	61	52	44	39
45–49	851	734	663	561	466	437	85	104	66	58	42	45
50–54	597	631	620	519	536	504	53	57	57	57	51	54
											32	28
55–59	362	339	381	315	312	334	28	32	33	25		
60–64 ≥65	186 134	213 160	226 167	182 166	171 166	198 158	15 6	10 10	18 9	11 5	17 7	14 5
		100	107	100	100	130	U	10	9	3	1	3
Region of residence		F00	E40	40.4	400	200	47		0.4	07	00	04
Northeast	607	590	512	424	422	398	47	56	31	37	32	31
Midwest	782	768	739	597	586	540	67	56	66	49	51	48
South	1,789	1,706	1,736	1,381	1,281	1,254	144	180	157	121	124	111
West	1,161	1,061	1,009	790	755	718	207	184	143	123	125	124
Total	4,339	4,125	3,996	3,192	3,044	2,910	465	476	397	330	332	314

Table 8a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States (cont)

		Ma	ale-to-male	sexual cont	act		N	lale-to-male	sexual cont	act <i>and</i> inje	ction drug	use
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multipl	e races					
Age at diagnosis (	yr)											
13–14	1	1	0	0	0	0	0	0	0	0	0	0
15–19	16	4	23	4	2	4	0	0	2	0	1	2
20–24	76	77	103	50	43	26	10	7	4	2	3	4
25–29	92	97	84	80	77	61	10	4	6	9	7	4
30-34	82	95	76	53	40	55	14	12	9	9	8	10
35–39	66	69	81	49	52	40	13	10	10	7	3	6
40-44	97	78	59	57	37	26	17	12	9	7	7	7
45-49	82	71	69	55	42	38	18	20	13	9	7	4
50-54	60	51	40	47	37	42	11	9	8	9	9	8
55-59	31	39	31	29	22	26	11	5	6	8	5	4
60-64	18	12	17	10	13	9	1	2	3	3	4	5
≥65	14	7	11	12	8	7	1	1	3	1	1	0
Region of residence	ce <sup>a</sup>											
Northeast	105	147	119	78	93	83	25	17	11	11	9	10
Midwest	115	72	83	71	53	39	12	8	7	9	8	10
South	309	288	282	218	162	145	45	36	32	23	19	21
West	107	92	109	79	65	66	25	21	20	20	19	12
Total	636	599	593	446	373	333	107	82	70	63	55	53
						To	otal					
Age at diagnosis (	yr)											
13–14	6	3	2	1	0	1	0	1	0	0	0	0
15–19	254	218	248	112	116	123	7	8	6	4	6	6
20-24	1,464	1,452	1,521	1,008	946	895	84	67	54	43	38	40
25-29	1,853	1,947	1,975	1,658	1,672	1,779	129	98	104	87	95	72
30-34	1,770	1,926	1,750	1,466	1,480	1,512	174	160	128	107	101	110
35–39	1,636	1,496	1,530	1,270	1,222	1,233	174	154	131	79	105	108
40-44	1,988	1,741	1,606	1,220	1,098	1,021	184	181	144	112	98	90
45-49	1,915	1,768	1,645	1,353	1,194	1,104	209	239	158	120	108	95
50-54	1,295	1,275	1,300	1,060	1,122	1,094	143	156	133	109	107	111
55-59	716	722	729	641	623	665	102	66	86	73	67	55
60-64	333	387	401	341	310	360	33	35	43	33	41	48
≥65	263	276	289	284	283	287	16	18	19	15	19	15
Region of residence	ce <sup>a</sup>											
Northeast	2,095	2,028	1,946	1,528	1,526	1,435	224	204	130	102	99	95
Midwest	1,953	1,881	1,877	1,522	1,453	1,443	151	139	144	110	105	101
South	6,546	6,418	6,438	5,161	5,031	5,070	489	485	449	326	337	326
West	2,899	2,886	2,737	2,203	2,057	2,127	391	357	282	244	245	229
Total	13,493	13,212	12,997	10,413	10,067	10,075	1,256	1,185	1,006	782	786	751

 $<sup>^{\</sup>mbox{\scriptsize a}}$  Data are based on residence at time of stage 3 (AIDS) classification.

 $<sup>^{\</sup>mbox{\scriptsize b}}$  Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

Table 8b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas

_		IVI	ale-to-male	sexual cont	acı		IVI	ale-to-male	sexual cont	act and mje	ction arug t	ıse
<u>-</u>	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Am	erican India	n/Alaska Na	ative				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	1	0	0	0	0	0	1	0
20–24	3	3	3	3	6	3	1	2	1	0	2	3
25–29	4	6	5	5	5	12	1	2	0	0	1	2
30–34	8	14	9	8	6	11	1	2	2	1	0	0
35–39	9	2	3	5	5	9	0	1	0	0	0	1
40–44	9	9	10	9	4	8	3	1	0	0	0	1
45–49	6	3	3	6	3	6	2	1	0	2	1	0
50–54	2	6	7	6	4	3	2	0	1	2	0	0
55–59	1	1	0	2	2	3	1	0	2	0	0	0
60–64	2	0	0	0	0	3 1	0	0	0	0	0	0
≥65	0	1	1	1	1	2	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	2	3	1	1	0	3	0	0	1	0	0	0
Midwest	3	2	3	4	3	8	2	1	0	2	0	1
South	10	14	9	9	15	16	0	1	0	1	2	2
West	30	26	29	30	18	30	10	9	5	3	4	4
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	45	45	42	44	36	57	12	11	6	6	6	7
						Asi	i <b>an</b> <sup>b</sup>					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	2	1	0	2	2	0	0	0	0	0	0
20–24	11	9	21	16	14	- 18	0	1	0	0	0	0
25–29	33	30	34	26	37	46	1	2	1	3	0	0
30–34	35	31	39	32	32	38	1	0	1	0	1	1
35–39	47	45	32	39	25	24	4	2	1	2	0	0
40–44	42	41	52 51	37	41	37	1	4	4	6	2	0
45–49	26	39	35	39	28	29	2	0	0	0	1	0
								1	0		1	1
50–54	12	20	20	14	30	19	0	'	-	0	ļ	1
55–59	9	11	8	4	12	11	0	0	0	0	0	0
60–64	6	6	4	3	1	3	0	1	0	0	0	0
≥65	3	4	4	5	3	6	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	33	35	35	40	46	38	0	1	2	0	1	0
Midwest	22	16	23	25	29	23	0	1	2	3	3	0
South	52	49	51	48	32	56	1	2	1	1	0	0
West	114	138	139	101	118	115	8	6	2	7	3	2
U.S. dependent areas	1	0	0	1	1	0	0	0	0	0	0	0
Total	222	238	248	215	226	232	9	10	7	11	7	2

Table 8b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

-		Ma	ale-to-male	sexual cont	act		Ma	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ι	use
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	an Americai	1				
Age at diagnosis (yr)												
13–14	3	3	2	1	0	0	0	0	0	0	0	0
15–19	163	148	155	85	84	88	2	4	2	3	1	2
20–24	896	852	924	593	561	537	27	20	22	13	10	9
25–29	866	925	997	855	861	950	35	28	33	21	27	21
30-34	708	742	704	580	625	617	37	47	30	26	18	30
35–39	523	528	495	413	414	439	44	35	29	14	26	26
40-44	586	565	475	384	347	335	45	40	40	26	24	21
45-49	550	528	482	371	359	316	66	69	49	34	31	27
50-54	390	350	372	292	307	300	54	61	41	28	29	29
55-59	199	212	197	187	163	181	47	22	37	28	18	19
60–64	66	95	104	91	75	95	14	17	17	12	15	24
≥65	61	66	61	59	70	64	7	6	4	7	9	8
Region of residence <sup>a</sup>												
Northeast	683	637	655	486	471	466	58	59	39	24	28	24
Midwest	788	784	798	624	582	642	54	54	50	36	31	32
South	3,144	3,167	3,143	2,487	2,520	2,485	229	193	179	121	129	133
West	394	423	372	310	290	329	39	42	35	31	19	27
U.S. dependent areas	1	3	0	1	3	0	0	0	0	0	0	0
Total	5,010	5,014	4,968	3,908	3,866	3,922	380	348	303	212	207	216
						Hisnanio	c/Latino <sup>c</sup>					
Age at diagnosis (yr)						mopuni	o, Lutino					
13–14	2	0	1	0	0	1	0	1	0	0	0	0
15–19	47	42	52	19	15	22	4	2	3	0	1	1
20–24	307	361	309	249	221	227	26	20	14	9	9	12
25–29	549	539	534	438	429	467	39	24	29	24	32	16
30–34	496	589	544	467	457	483	57	40	36	33	29	27
35–39	537	443	507	443	418	446	48	50	45	22	26	32
40–44	503	447	445	346	329	299	45	46	32	25	24	30
45–49	420	410	404	333	304	288	40	47	30	19	26	21
50–54	245	228	256	190	214	235	26	29	27	16	23	22
55–59	122	126	115	107	117	115	16	10	9	12	15	7
60–64	57	62	58	61	52	57	5	5	5	7	5	5
≥65	55	43	50	44	36	51	2	3	3	3	3	1
Region of residence <sup>a</sup>							-	-	•	Ź	,	•
Northeast	663	615	624	498	493	446	94	70	46	30	30	28
Midwest	243	237	231	200	200	191	16	18	19	11	12	10
South	1,243	1,192	1,217	1,017	1,016	1,115	71	73	79	58	63	58
West	1,073	1,132	1,064	885	800	861	102	94	77	60	74	61
U.S. dependent areas	117	114	137	96	82	79	23	21	12	9	13	18
			3,273			2,692	306	276	233		192	175
Total	3,339	3,290	3,213	2,696	2,591	2,092	300	2/0	233	168	192	1/3

Table 8b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

_		Ma	ale-to-male	sexual cont	act		Ma	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ι	ıse
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	Hawaiian/Ot	her Pacific	Islander				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	4	2	0	0	3	2	1	0	0	0	1	0
25–29	4	3	5	0	4	1	0	0	0	0	0	1
30–34	3	4	2	3	1	4	0	0	0	1	0	0
35–39	3	3	2	3	2	4	0	0	0	0	0	0
40–44	3	1	2	1	1	0	0	0	0	0	0	0
45-49	2	3	2	2	3	0	0	1	0	0	0	0
50-54	1	3	2	1	4	0	0	0	0	0	0	0
55–59	1	1	0	0	0	1	0	0	0	0	0	0
60–64	0	1	0	1	0	0	0	0	0	0	0	0
≥65	1	0	0	0	0	0	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	2	1	0	0	2	0	0	0	0	0	0	1
Midwest	0	2	0	1	0	0	0	0	0	0	0	0
South	1	2	0	2	3	0	0	0	0	0	0	0
West	19	14	15	8	12	8	1	1	0	1	1	0
U.S. dependent areas	0	1	0	0	2	4	0	0	0	0	0	0
Total	22	20	15	11	19	12	1	1	0	1	1	1
						Wi	nite					
Age at diagnosis (yr)												
13–14	1	0	0	0	0	0	0	0	0	0	0	0
15–19	29	22	18	6	12	10	1	1	0	1	2	1
20–24	177	160	177	113	107	91	19	17	15	18	12	13
25–29	318	368	334	264	276	249	45	40	36	30	28	28
30–34	449	462	401	337	328	317	66	61	53	37	46	44
35–39	473	418	425	330	318	288	70	63	49	36	51	45
40–44	763	620	585	400	351	324	77	82	61	52	44	39
45–49	851	734	663	561	466	437	85	104	66	58	42	45
50–54	597	631	620	519	537	504	53	57	57	57	51	54
55–59	362	339	381	316	312	334	28	32	33	25	32	28
60–64	186	214	226	182	171	198	15	10	18	11	17	14
≥65	134	160	167	166	166	158	6	10	9	5	7	5
Region of residence <sup>a</sup>	-		-				-	-	-	-		-
Northeast	607	590	512	424	422	398	47	56	31	37	32	31
Midwest	782	768	739	597	586	540	67	56	66	49	51	48
South	1,789	1,706	1,736	1,381	1,281	1,254	144	180	157	121	124	111
West	1,161	1,061	1,009	790	755	718	207	184	143	123	125	124
U.S. dependent areas	0	2	0	1	1	0	0	0	0	0	0	0
Total	4,339	4,127	3,996	3,193	3,045	2,910	465	476	397	330	332	314
ıvlaı	4,339	4,121	3,330	3,133	3,043	۷,5۱۷	400	410	331	<b>330</b>	JJZ	314

Table 8b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

		Ma	ale-to-male	sexual conta	act		Ma	ale-to-male	sexual cont	act <i>and</i> inje	ction drug ι	ıse
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multipl	e races					
Age at diagnosis (yr)												
13–14	1	1	0	0	0	0	0	0	0	0	0	0
15–19	16	4	23	4	2	4	0	0	2	0	1	2
20–24	76	77	103	50	43	26	10	7	4	2	3	4
25–29	92	97	84	80	77	61	10	4	6	9	7	4
30–34	82	95	76	53	40	55	14	12	9	9	8	10
35–39	66	69	81	49	52	40	13	10	10	7	3	6
40–44	97	78	59	57	37	26	17	12	9	7	7	7
45–49	82	71	69	55	42	38	18	20	13	9	7	4
50–54	60	51	40	47	37	42	11	9	8	9	9	8
55–59	31	39	31	29	22	26	11	5	6	8	5	4
60–64	18	12	17	10	13	9	1	2	3	3	4	5
≥65	14	7	11	12	8	7	1	1	3	1	1	0
Region of residence <sup>a</sup>												
Northeast	105	147	119	78	93	83	25	17	11	11	9	10
Midwest	115	72	83	71	53	39	12	8	7	9	8	10
South	309	288	282	218	162	145	45	36	32	23	19	21
West	107	92	109	79	65	66	25	21	20	20	19	12
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	636	599	593	446	373	333	107	82	70	63	55	53
						То	tal					
Age at diagnosis (yr)												
13–14	7	3	2	1	0	1	0	1	0	0	0	0
15–19	255	218	249	114	116	126	8	8	6	4	6	6
20–24	1,473	1,463	1,537	1,023	955	904	84	67	55	43	38	40
25–29	1,866	1,968	1,993	1,668	1,689	1,787	131	100	104	87	95	72
30–34	1,782	1,937	1,774	1,479	1,490	1,525	177	161	130	107	102	111
35–39	1,656	1,508	1,544	1,281	1,233	1,251	178	161	134	81	106	110
40–44	2,003	1,761	1,626	1,233	1,110	1,028	188	184	147	115	100	97
45–49	1,937	1,789	1,658	1,367	1,204	1,113	212	242	159	122	108	96
50–54	1,306	1,287	1,317	1,068	1,132	1,103	147	157	135	111	113	113
55–59	725	727	732	645	629	669	103	68	86	73	70	58
60–64	335	390	407	348	312	362	34	35	43	33	41	49
≥65	267	280	293	287	285	288	16	20	19	15	20	15
Region of residence <sup>a</sup>												
Northeast	2,095	2,028	1,946	1,528	1,526	1,435	224	204	130	102	99	95
Midwest	1,953	1,881	1,877	1,522	1,453	1,443	151	139	144	110	105	101
South	6,546	6,418	6,438	5,161	5,031	5,070	489	485	449	326	337	326
West	2,899	2,886	2,737	2,203	2,057	2,127	391	357	282	244	245	229
U.S. dependent areas	119	120	138	100	89	83	23	21	12	9	13	18
Total	13,612	13,332	13,134	10,513	10,155	10,157	1,279	1,206	1,018	7 <b>9</b> 1	800	769
		nary (subject t							-			109

 $<sup>^{\</sup>mathrm{a}}$  Data are based on residence at time of stage 3 (AIDS) classification.

b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

Table 9a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States

<u>-</u>			Ma	ale					Fer	nale		
<del>-</del>	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Am	erican India	n/Alaska Na	ative				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	1	0	0	0	0	1
25–29	0	2	0	2	0	0	0	0	1	0	1	1
30–34	1	1	1	1	2	0	2	2	1	1	1	1
35–39	2	0	0	0	0	0	3	2	1	3	2	1
40–44	0	0	0	4	1	1	0	0	0	2	1	1
45–49	3	1	2	1	0	3	1	1	1	0	1	1
50–54	1	1	1	2	2	0	1	0	1	1	2	0
55–59	2	1	0	1	1	1	1	4	0	0	1	2
60–64	0	0	0	0	0	0	1	0	1	1	0	0
≥65	0	0	1	0	0	0	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	0	0	0	0	0	1	0	1	0	0	0	0
Midwest	0	2	0	1	0	0	4	3	0	0	2	1
South	3	1	2	4	0	1	1	3	2	3	5	1
West	6	4	3	6	5	5	6	3	4	5	4	6
Total	9	7	5	11	5	7	11	10	6	8	11	8
						Δς	ian <sup>b</sup>					
Age at diagnosis (yr)						AS	ıuı ı					
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	1	0	2	0	0	0	0	0
25–29	1	0	0	0	0	1	0	0	0	0	0	0
30–34	3	2	2	1	4	2	0	0	0	0	0	1
35–39	1	5	1	2	3	1	1	2	0	1	0	1
40–44	4	4	1	2	1	1	1	1	1	0	0	0
45–49	2	2	1	0	1	2	1	0	0	1	0	0
50–54	1	1	0	1	1	1	0	0	1	1	0	0
55–59	0	1	2	0	1	1	0	0	0	1	1	0
60–64	0	0	1	0	1	1	0	0	0	0	1	0
≥65	0	0	0	1	1	1	0	0	0	0	0	0
Region of residence <sup>a</sup>	•	ŭ	J	•	•	•	ŭ	ŭ	•	•	ŭ	v
Northeast	4	3	3	3	5	4	1	3	0	0	1	1
Midwest	2	0	0	0	1	2	0	0	0	0	0	1
South	3	5	3	5	2	2	0	0	1	0	1	1
West	5	7	3	1	8	4	4	1	2	2	1	1
				•			•	•			•	4
Total	14	15	9	9	16	12	5	4	3	2	3	4

Table 9a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States (cont)

			Ma	ale					Fen	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	an Americai	า				
Age at diagnosis (y	r)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	3	2	1	0	1	4	3	1	2	1	1
20–24	7	12	8	5	4	4	17	14	7	9	9	6
25-29	23	25	21	12	20	12	39	27	25	17	17	13
30-34	41	38	38	22	19	20	54	49	37	24	27	25
35-39	57	56	42	46	28	42	79	68	59	37	34	41
40-44	99	91	55	49	38	38	106	97	64	65	39	42
45-49	139	118	118	80	60	47	145	110	83	74	54	45
50–54	169	169	141	87	91	67	121	114	89	80	55	50
55–59	135	141	109	90	84	76	85	75	80	57	43	49
60–64	67	71	71	64	62	58	29	37	35	20	34	34
≥65	40	55	50	51	40	41	20	25	21	20	15	20
Region of residence	e <sup>a</sup>											
Northeast	238	217	197	139	124	117	190	162	112	113	93	70
Midwest	74	82	68	39	51	41	81	79	69	60	29	46
South	423	440	351	302	251	220	383	338	293	212	179	187
West	42	38	39	26	21	27	46	38	27	21	27	23
Total	777	777	655	506	447	405	700	617	501	406	328	326
						Hispani	c/Latino <sup>c</sup>					
Age at diagnosis (y	r)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	2	0	0	0
20–24	10	4	8	2	6	5	3	4	5	5	6	3
25-29	33	19	13	16	13	17	14	12	10	13	8	3
30–34	38	43	34	25	29	25	26	17	20	14	13	12
35–39	46	45	36	44	36	31	22	24	18	19	17	23
40–44	75	48	47	41	37	30	35	30	28	19	18	13
45–49	79	80	70	45	38	32	35	35	29	24	25	20
50–54	67	70	49	51	39	31	38	26	24	25	18	19
55–59	49	40	37	43	29	33	21	17	15	17	9	9
60–64	21	30	25	15	16	20	8	12	12	6	8	5
≥65	17	16	13	14	15	25	5	3	9	3	8	6
Region of residence												
Northeast	225	193	170	132	111	108	113	90	96	71	71	51
Midwest	30	20	16	13	18	10	10	12	6	7	6	7
South	104	115	82	84	71	78	58	47	47	39	40	32
West	75	66	64	67	60	52	27	31	23	27	15	23
Total		394	332									
TOTAL	434	394	3 <b>3</b> Z	296	260	248	208	180	172	144	132	113

Table 9a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States (cont)

			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	Hawaiian/O	ther Pacific	Islander				
Age at diagnosis (yr	·)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	0	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	1	0	0	0	0	1	1	0	0	0	0	0
40-44	0	0	0	0	0	0	0	0	0	0	0	0
45-49	0	0	1	0	0	0	0	0	0	0	0	0
50–54	0	0	0	0	0	0	0	0	0	0	0	0
55–59	0	0	0	0	0	0	0	0	0	0	1	0
60–64	0	0	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence	а											
Northeast	0	0	0	0	0	1	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	0	0	0
West	1	0	1	0	0	0	1	0	0	0	1	0
Total	1	0	1	0	0	1	1	0	0	0	1	0
						W	hite					
Age at diagnosis (yr	.)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	1	0	0	0	1	0	0	2	0
20–24	7	9	2	7	7	5	8	2	3	12	6	4
25–29	13	17	8	11	18	20	23	20	15	22	22	23
30–34	20	18	26	21	19	21	38	30	31	14	27	38
35–39	48	21	25	31	16	20	29	42	32	27	39	36
40–44	49	43	35	46	36	35	48	45	45	38	40	34
45–49	73	61	59	54	47	39	59	55	55	37	39	32
50–54	71	64	60	44	50	40	44	50	52	38	36	31
55–59	37	32	45	39	24	33	22	29	24	22	29	19
60–64	20	16	20	17	19	17	6	16	16	14	9	12
≥65	7	7	13	16	9	11	7	4	6	5	7	6
Region of residence			-	-	-				-	-		-
Northeast	79	47	60	48	45	48	65	72	54	43	42	41
Midwest	37	38	25	34	30	28	38	34	39	21	39	36
South	127	117	123	114	101	97	123	132	133	108	114	115
West	102	85	85	90	67	67	58	54	52	55	61	44
Total	345	287	293	286	243	240	284	292	278	227	256	236

Table 9a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States (cont)

			Ma	ale					Fen	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multip	le races					
Age at diagnosis (y	r)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	1	1	0	0	0
20–24	1	1	0	1	0	0	2	2	2	1	0	0
25-29	8	2	0	2	4	2	5	7	4	4	3	3
30–34	5	6	3	5	1	1	8	7	7	4	11	7
35–39	8	3	2	4	1	3	7	10	8	5	4	3
40–44	5	7	11	2	2	3	11	13	12	6	9	2
45–49	9	15	7	6	9	4	19	16	8	9	7	8
50–54	18	14	13	9	7	9	14	9	9	10	11	10
55–59	15	13	4	14	6	5	6	5	9	4	7	7
60–64	2	10	6	4	4	6	2	2	4	4	4	2
≥65	4	5	7	4	5	8	2	2	2	3	1	0
		J	,	7	0	O		_	_	J	'	O
Region of residence		27	47	20	4.4	20	20	07	0.4	04	10	17
Northeast	24	37	17	20	14	20	32	27	24	21	12	17
Midwest	9	6	2	5	3	3	6	11	2	4	8	6
South	32	24	26	17	18	14	34	26	34	17	27	16
West	12	9	8	8	5	2	6	10	6	8	10	4
Total	77	76	53	50	40	39	78	74	66	50	57	43
						Te	otal					
Age at diagnosis (y	r)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	3	2	2	0	2	5	5	3	3	3	1
20–24	26	27	19	16	18	14	33	21	16	27	21	14
25-29	78	64	43	43	55	53	81	66	55	56	52	43
30-34	108	108	104	75	75	70	128	105	95	57	80	83
35-39	163	130	106	127	85	98	141	148	118	91	96	105
40-44	232	193	149	144	115	107	201	186	151	131	108	92
45-49	304	276	258	186	155	126	260	216	177	146	126	106
50-54	327	319	265	194	190	149	219	198	175	154	123	110
55-59	238	227	196	187	144	148	135	129	127	101	91	87
60-64	111	127	122	100	102	101	46	66	67	45	57	53
≥65	67	83	83	85	70	86	35	34	38	31	32	33
Region of residence	e <sup>a</sup>											
Northeast	569	498	446	342	298	299	400	354	285	248	217	180
Midwest	152	148	111	92	102	85	139	138	116	93	85	97
South	692	702	588	526	443	412	598	547	509	381	366	351
West	243	209	203	200	166	157	148	136	113	118	118	100
Total	1,657	1,557	1,348	1,159	1,010	952	1,285	1,176	1,023	840	786	728

<sup>&</sup>lt;sup>a</sup> Data are based on residence at time of stage 3 (AIDS) classification.

b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

Table 9b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas

			Ma	ale					Fer	nale		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Am	erican India	n/Alaska N	ative				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20-24	0	0	0	0	0	0	1	0	0	0	0	1
25-29	0	2	0	2	0	0	0	0	1	0	1	1
30–34	1	1	1	1	2	0	2	2	1	1	1	1
35–39	2	0	0	0	0	0	3	2	1	3	2	1
40–44	0	0	0	4	1	1	0	0	0	2	1	1
45-49	3	1	2	1	0	3	1	1	1	0	1	1
50-54	1	1	1	2	2	0	1	0	1	1	2	0
55–59	2	1	0	1	1	1	1	4	0	0	1	2
60-64	0	0	0	0	0	0	1	0	1	1	0	0
≥65	0	0	1	0	0	0	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	0	0	0	0	0	1	0	1	0	0	0	0
Midwest	0	2	0	1	0	0	4	3	0	0	2	1
South	3	1	2	4	0	1	1	3	2	3	5	1
West	6	4	3	6	5	5	6	3	4	5	4	6
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	9	7	5	11	5	7	11	10	6	8	11	8
Total	- 3	,	<u> </u>	- ''	J			10			- ''	- 0
						Asi	an <sup>b</sup>					
Age at diagnosis (yr)	•	0	^	0	0	0	0	^	•	•	0	•
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	1	0	2	0	0	0	0	0
25–29	1	0	0	0	0	1	0	0	0	0	0	0
30–34	3	2	2	1	4	2	0	0	0	0	0	1
35–39	1	5	1	2	3	2	1	2	0	1	0	1
40–44	4	4	1	2	1	1	1	1	1	0	0	0
45–49	2	2	1	0	1	2	1	0	0	1	0	0
50–54	1	1	0	1	1	1	0	0	1	1	0	0
55–59	0	1	2	0	1	1	0	0	0	1	1	0
60–64	0	0	1	0	1	1	0	0	0	0	1	0
≥65	0	0	0	1	1	1	0	0	0	0	0	0
Region of residence <sup>a</sup>												
Northeast	4	3	3	3	5	4	1	3	0	0	1	1
Midwest	2	0	0	0	1	2	0	0	0	0	0	1
South	3	5	3	5	2	2	0	0	1	0	1	1
West	5	7	3	1	8	4	4	1	2	2	1	1
U.S. dependent areas	0	0	0	0	0	1	0	0	0	0	0	0
Total	14	15	9	9	16	13	5	4	3	2	3	4

Table 9b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

_			Ma	ale					Fer	nale		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	an Americar	1				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	3	2	1	0	1	4	3	1	2	1	1
20–24	7	12	8	5	4	4	17	14	7	9	9	6
25-29	23	25	21	12	20	12	39	27	25	17	18	13
30-34	41	38	38	22	19	20	54	49	37	24	27	25
35–39	57	56	42	46	29	42	79	68	59	37	34	41
40–44	99	91	55	49	38	38	106	97	64	65	39	42
45–49	139	118	118	80	60	47	145	110	83	74	54	45
50–54	169	169	141	87	91	67	121	114	89	80	55	50
55–59	135	141	109	90	84	76	85	75	81	57	43	50
60–64	67	71	71	65	62	58	29	37	35	20	34	34
≥65	40	56	50	51	40	41	20	25	21	20	15	20
	40	00	00	01	40	71	20	20	21	20	10	20
Region of residence <sup>a</sup>	000	047	107	120	104	447	100	100	110	112	02	70
Northeast	238	217	197	139	124	117	190	162	112	113	93	70
Midwest	74	82	68	39	51	41	81	79	69	60	29	46
South	423	440	351	302	251	220	383	338	293	212	179	187
West	42	38	39	26	21	27	46	38	27	21	27	23
U.S. dependent areas	1	1	0	1	1	0	0	0	0	0	0	0
Total	778	778	655	507	448	405	700	617	501	406	328	326
						Hispani	c/Latino <sup>c</sup>					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	1	0	0	2	0	0	0
20-24	12	5	11	2	6	6	3	4	5	5	6	3
25-29	38	21	17	17	14	18	15	12	12	14	8	3
30-34	48	53	42	28	34	28	31	20	20	21	14	13
35-39	63	58	47	59	43	33	27	27	22	22	20	25
40-44	90	66	54	49	42	34	39	33	29	24	18	13
45-49	105	98	83	59	47	39	38	42	42	28	26	23
50-54	82	84	62	64	48	40	44	29	28	29	19	19
55–59	56	52	49	54	36	38	22	20	18	21	9	11
60–64	22	30	28	17	19	23	8	14	13	6	9	5
≥65	21	22	15	15	16	28	6	3	9	3	9	7
Region of residence <sup>a</sup>												
Northeast	225	193	170	132	111	108	113	90	96	71	71	51
Midwest	30	20	16	13	18	10	10	12	6	7	6	7
South	104	115	82	84	71	78	58	47	47	39	40	32
West	75	66	64	67	60	52	27	31	23	27	15	23
U.S. dependent areas	102	94	76	68	45	40	26	24	28	28	8	8
Total	536	488	408	364	<b>305</b>	288	234	204	200	172	140	121
Total	JJ0	400	400	504	303	200	234	204	200	1/2	140	121

Table 9b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

_			Ma	ale					Fer	nale		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	Hawaiian/O	ther Pacific	Islander				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25-29	0	0	0	0	0	0	0	0	0	0	0	0
30-34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	1	0	0	0	0	1	1	0	0	0	0	0
40–44	0	0	0	0	0	0	0	0	0	0	0	0
45–49	0	0	1	0	0	0	0	0	0	0	0	0
50–54	0	0	0	0	0	0	0	0	0	0	0	0
55–59	0	0	0	0	0	0	0	0	0	0	1	0
60–64	0	0	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
	U	U	U	U	U	U	U	U	U	U	U	U
Region of residence <sup>a</sup>	•	•	•	•	•	4	•	•	•	•	^	•
Northeast	0	0	0	0	0	1	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	0	0	0
West	1	0	1	0	0	0	1	0	0	0	1	0
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	1	0	1	0	0	1	1	0	0	0	1	0
						W	hite					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	1	0	0	0	1	0	0	2	0
20–24	7	9	2	7	7	5	8	2	3	12	6	4
25-29	13	17	8	11	18	20	23	20	15	22	22	23
30-34	20	18	26	21	19	21	38	30	31	14	27	38
35–39	48	21	25	31	16	20	29	42	32	27	39	36
40-44	49	43	35	46	36	35	48	45	45	38	40	34
45–49	73	61	59	54	47	39	59	55	55	37	39	32
50–54	71	64	60	44	50	40	44	50	52	38	36	31
55–59	37	32	45	39	24	33	22	29	24	22	29	19
60–64	20	16	20	17	19	17	6	16	16	14	9	12
≥65	7	7	13	16	9	11	7	4	6	5	7	6
Region of residence <sup>a</sup>												
Northeast	79	47	60	48	45	48	65	72	54	43	42	41
Midwest	37	38	25	34	30	28	38	34	39	21	39	36
South	127	117	123	114	101	97	123	132	133	108	114	115
West	102	85	85	90	67	67	58	54	52	55	61	44
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	345	287	293	286	243	240	284	<b>292</b>	278	227	256	236
IUIAI	343	201	233	200	243	240	204	ZJZ	210	221	230	230

Table 9b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

			Ma	ale					Fen	nale		
-	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
-	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multip	le races					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	1	1	0	0	0
20–24	1	1	0	1	0	0	2	2	2	1	0	0
25–29	8	2	0	2	4	2	5	7	4	4	3	3
30-34	5	6	3	5	1	1	8	7	7	4	11	7
35-39	8	3	2	4	1	3	7	10	8	5	4	3
40-44	5	7	11	2	2	3	11	13	12	6	9	2
45-49	9	15	7	6	9	4	19	16	8	9	7	8
50-54	18	14	13	9	7	9	14	9	9	10	11	10
55–59	15	13	4	14	6	5	6	5	9	4	7	7
60–64	2	10	6	4	4	6	2	2	4	4	4	2
≥65	4	5	7	4	5	8	2	2	2	3	1	0
Region of residence <sup>a</sup>												
Northeast	24	37	17	20	14	20	32	27	24	21	12	17
Midwest	9	6	2	5	3	3	6	11	2	4	8	6
South	32	24	26	17	18	14	34	26	34	17	27	16
West	12	9	8	8	5	2	6	10	6	8	10	4
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	77	76	53	50	40	39	78	74	66	50	57	43
							otal				-	
Age at diagnosis (yr)						• •						
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	3	2	2	0	2	5	5	3	3	3	1
20–24	28	28	22	16	18	15	33	21	16	27	21	14
25–29	83	66	47	44	56	53	82	66	57	57	52	43
30–34	118	118	112	78	79	73	133	108	95	64	81	84
35–39	180	143	117	142	92	102	146	151	122	94	99	107
40–44	247	210	156	152	120	111	205	189	152	136	108	92
45–49	331	295	271	200	164	132	263	223	190	150	127	110
50–54	342	333	278	208	199	158	225	201	179	158	124	110
55–59	245	239	208	198	151	154	136	132	130	105	91	89
60–64	112	127	125	103	105	105	46	68	68	45	58	53
≥65	71	90	85	87	71	89	36	34	38	31	33	33
Region of residence <sup>a</sup>												
Northeast	569	498	446	342	298	299	400	354	285	248	217	180
Midwest	152	148	111	92	102	85	139	138	116	93	85	97
South	692	702	588	526	443	412	598	547	509	381	366	351
		209	203	200	166	157	148	136	113	118	118	100
West	/4.5										110	
West U.S. dependent areas	243 103	209 95	76	70	46	41	26	24	28	29	8	8

 $<sup>^{</sup>m a}$  Data are based on residence at time of stage 3 (AIDS) classification.

 $<sup>^{\</sup>mbox{\scriptsize b}}$  Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

Table 10a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States

_			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
_	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Am	erican India	n/Alaska Na	ative				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	0	1	0	0	0	0	0
20–24	1	0	0	0	0	0	0	1	0	0	2	0
25–29	0	0	1	0	1	0	2	0	2	1	6	1
30–34	1	1	2	1	2	1	4	3	3	2	3	2
35–39	0	0	3	0	0	1	3	2	0	1	4	5
40–44	1	0	0	1	0	1	2	1	1	2	3	4
45–49	0	1	3	0	1	1	0	2	1	0	3	1
50-54	1	0	0	0	1	0	3	0	4	4	4	1
55–59	0	2	0	1	0	0	1	2	2	1	4	2
60–64	1	1	1	0	0	0	0	2	0	2	1	0
≥65	1	0	0	0	0	1	0	1	3	0	0	0
Region of residence <sup>a</sup>												
Northeast	0	1	1	1	0	0	0	1	0	1	0	1
Midwest	1	1	6	0	0	1	4	2	4	2	6	6
South	2	0	1	0	1	1	3	1	4	2	17	3
West	4	4	4	2	5	4	8	8	6	8	5	6
Total	7	6	12	3	6	6	15	12	14	13	28	16
						Δεί	ian <sup>b</sup>					
Age at diagnosis (yr)						ASI	iaii					
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	1	2	1	0	0	0
20–24	0	0	0	0	0	0	2	3	0	5	2	2
25–29	0	0	4	2	2	1	10	6	5	8	4	3
30–34	3	3	3	5	2	2	6	8	6	5	7	9
35–39	5	2	5	5	4	7	12	12	14	12	6	18
40–44	8	7	5	6	5	2	9	12	9	5	8	8
45–49	8	4	4	5	2	4	5	5	5	7	8	4
50–54	2	7	5	5	2	4	6	4	1	3	1	3
55–59	1	2	2	2	1	3	5	0	2	6	5	6
60–64	4	6	2	0	0	1	3	4	2	2	4	3
≥65	5	0	0	2	2	2	1	0	3	1	3	2
Region of residence <sup>a</sup>	Ü	v	v	-	-	-	·	v	ŭ	•	ŭ	_
Northeast	6	12	6	3	5	5	10	11	11	7	6	16
Midwest	8	7	2	8	6	5	7	8	9	7	9	8
South	6	6	8	10	4	10	16	11	11	17	14	13
West	14	7	13	10	5	5	24	24	16	24	17	19
Total	34	32	29	31	20	25	57	54	47	55	46	56

Table 10a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States (cont)

			M	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	an Americai	1				
Age at diagnosis (	yr)											
13–14	1	0	0	1	0	0	1	1	0	1	2	0
15–19	4	7	8	3	3	6	54	41	37	19	20	16
20–24	37	47	48	33	30	37	197	154	157	106	107	105
25-29	83	89	102	75	64	86	317	306	302	239	241	207
30-34	164	150	152	122	113	116	493	479	391	337	325	269
35–39	215	198	168	155	129	141	507	499	423	372	349	349
40–44	293	279	229	182	190	169	493	508	451	373	335	321
45–49	375	334	260	219	196	179	511	468	464	352	335	276
50–54	278	277	237	223	179	187	352	372	344	294	263	250
55–59	188	168	174	160	176	156	229	249	251	211	189	188
60–64	113	108	120	89	90	106	138	148	129	132	121	127
≥65	115	114	109	107	92	111	103	95	88	105	113	93
Region of residence												
Northeast	362	324	296	262	244	217	603	576	500	430	386	307
Midwest	164	159	157	112	112	129	362	325	287	291	227	257
South	1,277	1,233	1,097	950	850	891	2,275	2,264	2,131	1,707	1,660	1,520
West	63	53	57	44	54	56	155	156	119	113	125	119
Total	1,866	1,769	1,607	1,368	1,260	1,293	3,395	3,321	3,037	2,541	2,398	2,203
	-,,	-,	-,	-,	-,			-,	-,		_,-,	
Ana at diampasia (						Hispani	c/Latino <sup>c</sup>					
Age at diagnosis ( 13-14	<b>yr)</b> 0	0	0	0	0	0	1	0	0	1	0	1
15–14	0	1	0	0	0	0	9	2	8	7	2	5
20–24	9	11	16	8	10	16	35	33	36	15	22	28
25–29	51	27	42	40	27	30	87	67	58	46	50	50
30–34	71	72	86	48	64	46	108	91	93	79	65	70
35–39	79	72	77	64	47	55	100	99	102	97	86	81
40–44	73	74	69	63	59	51	131	103	102	86	79	71
45–49	73 74	74 77	71	64	60	66	124	99	93	77	79 74	63
50–54	74 56	58	64	48	56	47	69	79	93 89	54	68	71
	40	44	41	46 37		33	42	79 56	37	5 <del>4</del> 50	37	55
55–59 60, 64		22			32 19	20						22
60–64 ≥65	23 26	22 26	21 28	23 22	22	20	28 29	38 33	33 29	26 17	29 18	38
		20	20	22	22	20	23	33	23	17	10	30
Region of residen		400	450	404	407	404	004	000	055	404	470	0.10
Northeast	165	169	152	131	107	101	304	269	255	194	170	212
Midwest	40	32	27	19	30	25	41	42	36	32	26	32
South	238	219	255	202	205	202	310	278	276	229	233	213
West	60	63	80	64	54	55	117	111	110	100	100	99
Total	503	483	514	416	396	383	772	700	677	555	529	556

Table 10a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States (cont)

			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	Hawaiian/O	ther Pacific	Islander				
Age at diagnosis (	(yr)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	1	0	0	0
25–29	0	0	0	0	0	0	1	0	0	0	0	0
30–34	0	0	0	0	0	0	0	1	0	1	1	1
35–39	1	0	0	0	1	1	1	0	0	0	1	1
40–44	0	0	0	2	0	0	0	0	0	0	0	0
45–49	0	0	0	0	1	1	1	1	2	0	0	0
50–54	0	0	0	0	1	0	0	1	2	0	0	1
55–59	0	0	0	0	0	0	1	0	0	1	0	0
60–64	0	0	0	0	0	0	0	0	0	1	0	0
≥65	0	0	1	0	0	0	0	0	0	0	0	0
Region of residen												
Northeast	0	0	0	0	0	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	1	0	0	0	0	1	0
South	0	0	0	1	0	1	0	0	3	1	0	0
West	1	1	1	1	3	0	4	3	2	2	1	3
Total	1	1	1	2	3	2	4	3	5	3	2	3
							hite					
Age at diagnosis (	(vr)											
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	3	5	2	2	0	2
20–24	5	6	4	3	1	3	20	13	21	16	14	20
25–29	14	14	14	14	17	13	49	39	41	41	37	37
30–34	12	21	18	15	15	20	89	79	58	57	53	45
35–39	34	23	30	19	18	14	93	77	68	69	59	70
40–44	46	44	47	35	23	31	92	101	80	74	59	59
45–49	60	48	44	41	41	29	87	96	90	66	73	64
50–54	48	59	45	52	37	48	63	71	75	68	84	64
55–59	33	30	40	32	33	28	45	64	59	60	58	61
60–64	34	22	26	26	27	25	33	29	44	15	28	31
<sup>00–04</sup> ≥65	35	20	31	25	26	28	12	14	16	23	26	25
=oo Region of residen			•									23
Northeast	79	65	63	64	49	42	94	99	86	71	58	68
Midwest	56	49	35	34	34	31	101	100	90	84	80	79
							316					253
South	139 46	133	148 51	115 47	117	128		299	293	265 71	276 76	
West		42	51		38	37	76 	90	86	71	76	79
Total	320	289	297	260	238	238	587	588	555	491	490	479

Table 10a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States (cont)

			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multipl	le races					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	2	4	5	1	0	0
20–24	3	3	4	1	2	2	15	13	28	9	8	6
25-29	2	8	4	3	6	2	26	25	16	13	14	13
30-34	2	7	10	8	7	2	28	38	19	19	15	16
35-39	14	15	8	8	4	5	31	30	34	32	22	15
40-44	14	13	9	13	6	4	34	28	33	26	21	16
45-49	19	12	16	17	12	9	24	30	27	22	20	23
50-54	17	12	14	6	11	8	22	13	22	18	12	16
55–59	14	9	11	12	7	3	21	12	22	6	9	7
60–64	2	5	5	2	2	5	9	6	12	11	6	7
≥65	5	2	9	5	9	4	9	7	8	8	4	5
Region of residence <sup>a</sup>		_	·	·	•	·	·	•		·	·	
Northeast	41	28	29	24	24	8	75	51	59	44	34	30
Midwest	6	13	8	11	4	6	73 24	26	15	21	13	15
South	41	44	50	36	32	25	103	107	136	89	72	64
West		2	4		52 5	25 4	103	20	17	10	11	13
	4			6								
Total	92	87	91	77	65	43	219	204	227	164	130	122
						To	otal					
Age at diagnosis (yr)												
13–14	1	0	0	1	0	0	1	1	0	2	2	1
15–19	5	9	9	3	3	6	69	53	54	28	21	23
20–24	56	67	72	45	43	58	268	218	242	151	155	161
25–29	149	138	167	134	117	131	491	443	423	347	352	312
30–34	252	255	272	198	203	188	728	698	569	500	468	413
35–39	349	310	290	250	204	224	756	719	641	584	527	538
40–44	436	416	358	302	283	258	760	752	673	565	504	479
45-49	535	477	398	346	312	289	752	701	681	523	512	430
50-54	401	412	365	334	286	294	515	539	538	441	431	405
55-59	276	255	268	244	250	223	343	382	372	335	302	319
60-64	176	164	174	140	138	156	211	226	221	189	187	191
≥65	186	162	178	161	150	164	154	150	146	154	164	162
Region of residence												
Northeast	653	599	548	485	430	373	1,085	1,007	911	746	655	634
Midwest	274	261	234	184	187	199	539	503	439	437	362	396
South	1,703	1,635	1,559	1,315	1,208	1,259	3,024	2,960	2,855	2,309	2,273	2,066
West	192	171	209	174	163	161	401	412	355	328	336	338
		2,666	2,550	2,157	1,989	1,992	5,049	4,882	4,560	3,820		3,434

<sup>&</sup>lt;sup>a</sup> Data are based on residence at time of stage 3 (AIDS) classification.

b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

Table 10b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6 dependent areas

_			Ma	ale					Fer	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Am	erican India	n/Alaska Na	ative				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	0	1	0	0	0	0	0
20-24	1	0	0	0	0	0	0	1	0	0	2	0
25–29	0	0	1	0	1	0	2	0	2	1	6	1
30-34	1	1	2	1	2	1	4	3	3	2	3	2
35–39	0	0	3	0	0	1	3	2	0	1	4	5
40–44	1	0	0	1	0	1	2	1	1	2	3	4
45–49	0	1	3	0	1	1	0	2	1	0	3	1
50–54	1	0	0	0	1	0	3	0	4	4	4	1
55–59	0	2	0	1	0	0	1	2	2	1	4	2
60–64	1	1	1	0	0	0	0	2	0	2	1	0
≥65	1	0	0	0	0	1	0	1	3	0	0	0
Region of residence <sup>a</sup>		Ü	Ŭ	Ü	Ŭ	•	Ū		Ü	v	Ü	Ü
Northeast	0	1	1	1	0	0	0	1	0	1	0	1
Midwest	1	1	6	0	0	1	4	2	4	2	6	6
South	2	0	1	0	1	1	3	1	4	2	17	3
West	4	4	4	2	•	4	8			8	5	
					5	-		8	6			6
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	7	6	12	3	6	6	15	12	14	13	28	16
						Asi	ian <sup>b</sup>					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	1	2	1	0	0	0
20-24	0	0	0	0	0	0	2	3	0	5	2	2
25–29	0	0	4	2	2	1	10	6	5	8	4	3
30-34	3	3	3	5	2	2	7	8	6	5	7	9
35–39	5	2	5	5	4	7	12	12	14	12	6	18
40-44	8	7	5	6	5	2	9	12	9	5	8	8
45-49	8	4	4	5	2	4	5	5	5	7	8	4
50-54	2	7	5	5	2	4	6	4	1	3	1	3
55–59	1	2	2	2	1	3	5	0	2	6	5	6
60–64	4	6	2	0	0	1	3	4	2	2	4	3
≥65	5	0	0	2	2	2	1	0	3	1	3	2
Region of residence <sup>a</sup>												
Northeast	6	12	6	3	5	5	10	11	11	7	6	16
Midwest	8	7	2	8	6	5	7	8	9	7	9	8
South	6	6	8	10	4	10	16	11	11	17	14	13
West	14	7	13	10	5	5	24	24	16	24	17	19
U.S. dependent areas	0	0	0	0	0	0	1	0	0	0	0	0
Total	34	32	29	31	20	25	58	54	47	55	46	56
TOTAL	34	JZ	23	JI	20	20	JO	J4	41	JJ	40	30

Table 10b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

_			M	ale					Fen	nale		
	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Black/Africa	an Americar	1				
Age at diagnosis (yr)												
13–14	1	0	0	1	0	0	1	1	0	1	2	0
15–19	4	7	8	3	3	6	54	41	37	19	20	16
20–24	37	47	48	33	30	37	197	154	157	106	107	105
25-29	83	89	102	75	65	86	318	306	302	239	241	207
30-34	164	150	152	122	113	116	493	480	391	337	325	269
35–39	215	198	168	155	129	141	507	500	423	372	349	349
40–44	294	280	229	183	191	169	493	508	451	373	335	321
45–49	376	334	260	219	196	180	511	468	466	352	336	276
50-54	278	277	237	226	179	187	352	372	344	295	263	250
55–59	188	168	175	160	176	156	229	249	251	211	189	189
60–64	114	108	121	90	90	106	138	148	129	133	121	127
≥65	115	115	109	107	92	111	103	95	88	105	114	93
Region of residence <sup>a</sup>												
Northeast	362	324	296	262	244	217	603	576	500	430	386	307
Midwest	164	159	157	112	112	129	362	325	287	291	227	257
South	1,277	1,233	1,097	950	850	891	2,275	2,264	2,131	1,707	1,660	1,520
West	63	53	57	44	54	56	155	156	119	113	125	119
U.S. dependent areas	3	3	2	3	2	1	1	2	3	2	3	1
Total	1,869	1,772	1,609	1,371	1,262	1,294	3,396	3,323	3,040	2,543	2,401	2,204
10001	1,000	1,172	1,000	1,071	1,202		-	0,020	0,040	2,040	2,401	2,204
						Hispani	c/Latino <sup>c</sup>					
Age at diagnosis (yr)	•	•	•	•	•	•		•	•		•	
13–14	0	0	0	0	0	0	1	0	0	1	0	1
15–19	0	1	0	0	0	0	11	2	10	9	2	5
20–24	10	12	17	8	12	16	37	36	37	16	23	29
25–29	56	29	43	44	27	32	94	73	60	48	50	52
30–34	76	76	91	50	66	49	118	102	101	92	71	70
35–39	90	82	83	72	53	60	121	109	115	106	91	89
40–44	91	84	79	75	65	55	145	120	116	102	87	75
45–49	92	92	82	77	69	78	145	116	109	83	83	71
50–54	74	70	79	55	67	54	94	96	104	63	75	76
55–59	47	51	56	46	34	40	49	66	50	60	42	62
60–64	29	28	31	32	21	23	34	48	37	28	29	26
≥65	39	33	38	30	28	28	38	43	34	21	24	38
Region of residence <sup>a</sup>												
Northeast	165	169	152	131	107	101	304	269	255	194	170	212
Midwest	40	32	27	19	30	25	41	42	36	32	26	32
South	238	219	255	202	205	202	310	278	276	229	233	213
West	60	63	80	64	54	55	117	111	110	100	100	99
U.S. dependent areas	103	74	86	71	46	52	115	111	96	74	47	41

Table 10b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

_			Ma	ale					Fer	male		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
					Native I	Hawaiian/O	ther Pacific	Islander				
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	1	0	0	0
25–29	0	0	0	0	0	0	1	0	0	0	0	0
30-34	0	0	0	0	0	0	0	1	0	1	1	1
35–39	1	0	0	0	1	1	1	0	0	0	1	1
40–44	0	0	0	2	0	0	0	0	0	0	0	1
45–49	0	0	0	0	1	1	1	1	2	0	0	0
50–54	0	0	0	0	2	0	0	1	2	0	0	1
55–59	0	0	0	0	0	0	1	0	0	1	0	0
60–64	0	0	0	0	0	0	0	0	0	1	0	0
≥65	0	0	1	0	0	0	0	0	0	0	0	0
	U	U	1	U	U	U	U	U	U	U	U	U
Region of residence <sup>a</sup>	•	•	•	•	•	•	•	•	•	•	•	•
Northeast	0	0	0	0	0	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	1	0	0	0	0	1	0
South	0	0	0	1	0	1	0	0	3	1	0	0
West	1	1	1	1	3	0	4	3	2	2	1	3
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	1
Total	1	1	1	2	3	2	4	3	5	3	2	4
						W	hite					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	3	5	2	2	0	2
20–24	5	6	4	3	1	3	20	13	21	16	14	21
25-29	14	14	14	14	17	13	49	39	41	41	37	37
30-34	12	21	18	15	15	20	89	79	58	57	53	45
35–39	34	23	30	19	18	14	93	77	68	70	59	70
40-44	46	44	47	35	23	31	92	101	80	74	59	59
45–49	60	48	44	41	41	29	87	96	90	66	73	64
50–54	48	59	45	52	37	48	63	71	75	68	84	64
55–59	33	30	40	32	33	28	45	64	59	60	58	61
60–64	34	22	26	26	27	25	33	29	44	15	28	31
≥65	35	20	31	25	26	28	12	14	16	23	26	25
Region of residence <sup>a</sup>												
Northeast	79	65	63	64	49	42	94	99	86	71	58	68
Midwest	56	49	35	34	34	31	101	100	90	84	80	79
South	139	133	148	115	117	128	316	299	293	265	276	253
West	46	42	51	47	38	37	76	90	86	71	76	79
U.S. dependent areas	0	0	0	0	0	0	0	0	0	1	0	1
Total	320	289	297	260	238	238	587	588	555	492	490	480
rotar	320	203	LJI	200	230	230	501	500	555	732	730	700

Table 10b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2011–2016—United States and 6 dependent areas (cont)

<u>-</u>			Ma	ale					Fer	nale		
_	2011	2012	2013	2014	2015	2016	2011	2012	2013	2014	2015	2016
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
						Multip	e races					
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	2	4	5	1	0	0
20–24	3	3	4	1	2	2	15	13	28	9	8	6
25–29	2	8	4	3	6	2	26	25	16	13	14	13
30–34	2	7	10	8	7	2	28	38	19	19	15	16
35–39	14	15	8	8	4	5	33	30	34	32	22	15
40-44	14	13	9	13	6	4	34	28	33	26	21	16
45-49	19	12	16	17	12	9	24	30	27	22	20	23
50-54	17	12	14	6	11	8	22	13	22	18	12	16
55–59	14	9	11	12	7	3	21	12	22	6	9	7
60–64	2	5	5	2	2	5	9	6	12	11	6	7
≥65	5	2	9	5	9	4	9	7	8	8	4	5
Region of residence <sup>a</sup>												
Northeast	41	28	29	24	24	8	75	51	59	44	34	30
Midwest	6	13	8	11	4	6	24	26	15	21	13	15
South	41	44	50	36	32	25	103	107	136	89	72	64
West	4	2	4	6	5	4	17	20	17	10	11	13
U.S. dependent areas	0	0	0	0	0	0	2	0	0	0	0	0
Total	92	87	91	77	65	43	221	204	227	164	130	122
							otal					
Age at diagnosis (yr)							, tai					
13–14	1	0	0	1	0	0	1	1	0	2	2	1
15–19	5	9	9	3	3	6	71	53	56	30	21	23
20–24	57	68	73	45	45	58	270	221	243	152	156	163
25–29	154	140	168	138	118	134	499	449	425	349	353	314
30–34	257	259	277	200	205	191	739	710	577	513	474	413
35–39	360	320	296	258	209	229	770	730	654	593	532	546
40–44	455	428	368	314	290	263	774	769	689	581	512	484
45–49	555	492	410	359	321	302	773	718	699	529	522	439
50–54	419	424	380	344	299	301	540	556	553	451	438	409
55–59	283	262	284	253	252	230	350	392	386	345	307	327
60–64	183	170	185	150	140	159	217	236	225	192	187	195
≥65	199	170	188	168	157	173	163	160	152	158	171	162
Region of residence <sup>a</sup>	100	.,,	100	100	107	170	100	100	102	100	.,,	102
Northeast	653	599	548	485	430	373	1,085	1,007	911	746	655	634
Midwest	274	261	234	184	430 187	199	539	503	439	437	362	396
South	1,703	1,635	1,559	1,315	1,208	1,259	3,024	2,960	2,855	2,309		2,066
West	1,703	171	209	1,315	1,206		3,024 401	2,960 412	2,055 355		2,273	338
U.S. dependent areas	192	17 I 77	209 88	174 75	49	161 53	401 119	113	355 99	328 76	336 50	338 44
•												
Total	2,928	2,743	2,638	2,232	2,038	2,045	5,168	4,994	4,659	3,896	3,675	3,478

 $<sup>^{\</sup>mbox{\scriptsize a}}$  Data are based on residence at time of stage 3 (AIDS) classification.

b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

 $<sup>^{\</sup>rm C}$  Hispanics/Latinos can be of any race.

Table 11a. Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2011–2016—United States

	20	011	20	012	2	013	20	014	2	015	20	016
Race/ethnicity	No.	Rate <sup>a</sup>	No.	Ratea								
American Indian/Alaska Native	0	0.0	0	0.0	0	0.0	3	0.7	2	0.4	0	0.0
Asian	8	0.3	13	0.5	16	0.6	12	0.5	9	0.4	8	0.3
Black/African American	118	1.6	168	2.3	122	1.7	112	1.6	87	1.2	78	1.1
Hispanic/Latino <sup>b</sup>	24	0.2	16	0.1	11	0.1	18	0.1	13	0.1	16	0.1
Native Hawaiian/Other Pacific Islander	0	0.0	0	0.0	0	0.0	1	1.0	0	0.0	0	0.0
White	35	0.1	32	0.1	24	0.1	29	0.1	18	0.1	16	0.1
Multiple races	13	0.6	11	0.5	13	0.6	5	0.2	6	0.3	4	0.2
Total	198	0.4	240	0.5	186	0.4	180	0.3	135	0.3	122	0.2

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

Table 11b.Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2011–2016—United States and 6 dependent areas

	2011	2012	2013	2014	2015	2016
Race/ethnicity	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native	0	0	0	3	2	0
Asian	8	13	16	12	9	8
Black/African American	118	168	122	112	87	78
Hispanic/Latino <sup>a</sup>	26	16	11	18	13	16
Native Hawaiian/Other Pacific Islander	0	0	0	1	0	0
White	35	32	24	29	18	16
Multiple races	13	11	13	5	6	4
Total	200	240	186	180	135	122

*Note*. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Rates are per 100,000 population.

b Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>a</sup> Hispanics/Latinos can be of any race.

Table 12a.Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2011–2016 and cumulative—United States

	20	011	2	012	20	013	2	014	2	015	2	016	<b>Cumulative</b> <sup>a</sup>
Race/ethnicity	No.	<b>Rate</b> <sup>b</sup>	No.	<b>Rate</b> b	No.								
American Indian/Alaska Native	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	1	0.2	28
Asian <sup>c</sup>	2	0.1	0	0.0	0	0.0	0	0.0	2	0.1	1	0.0	50
Black/African American	12	0.2	9	0.1	5	0.1	49	0.7	28	0.4	25	0.3	5,633
Hispanic/Latino <sup>d</sup>	2	0.0	1	0.0	2	0.0	13	0.1	5	0.0	2	0.0	2,037
Native Hawaiian/Other Pacific Islander	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6
White	2	0.0	1	0.0	0	0.0	6	0.0	3	0.0	5	0.0	1,536
Multiple races	0	0.0	0	0.0	2	0.1	2	0.1	2	0.1	4	0.2	281
Total <sup>e</sup>	18	0.0	11	0.0	9	0.0	71	0.1	40	0.1	38	0.1	9,573

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution. The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

Table 12b.Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2011–2016 and cumulative—United States and 6 dependent areas

	2011	2012	2013	2014	2015	2016	<b>Cumulative</b> <sup>a</sup>
Race/ethnicity	No.						
American Indian/Alaska Native	0	0	0	1	0	1	28
Asian <sup>b</sup>	2	0	0	0	2	1	51
Black/African American	12	9	5	49	28	26	5,646
Hispanic/Latino <sup>c</sup>	2	1	2	13	5	2	2,449
Native Hawaiian/Other Pacific Islander	1	0	0	0	0	0	7
White	2	1	0	6	3	5	1,536
Multiple races	0	0	2	2	2	4	281
Total <sup>d</sup>	19	11	9	71	40	39	10,000

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution. The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

<sup>&</sup>lt;sup>a</sup> From the beginning of the epidemic through 2016.

b Rates are per 100,000 population.

<sup>&</sup>lt;sup>C</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>d</sup> Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>e</sup> Cumulative total includes 2 persons whose race/ethnicity is unknown.

<sup>&</sup>lt;sup>a</sup> From the beginning of the epidemic through 2016.

b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>d</sup> Cumulative total includes 2 persons whose race/ethnicity is unknown.

Table 13. Stage 3 (AIDS) among children aged <13 years, by year of diagnosis, 1992–2016—United States and 6 dependent areas

	United States	United States and dependent areas
Year of diagnosis	No.	No.
1992	906	955
1993	885	923
1994	818	844
1995	675	697
1996	521	535
1997	336	348
1998	250	257
1999	201	206
2000	135	137
2001	130	131
2002	108	115
2003	75	77
2004	61	62
2005	55	55
2006	40	43
2007	35	36
2008	39	40
2009	15	16
2010	22	22
2011	18	19
2012	11	11
2013	9	9
2014	71	71
2015	40	40
2016	38	39

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and trends based on these numbers, should be interpreted with caution. The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

Table 14. Diagnoses of HIV infection among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2016—United States and 6 dependent areas

		ntral erica	Cı	uba	Me	xico	Puert	to Rico	South	America	United	States	To	tal
Transmission category <sup>a</sup>	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.b	%
Male adult or adolescent														
Male-to-male sexual contact	391	84.0	464	91.2	898	85.1	386	66.0	633	92.6	2,697	86.5	7,689	85.4
Injection drug use	11	2.3	3	0.6	29	2.8	64	11.0	4	0.6	131	4.2	345	3.8
Male-to-male sexual contact and injection drug use	7	1.4	6	1.3	25	2.4	23	3.9	6	0.9	132	4.2	278	3.1
Heterosexual contact <sup>c</sup>	56	12.0	35	6.9	102	9.7	112	19.2	40	5.8	154	4.9	680	7.6
Other <sup>d</sup>	2	0.3	0	0.0	1	0.1	0	0.0	0	0.0	3	0.1	7	0.1
Subtotal	465	100	509	100	1,055	100	585	100	683	100	3,117	100	8,999	100
Female adult or adolescent														
Injection drug use	5	4.5	0	0.5	4	4.5	15	9.6	2	2.8	71	18	152	11.9
Heterosexual contact <sup>c</sup>	98	95.1	42	99.3	91	95.2	137	90.4	56	97.1	322	81.6	1,121	87.8
Other <sup>d</sup>	0	0.4	0	0.2	0	0.3	0	0.0	0	0.2	1	0.3	4	0.3
Subtotal	103	100	42	100	96	100	152	100	58	100	394	100	1,277	100
Total	568	100	551	100	1,151	100	737	100	741	100	3,511	100	10,276	100

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>b</sup> Entries include persons whose place of birth is not among those listed and persons whose place of birth is unknown.

 $<sup>^{\</sup>mathbf{C}}$  Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

<sup>&</sup>lt;sup>d</sup> Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

Table 15. Stage 3 (AIDS) among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2016— United States and 6 dependent areas

		ntral erica	Cı	uba	Me	xico	Puert	o Rico	South A	America	United	States	To	otal
Transmission category <sup>a</sup>	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.b	%
Male adult or adolescent														
Male-to-male sexual contact	212	77.7	115	86.1	436	77.5	123	43.4	129	78.7	1,006	76.7	2,692	74.6
Injection drug use	12	4.2	1	1.1	30	5.4	73	25.7	5	2.9	100	7.6	288	8.0
Male-to-male sexual contact and injection drug use	5	1.6	1	1.0	14	2.6	24	8.3	3	2.0	98	7.5	174	4.8
Heterosexual contact <sup>c</sup>	45	16.3	16	11.9	81	14.4	61	21.5	27	16.2	93	7.1	435	12.1
Other <sup>d</sup>	0	0.1	0	0.0	1	0.1	3	1.1	0	0.1	13	1.0	20	0.6
Subtotal	273	100	133	100	563	100	284	100	164	100	1,311	100	3,609	100
Female adult or adolescent														
Injection drug use	4	5.5	1	7.9	4	6.1	13	15.3	4	13.7	67	22.6	121	16.4
Heterosexual contact <sup>c</sup>	62	93.8	13	91.4	57	93.6	74	84.7	23	85.9	209	71.1	596	80.7
Other <sup>d</sup>	1	0.8	0	0.7	0	0.3	0	0.0	0	0.4	19	6.3	22	2.9
Subtotal	66	100	14	100	61	100	87	100	27	100	294	100	739	100
Total	339	100	147	100	624	100	371	100	191	100	1,605	100	4,348	100

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>b</sup> Entries include persons whose place of birth is not among those listed and persons whose place of birth is unknown.

<sup>&</sup>lt;sup>C</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

 $<sup>^{\</sup>rm d}$  Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

VOI. 28

Table 16a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2011–2015—United States

	20	)11	20	12	20	)13	20	14	20	)15
	No.	Rate <sup>a</sup>								
Age at death (yr)										
<13	1	0.0	4	0.0	1	0.0	1	0.0	4	0.0
13–14	2	0.0	2	0.0	1	0.0	3	0.0	0	0.0
15–19	25	0.1	23	0.1	9	0.0	13	0.1	12	0.1
20–24	203	0.9	174	8.0	170	0.7	171	0.7	143	0.6
25–29	420	2.0	417	1.9	426	2.0	366	1.7	391	1.7
30–34	686	3.3	704	3.4	632	3.0	644	3.0	581	2.7
35–39	1,064	5.4	958	4.9	858	4.4	889	4.5	787	3.9
40–44	1,850	8.8	1,639	7.8	1,479	7.1	1,358	6.6	1,201	6.0
45–49	2,932	13.2	2,662	12.3	2,459	11.6	2,202	10.6	1,931	9.3
50–54	3,152	14.0	3,141	13.9	3,095	13.7	2,999	13.3	2,881	12.9
55–59	2,675	13.2	2,672	12.9	2,755	13.0	2,926	13.6	2,776	12.8
60–64	1,745	9.8	1,877	10.5	1,961	10.8	2,225	12.0	2,109	11.1
≥65	1,842	4.5	2,011	4.7	2,257	5.1	2,457	5.3	2,642	5.5
Race/ethnicity										
American Indian/Alaska Native	58	2.5	54	2.3	64	2.7	61	2.6	58	2.4
Asian <sup>b</sup>	87	0.6	72	0.5	73	0.5	62	0.4	76	0.4
Black/African American	7,914	20.6	7,682	19.8	7,486	19.1	7,420	18.8	6,960	17.5
Hispanic/Latino <sup>c</sup>	2,734	5.3	2,485	4.7	2,651	4.9	2,765	5.0	2,481	4.4
Native Hawaiian/Other Pacific Islander	10	2.0	7	1.3	10	1.9	8	1.5	6	1.1
White	4,991	2.5	5,122	2.6	4,909	2.5	5,017	2.5	4,915	2.5
Multiple races	801	13.7	840	14.0	906	14.6	917	14.4	957	14.6
Transmission category <sup>d</sup>										
Male adult or adolescent										
Male-to-male sexual contact	6,461	_	6,398	_	6,493	_	6,577	_	6,458	_
Injection drug use	2,680	_	2,556	_	2,467	_	2,482	_	2,258	_
Male-to-male sexual contact and injection drug use	1,316	_	1,291	_	1,311	_	1,323	_	1,325	_
Heterosexual contact <sup>e</sup>	1,713	_	1,625	_	1,614	_	1,567		1,495	_
Perinatal	37	_	43	_	37	_	32		28	_
Other <sup>f</sup>	88	_	79	_	78	_	64	_	74	_
Subtotal	12,296	9.7	11,992	9.4	12,000	9.3	12,045	9.3	11,638	8.9

Table 16a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2011–2015—United States (cont)

	20	)11	20	12	20	13	20	14	20	15
	No.	Rate <sup>a</sup>								
Female adult or adolescent										
Injection drug use	1,612	_	1,510	_	1,518	_	1,470	_	1,337	_
Heterosexual contact <sup>e</sup>	2,606	_	2,698	_	2,520	_	2,674	_	2,407	_
Perinatal	48	_	43	_	32	_	31		46	_
Other <sup>f</sup>	33	_	37	_	32	_	33	_	26	_
Subtotal	4,300	3.2	4,288	3.2	4,102	3.0	4,208	3.1	3,816	2.8
Child (<13 yrs at death)										
Perinatal	1	_	3	_	1	_	1		2	_
Other <sup>f</sup>	0	_	1	_	0	_	0	_	2	_
Subtotal	1	0.0	4	0.0	1	0.0	1	0.0	4	0.0
Region of residence <sup>g</sup>										
Northeast	4,248	7.6	3,915	7.0	3,950	7.1	3,805	6.8	3,585	6.4
Midwest	1,887	2.8	1,906	2.8	1,775	2.6	1,790	2.6	1,741	2.6
South	7,955	6.9	7,976	6.8	7,836	6.6	8,071	6.7	7,602	6.3
West	2,507	3.4	2,487	3.4	2,542	3.4	2,588	3.4	2,530	3.3
<b>Total</b> <sup>h</sup>	16,597	5.3	16,284	5.2	16,103	5.1	16,254	5.1	15,458	4.8

<sup>&</sup>lt;sup>a</sup> Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>&</sup>lt;sup>b</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

h Includes persons whose race/ethnicity is unknown.

Table 16b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2011–2015—United States and 6 dependent areas

	20	)11	20	12	20	13	20	)14	20	15
	No.	Rate <sup>a</sup>	No.	Ratea						
Age at death (yr)										
<13	1	0.0	4	0.0	1	0.0	1	0.0	4	0.0
13–14	2	0.0	2	0.0	1	0.0	3	0.0	0	0.0
15–19	26	0.1	24	0.1	11	0.1	13	0.1	12	0.1
20–24	207	0.9	178	0.8	173	0.7	173	0.7	145	0.6
25–29	432	2.0	430	2.0	435	2.0	373	1.7	395	1.7
30–34	708	3.4	734	3.5	656	3.0	660	3.0	601	2.8
35–39	1,110	5.6	1,003	5.1	889	4.5	909	4.5	806	3.9
40–44	1,920	9.0	1,687	7.9	1,516	7.2	1,395	6.7	1,239	6.1
45–49	3,039	13.5	2,742	12.5	2,549	11.9	2,265	10.7	1,979	9.4
50–54	3,256	14.3	3,225	14.1	3,186	14.0	3,096	13.6	2,974	13.2
55–59	2,744	13.4	2,727	13.0	2,819	13.1	3,011	13.9	2,837	12.9
60–64	1,792	9.9	1,923	10.7	2,010	11.0	2,286	12.2	2,154	11.2
≥65	1,903	4.5	2,075	4.7	2,326	5.1	2,538	5.4	2,703	5.6
Race/ethnicity										
American Indian/Alaska Native	58	_	54	_	64	_	61	_	58	_
Asian <sup>b</sup>	89	_	74	_	73	_	64	_	77	_
Black/African American	7,922	_	7,693	_	7,492	_	7,429	_	6,965	_
Hispanic/Latino <sup>c</sup>	3,264	_	2,940	_	3,108	_	3,223	_	2,863	_
Native Hawaiian/Other Pacific Islander	12	_	7	_	12	_	8	_	7	_
White	4,991	_	5,123	_	4,911	_	5,017	_	4,916	_
Multiple races	802	_	841	_	908	_	917	_	958	_
Transmission category <sup>d</sup>										
Male adult or adolescent										
Male-to-male sexual contact	6,546	_	6,456	_	6,577	_	6,663	_	6,531	_
Injection drug use	2,892	_	2,724	_	2,613	_	2,624	_	2,383	_
Male-to-male sexual contact and injection drug use	1,348	_	1,320	_	1,338	_	1,350	_	1,355	_
Heterosexual contact <sup>e</sup>	1,792	_	1,714	_	1,700	_	1,648	_	1,555	_
Perinatal	38	_	45	_	39	_	32	_	29	_
Other <sup>f</sup>	88	_	80	_	78	_	66	_	75	_
Subtotal	12,704	9.9	12,339	9.6	12,346	9.5	12,382	9.4	11,928	9.0

Table 16b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2011–2015—United States and 6 dependent areas *(cont)* 

	20	)11	20	12	20	)13	20	)14	20	15
	No.	Rate <sup>a</sup>								
Female adult or adolescent										
Injection drug use	1,658	_	1,543	_	1,560	_	1,510	_	1,358	_
Heterosexual contact <sup>e</sup>	2,693	_	2,783	_	2,600	_	2,765	_	2,486	_
Perinatal	50	_	45	_	33	_	32	_	47	_
Other <sup>f</sup>	34	_	39	_	32	_	33	_	26	_
Subtotal	4,435	3.3	4,411	3.3	4,225	3.1	4,340	3.2	3,917	2.8
Child (<13 yrs at death)										
Perinatal	1	_	3	_	1	_	1	_	2	_
Other <sup>f</sup>	0	_	1	_	0	_	0	_	2	
Subtotal	1	0.0	4	0.0	1	0.0	1	0.0	4	0.0
Region of residence <sup>9</sup>										
Northeast	4,248	7.6	3,915	7.0	3,950	7.1	3,805	6.8	3,585	6.4
Midwest	1,887	2.8	1,906	2.8	1,775	2.6	1,790	2.6	1,741	2.6
South	7,955	6.9	7,976	6.8	7,836	6.6	8,071	6.7	7,602	6.3
West	2,507	3.4	2,487	3.4	2,542	3.4	2,588	3.4	2,530	3.3
U.S. dependent areas	543	13.3	470	11.7	469	11.8	469	11.9	391	10.1
Total <sup>h</sup>	17,140	5.4	16,754	5.3	16,572	5.2	16,723	5.2	15,849	4.9

<sup>&</sup>lt;sup>a</sup> Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>&</sup>lt;sup>b</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>d</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

h Includes persons whose race/ethnicity is unknown.

Table 17a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2011–2015 and cumulative—United States

	20	011	20	12	20	13	20	14	20	15	Cumulative <sup>2</sup>
	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.
Age at death (yr)											
<13	0	0.0	1	0.0	1	0.0	0	0.0	2	0.0	4,968
13–14	1	0.0	1	0.0	0	0.0	1	0.0	0	0.0	296
15–19	20	0.1	16	0.1	6	0.0	8	0.0	7	0.0	1,313
20–24	149	0.7	131	0.6	123	0.5	116	0.5	106	0.5	10,077
25–29	317	1.5	320	1.5	315	1.5	270	1.2	296	1.3	47,563
30–34	546	2.7	559	2.7	512	2.4	493	2.3	446	2.1	102,737
35–39	893	4.6	781	4.0	704	3.6	714	3.6	631	3.1	129,420
40–44	1,545	7.3	1,355	6.4	1,224	5.9	1,115	5.4	976	4.8	124,221
45–49	2,467	11.1	2,249	10.4	2,050	9.7	1,820	8.7	1,602	7.7	98,819
50–54	2,622	11.6	2,592	11.5	2,570	11.4	2,511	11.1	2,422	10.9	70,633
55–59	2,183	10.8	2,190	10.5	2,265	10.7	2,368	11.0	2,286	10.5	46,000
60–64	1,404	7.9	1,509	8.5	1,592	8.8	1,805	9.7	1,698	8.9	27,909
≥65	1,409	3.4	1,542	3.6	1,750	3.9	1,908	4.1	2,025	4.2	28,833
Race/ethnicity											
American Indian/Alaska Native	48	2.1	41	1.8	52	2.2	43	1.8	49	2.1	1,988
Asian <sup>c</sup>	69	0.5	61	0.4	64	0.4	47	0.3	62	0.4	3,542
Black/African American	6,415	16.7	6,233	16.1	6,038	15.4	5,974	15.1	5,586	14.0	285,744
Hispanic/Latino <sup>d</sup>	2,316	4.5	2,119	4.0	2,257	4.2	2,335	4.2	2,100	3.7	106,644
Native Hawaiian/Other Pacific Islander	9	1.8	6	1.2	8	1.5	5	0.9	4	0.7	369
White	3,993	2.0	4,065	2.1	3,904	2.0	3,950	2.0	3,879	2.0	279,807
Multiple races	706	12.1	720	12.0	788	12.7	775	12.1	817	12.4	14,647
Transmission category <sup>e</sup>											
Male adult or adolescent											
Male-to-male sexual contact	5,248	_	5,188	_	5,228	_	5,269	_	5,180	_	325,330
Injection drug use	2,179	_	2,097		2,032	_	2,032		1,869	_	134,466
Male-to-male sexual contact and injection drug use	1,125	_	1,105	_	1,119	_	1,137	_	1,124	_	53,521
Heterosexual contact <sup>f</sup>	1,373	_	1,317	_	1,290	_	1,268	_	1,192		38,727
Perinatal	34	_	40	_	32	_	28	_	26	_	463
Other <sup>g</sup>	74	_	65	_	60	_	55	_	62	_	8,789
Subtotal	10,032	7.9	9,812	7.7	9,762	7.6	9,789	7.5	9,453	7.2	561,296

Table 17a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2011–2015 and cumulative—United States (cont)

	20	)11	20	12	20	13	20	)14	20	)15	Cumulative <sup>a</sup>
	No.	Rate <sup>b</sup>	No.								
Female adult or adolescent											
Injection drug use	1,341	_	1,243	_	1,267	_	1,198	_	1,090	_	59,438
Heterosexual contact <sup>f</sup>	2,113		2,117	_	2,025	_	2,086	_	1,885	_	62,839
Perinatal	44	_	43	_	31	_	30	_	45	_	592
Other <sup>g</sup>	26		30		26	_	25	_	22	_	3,655
Subtotal	3,524	2.7	3,433	2.6	3,349	2.5	3,340	2.5	3,042	2.2	126,525
Child (<13 yrs at death)											
Perinatal	0	_	1	_	1	_	0	_	0	_	4,507
Other <sup>g</sup>	0	_	0	_	0	_	0	_	2	_	461
Subtotal	0	0.0	1	0.0	1	0.0	0	0.0	2	0.0	4,968
Region of residence <sup>h</sup>											
Northeast	3,474	6.2	3,237	5.8	3,253	5.8	3,057	5.4	2,883	5.1	213,084
Midwest	1,521	2.3	1,495	2.2	1,415	2.1	1,414	2.1	1,365	2.0	73,965
South	6,483	5.6	6,449	5.5	6,336	5.4	6,515	5.4	6,159	5.1	272,756
West	2,078	2.9	2,065	2.8	2,108	2.8	2,143	2.9	2,090	2.8	132,984
Total <sup>i</sup>	13,556	4.3	13,246	4.2	13,112	4.1	13,129	4.1	12,497	3.9	692,789

<sup>&</sup>lt;sup>a</sup> From the beginning of the epidemic through 2015.

<sup>&</sup>lt;sup>b</sup> Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>&</sup>lt;sup>C</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

d Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>e</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

<sup>&</sup>lt;sup>g</sup> Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

h Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

i Includes persons whose race/ethnicity is unknown.

Table 17b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2011–2015 and cumulative—United States and 6 dependent areas

	20	)11	20	)12	20	)13	20	)14	20	)15	<b>Cumulative</b> <sup>a</sup>
	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.						
Age at death (yr)											
<13	0	0.0	1	0.0	1	0.0	0	0.0	2	0.0	5,210
13–14	1	0.0	1	0.0	0	0.0	1	0.0	0	0.0	306
15–19	21	0.1	17	0.1	8	0.0	8	0.0	7	0.0	1,383
20–24	151	0.7	134	0.6	126	0.5	118	0.5	108	0.5	10,606
25–29	327	1.5	327	1.5	317	1.5	273	1.2	298	1.3	49,797
30–34	560	2.7	577	2.7	527	2.4	506	2.3	462	2.1	107,006
35–39	925	4.7	807	4.1	723	3.6	730	3.6	644	3.1	134,641
40–44	1,597	7.5	1,394	6.5	1,249	5.9	1,138	5.5	1,000	4.9	128,802
45–49	2,561	11.4	2,310	10.5	2,115	9.8	1,864	8.8	1,640	7.8	102,184
50-54	2,703	11.8	2,659	11.6	2,636	11.5	2,586	11.3	2,490	11.0	72,907
55–59	2,234	10.9	2,231	10.6	2,313	10.8	2,436	11.2	2,331	10.6	47,297
60–64	1,438	8.0	1,544	8.6	1,631	8.9	1,851	9.9	1,735	9.0	28,794
≥65	1,456	3.5	1,587	3.6	1,798	4.0	1,970	4.2	2,070	4.3	29,973
Race/ethnicity											
American Indian/Alaska Native	48	_	41	_	52	_	43	_	49	_	1,988
Asian <sup>c</sup>	71	_	62	_	64	_	48	_	62	_	3,587
Black/African American	6,423	_	6,242	_	6,041	_	5,978	_	5,589	_	286,031
Hispanic/Latino <sup>d</sup>	2,721	_	2,450	_	2,580	_	2,682	_	2,384	_	132,300
Native Hawaiian/Other Pacific Islander	11	_	6	_	10	_	5	_	5	_	384
White	3,993	_	4,066	_	3,906	_	3,950	_	3,880	_	279,910
Multiple races	707	_	721	_	790	_	775	_	818	_	14,658
Transmission category <sup>e</sup>											
Male adult or adolescent											
Male-to-male sexual contact	5,318	_	5,228	_	5,293	_	5,330	_	5,234	_	329,540
Injection drug use	2,333	_	2,221	_	2,128	_	2,141	_	1,963	_	145,608
Male-to-male sexual contact and injection drug use	1,154	_	1,131	_	1,143	_	1,159	_	1,149	_	55,568
Heterosexual contact <sup>f</sup>	1,434	_	1,376	_	1,353	_	1,321	_	1,235	_	41,359
Perinatal	35	_	42	_	34	_	28	_	27	_	491
Other <sup>g</sup>	74	_	67	_	60	_	57	_	62	_	8,923
Subtotal	10,348	8.1	10,065	7.8	10,011	7.7	10,036	7.6	9,670	7.3	581,490

Table 17b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2011–2015 and cumulative—United States and 6 dependent areas (cont)

	20	)11	20	12	20	)13	20	)14	20	)15	<b>Cumulative</b> <sup>a</sup>
	No.	Rate <sup>b</sup>	No.								
Female adult or adolescent											
Injection drug use	1,380	_	1,266	_	1,297	_	1,234		1,103		61,676
Heterosexual contact <sup>f</sup>	2,174	_	2,180	_	2,077	_	2,155	_	1,944	_	66,145
Perinatal	45	_	45	_	32		31		46		625
Other <sup>g</sup>	27	_	32	_	26		25		22		3,760
Subtotal	3,626	2.7	3,523	2.6	3,432	2.5	3,445	2.5	3,115	2.2	132,206
Child (<13 yrs at death)											
Perinatal	0	_	1	_	1	_	0	_	0	_	4,734
Other <sup>g</sup>	0	_	0	_	0		0		2		476
Subtotal	0	0.0	1	0.0	1	0.0	0	0.0	2	0.0	5,210
Region of residence <sup>h</sup>											
Northeast	3,474	6.2	3,237	5.8	3,253	5.8	3,057	5.4	2,883	5.1	213,084
Midwest	1,521	2.3	1,495	2.2	1,415	2.1	1,414	2.1	1,365	2.0	73,965
South	6,483	5.6	6,449	5.5	6,336	5.4	6,515	5.4	6,159	5.1	272,756
West	2,078	2.9	2,065	2.8	2,108	2.8	2,143	2.9	2,090	2.8	132,984
U.S. dependent areas	418	10.3	343	8.5	332	8.3	352	9.0	290	7.5	26,117
Total <sup>i</sup>	13,974	4.4	13,589	4.3	13,444	4.2	13,481	4.2	12,787	3.9	718,906

<sup>&</sup>lt;sup>a</sup> From the beginning of the epidemic through 2015.

b Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>&</sup>lt;sup>C</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>d</sup> Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>e</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

<sup>&</sup>lt;sup>g</sup> Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

h Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

i Includes persons whose race/ethnicity is unknown.

Table 18a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2015—United States

		an Indian/ a Native	As	ian <sup>a</sup>		African erican	Hispanio	c/Latino <sup>b</sup>	Other	Hawaiian/ Pacific Inder	wi	nite	Multip	le races	То	tal <sup>c</sup>
	No.	Rated	No.	Rated	No.	Rated	No.	Rate <sup>d</sup>	No.	Rated	No.	Rated	No.	Rated	No.	Rated
Age at death (yr)																
<13	0	0.0	0	0.0	3	0.0	0	0.0	0	0.0	1	0.0	0	0.0	4	0.0
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	7	0.2	1	0.0	0	0.0	4	0.0	0	0.0	12	0.1
20–24	0	0.0	1	0.1	98	2.9	18	0.4	0	0.0	16	0.1	10	1.7	143	0.6
25–29	1	0.5	3	0.2	225	7.2	74	1.6	1	1.9	63	0.5	24	5.2	391	1.7
30–34	6	3.7	7	0.5	294	10.6	121	2.7	0	0.0	117	0.9	36	9.4	581	2.7
35–39	5	3.4	8	0.6	400	15.4	163	3.9	1	2.4	170	1.5	40	12.3	787	3.9
40–44	5	3.5	11	8.0	554	21.8	229	5.9	1	2.7	331	2.8	70	25.1	1,201	6.0
45–49	8	5.4	12	1.0	820	31.8	352	10.2	0	0.0	615	4.7	121	48.7	1,931	9.3
50-54	13	8.0	13	1.2	1,185	43.7	473	15.7	1	2.9	1,014	6.8	181	75.1	2,881	12.9
55–59	10	6.5	7	0.7	1,229	48.1	383	15.8	1	3.3	956	6.2	189	86.5	2,776	12.8
60–64	4	3.2	5	0.6	1,011	49.1	299	16.4	0	0.0	644	4.6	146	85.2	2,109	11.1
≥65	6	2.4	9	0.5	1,134	27.0	368	9.8	1	2.2	984	2.6	140	40.8	2,642	5.5
Transmission category <sup>e</sup>																
Male adult or adolescent																
Male-to-male sexual contact	20	_	53	_	2,037	_	1,050	_	4	_	2,950	_	341	_	6,458	_
Injection drug use	5	_	3	_	1,170	_	479	_	0	_	438	_	164	_	2,258	_
Male-to-male sexual contact and injection drug use	10	_	4	_	407	_	221	_	0	_	543	_	138	_	1,325	_
Heterosexual contact <sup>f</sup>	7	_	9	_	973	_	215	_	2	_	218	_	70	_	1,495	_
Perinatal	0	_	1	_	16	_	5	_	0	_	3	_	3	_	28	_
Other <sup>g</sup>	0	_	0	_	19	_	10	_	0	_	37	_	8	_	74	_
Subtotal	41	4.4	70	1.0	4,622	30.0	1,980	9.1	6	2.6	4,190	5.0	724	35.3	11,638	8.9

Table 18a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2015—United States (cont)

		an Indian/ a Native	As	sian <sup>a</sup>		African erican	Hispani	c/Latino <sup>b</sup>	Other	Hawaiian/ Pacific ander	W	hite	Multip	le races	То	tal <sup>c</sup>
	No.	Rate <sup>d</sup>	No.	Rated	No.	Rated	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rated
Female adult or adolescent																
Injection drug use	9	_	0	_	662	_	215	_	0	_	343	_	108	_	1,337	_
Heterosexual contact <sup>f</sup>	8	_	6	_	1,631	_	274	_	0	_	366	_	122	_	2,407	_
Perinatal	0	_	0	_	32	_	7	_	0	_	6	_	1	_	46	_
Other <sup>g</sup>	1	_	0	_	10	_	5	_	0	_	9	_	2	_	26	_
Subtotal	17	1.7	6	0.1	2,335	13.5	501	2.4	0	0.0	724	8.0	233	10.6	3,816	2.8
Child (<13 yrs at death)																
Perinatal	0	_	0	_	1	_	0	_	0	_	1	_	0	_	2	_
Other <sup>g</sup>	0	_	0	_	2	_	0	_	0	_	0	_	0	_	2	_
Subtotal	0	0.0	0	0.0	3	0.0	0	0.0	0	0.0	1	0.0	0	0.0	4	0.0
Region of residence <sup>h</sup>																
Northeast	0	0.0	12	0.3	1,471	23.2	929	11.8	1	4.8	817	2.2	355	39.2	3,585	6.4
Midwest	9	2.2	4	0.2	768	10.9	125	2.4	0	0.0	737	1.4	98	7.8	1,741	2.6
South	22	2.8	17	0.4	4,242	18.4	836	4.0	1	1.2	2,129	3.0	350	16.2	7,602	6.3
West	27	2.6	43	0.6	479	13.9	591	2.6	4	1.0	1,232	3.2	154	6.8	2,530	3.3
Total	58	2.4	76	0.4	6,960	17.5	2,481	4.4	6	1.1	4,915	2.5	957	14.6	15,458	4.8

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

b Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Includes persons whose race/ethnicity is unknown.

d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

<sup>&</sup>lt;sup>g</sup> Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

h Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 18b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2015—United States and 6 dependent areas

	American Indian/ Alaska Native	<b>Asian</b> <sup>a</sup>	Black/African American	Hispanic/Latino <sup>b</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	<b>Total</b> <sup>c</sup>
	No.	No.	No.	No.	No.	No.	No.	No.
Age at death (yr)								
<13	0	0	3	0	0	1	0	4
13–14	0	0	0	0	0	0	0	C
15–19	0	0	7	1	0	4	0	12
20–24	0	1	98	20	0	16	10	145
25–29	1	3	225	78	1	63	24	395
30–34	6	8	294	140	0	117	36	601
35–39	5	8	400	181	1	170	41	808
40–44	5	11	555	266	1	331	70	1,239
45–49	8	12	820	399	0	616	121	1,979
50–54	13	13	1,187	563	2	1,014	181	2,974
55–59	10	7	1,229	444	1	956	189	2,837
60–64	4	5	1,011	344	0	644	146	2,154
≥65	6	9	1,136	427	1	984	140	2,703
Transmission category <sup>d</sup>								
Male adult or adolescent								
Male-to-male sexual contact	20	53	2,037	1,120	5	2,951	342	6,531
Injection drug use	5	3	1,171	603	0	438	164	2,383
Male-to-male sexual contact and injection drug use	10	4	407	251	0	543	138	1,355
Heterosexual contact <sup>e</sup>	7	9	975	275	2	218	70	1,555
Perinatal	0	1	16	6	0	3	3	29
Other <sup>f</sup>	0	0	19	11	0	37	8	75
Subtotal	41	70	4,624	2,265	7	4,191	725	11,928

Table 18b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2015—United States and 6 dependent areas (cont)

	American Indian/ Alaska Native	<b>Asian</b> <sup>a</sup>	Black/African American	Hispanic/Latino <sup>b</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	<b>Total</b> <sup>c</sup>
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	9	0	662	236	0	343	108	1,358
Heterosexual contact <sup>e</sup>	8	7	1,634	350	0	366	122	2,486
Perinatal	0	0	32	8	0	6	1	47
Other <sup>f</sup>	1	0	10	5	0	9	2	26
Subtotal	17	7	2,338	598	0	724	233	3,917
Child (<13 yrs at end of year)								
Perinatal	0	0	1	0	0	1	0	2
Other <sup>f</sup>	0	0	2	0	0	0	0	2
Subtotal	0	0	3	0	0	1	0	4
Region of residence <sup>g</sup>								
Northeast	0	12	1,471	929	1	817	355	3,585
Midwest	9	4	768	125	0	737	98	1,741
South	22	17	4,242	836	1	2,129	350	7,602
Vest	27	43	479	591	4	1,232	154	2,530
J.S. dependent areas	0	1	5	382	1	1	1	391
Total	58	77	6,965	2,863	7	4,916	958	15,849

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Numbers less than 12 should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

b Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Includes persons whose race/ethnicity is unknown.

d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Vol. 28

Table 19a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2015—United States

		an Indian/ a Native	As	ian <sup>a</sup>		African rican	Hispanio	c/Latino <sup>b</sup>	Other	Hawaiian/ Pacific ander	Wi	nite	Multip	le races	To	otal
	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>
Age at death (yr)																
<13	0	0.0	0	0.0	2	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.0
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	4	0.1	0	0.0	0	0.0	3	0.0	0	0.0	7	0.0
20–24	0	0.0	0	0.0	75	2.2	14	0.3	0	0.0	11	0.1	6	1.0	106	0.5
25–29	1	0.5	2	0.1	164	5.3	63	1.4	0	0.0	44	0.3	22	4.8	296	1.3
30–34	5	3.1	5	0.3	235	8.5	97	2.2	0	0.0	75	0.6	29	7.6	446	2.1
35–39	2	1.4	5	0.4	336	12.9	135	3.2	1	2.4	118	1.0	34	10.5	631	3.1
40–44	5	3.5	10	0.7	464	18.2	193	4.9	1	2.7	243	2.0	60	21.5	976	4.8
45–49	8	5.4	9	0.7	682	26.4	315	9.1	0	0.0	489	3.7	99	39.9	1,602	7.7
50–54	10	6.2	11	1.0	999	36.9	403	13.3	1	2.9	842	5.6	156	64.7	2,422	10.9
55–59	8	5.2	7	0.7	980	38.4	331	13.6	1	3.3	796	5.2	163	74.6	2,286	10.5
60–64	4	3.2	4	0.5	789	38.3	249	13.6	0	0.0	518	3.7	134	78.2	1,698	8.9
≥65	6	2.4	9	0.5	856	20.4	300	8.0	0	0.0	740	2.0	114	33.2	2,025	4.2
Transmission category <sup>d</sup>																
Male adult or adolescent																
Male-to-male sexual contact	16	_	43	_	1,640	_	878	_	2	_	2,329	_	271	_	5,180	_
Injection drug use	4	_	3	_	950	_	411	_	0	_	348	_	153	_	1,869	_
Male-to-male sexual contact and injection drug use	7	_	3	_	349	-	200	_	0	_	443	_	122	_	1,124	_
Heterosexual contacte	5	_	7	_	764	_	183	_	2	_	171	_	59	_	1,192	_
Perinatal	0	_	1	_	14	_	5	_	0	_	3	_	3	_	26	_
Other <sup>f</sup>	0	_	0	_	15	_	7	_	0	_	32	_	7	_	62	_
Subtotal	33	3.5	57	0.8	3,734	24.3	1,684	7.8	4	1.8	3,326	4.0	615	30.0	9,453	7.2

Table 19a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2015—United States (cont)

		an Indian/ a Native	As	ian <sup>a</sup>		African rican	Hispanio	c/Latino <sup>b</sup>	Other	lawaiian/ Pacific Inder	W	nite	Multip	le races	To	otal
	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>	No.	Rate <sup>c</sup>
Female adult or adolescent																
Injection drug use	8	_	0	_	539	_	182	_	0	_	265	_	97	_	1,090	_
Heterosexual contact <sup>e</sup>	8	_	5	_	1,271	_	223	_	0	_	276	_	102	_	1,885	_
Perinatal	0	_	0	_	31	_	7	_	0	_	6	_	1	_	45	_
Other <sup>f</sup>	1	_	0	_	9	_	4	_	0	_	6	_	2	_	22	_
Subtotal	16	1.6	5	0.1	1,850	10.7	416	2.0	0	0.0	553	0.6	202	9.2	3,042	2.2
Child (<13 yrs at death)																
Perinatal	0	_	0	_	2	_	0	_	0	_	0	_	0	_	2	_
Other <sup>f</sup>	0	_	0	_	0	_	0	_	0	_	0	_	0	_	0	_
Subtotal	0	0.0	0	0.0	2	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.0
Region of residence <sup>g</sup>																
Northeast	0	0.0	8	0.2	1,183	18.7	767	9.7	0	0.0	624	1.7	301	33.2	2,883	5.1
Midwest	8	2.0	4	0.2	617	8.8	101	2.0	0	0.0	557	1.1	78	6.2	1,365	2.0
South	20	2.5	11	0.3	3,405	14.8	722	3.5	0	0.0	1,690	2.4	311	14.4	6,159	5.1
West	21	2.0	39	0.5	381	11.1	510	2.3	4	1.0	1,008	2.6	127	5.6	2,090	2.8
Total	49	2.1	62	0.4	5,586	14.0	2,100	3.7	4	0.7	3,879	2.0	817	12.4	12,497	3.9

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

b Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>c</sup> Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 19b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2015—United States and 6 dependent areas

	American Indian/ Alaska Native	<b>Asian</b> <sup>a</sup>	Black/ African American	Hispanic/Latino <sup>b</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Age at death (yr)								
<13	0	0	2	0	0	0	0	2
13–14	0	0	0	0	0	0	0	C
15–19	0	0	4	0	0	3	0	7
20–24	0	0	75	16	0	11	6	108
25–29	1	2	164	65	0	44	22	298
30–34	5	5	235	113	0	75	29	462
35–39	2	5	336	147	1	118	35	644
40–44	5	10	464	217	1	243	60	1,000
45–49	8	9	682	352	0	490	99	1,640
50–54	10	11	1,000	469	2	842	156	2,490
55–59	8	7	980	376	1	796	163	2,331
60–64	4	4	789	286	0	518	134	1,735
≥65	6	9	858	343	0	740	114	2,070
Fransmission category <sup>c</sup>								
Male adult or adolescent								
Male-to-male sexual contact	16	43	1,641	929	3	2,330	272	5,234
Injection drug use	4	3	951	504	0	348	153	1,963
Male-to-male sexual contact and injection drug use	7	3	349	225	0	443	122	1,149
Heterosexual contact <sup>d</sup>	5	7	765	225	2	171	59	1,235
Perinatal	0	1	14	6	0	3	3	27
Other <sup>e</sup>	0	0	15	7	0	32	7	62
Subtotal	33	57	3,735	1,897	5	3,327	616	9,670

Table 19b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2015—United States and 6 dependent areas (cont)

	American Indian/ Alaska Native	<b>A</b> sian <sup>a</sup>	Black/ African American	Hispanic/Latino <sup>b</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	8	0	539	195	0	265	97	1,103
Heterosexual contact <sup>d</sup>	8	5	1,273	280	0	276	102	1,944
Perinatal	0	0	31	8	0	6	1	46
Other <sup>e</sup>	1	0	9	4	0	6	2	22
Subtotal	16	5	1,852	487	0	553	202	3,115
Child (<13 yrs at end of year)								
Perinatal	0	0	2	0	0	0	0	2
Other <sup>e</sup>	0	0	0	0	0	0	0	0
Subtotal	0	0	2	0	0	0	0	2
Region of residence <sup>f</sup>								
Northeast	0	8	1,183	767	0	624	301	2,883
Midwest	8	4	617	101	0	557	78	1,365
South	20	11	3,405	722	0	1,690	311	6,159
West	21	39	381	510	4	1,008	127	2,090
J.S. dependent areas	0	0	3	284	1	1	1	290
Total	49	62	5,589	2,384	5	3,880	818	12,787

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Numbers less than 12 should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

b Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>c</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

<sup>&</sup>lt;sup>e</sup> Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

f Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 20a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2011–2015—United States

	20	11	20	12	20	13	20	14	20	)15
	No.	Rate <sup>a</sup>								
Age at end of year (yr)										
<13	2,808	5.3	2,713	5.1	2,589	4.9	2,465	4.7	2,322	4.4
13–14	1,065	12.9	894	10.8	780	9.3	746	8.9	721	8.7
15–19	6,813	31.4	6,300	29.5	5,703	26.9	5,305	25.2	4,959	23.5
20–24	30,663	138.3	31,896	141.1	32,056	140.4	31,723	138.6	30,812	135.8
25–29	51,527	242.0	53,945	252.2	57,405	266.1	61,540	280.3	65,540	292.6
30–34	69,908	340.7	71,675	342.7	72,943	342.9	74,731	347.5	76,656	354.6
35–39	85,520	436.2	84,090	431.2	84,290	429.6	85,542	430.1	88,220	434.3
40–44	129,318	614.4	123,550	587.2	116,978	560.6	110,690	538.4	103,583	513.9
45–49	167,492	755.4	164,020	755.7	158,609	747.1	151,482	726.4	146,349	703.6
50–54	142,621	631.8	151,584	671.1	160,339	710.4	167,641	743.7	171,172	767.9
55–59	95,194	469.8	104,566	503.2	113,356	534.9	121,961	567.6	131,430	603.8
60–64	52,359	293.9	58,976	330.9	65,910	363.7	73,780	397.8	81,438	427.8
≥65	38,978	94.2	45,483	105.4	52,819	118.2	60,888	131.8	70,644	148.0
Race/ethnicity										
American Indian/Alaska Native	2,424	105.9	2,546	110.2	2,636	113.1	2,763	117.5	2,904	122.6
Asian <sup>b</sup>	9,508	62.5	10,250	65.3	11,028	68.2	11,945	71.6	12,887	74.8
Black/African American	363,650	947.2	374,384	965.5	384,587	982.7	394,977	999.7	405,857	1,017.8
Hispanic/Latino <sup>c</sup>	185,278	356.9	192,350	363.0	198,971	368.0	206,185	373.6	213,736	379.4
Native Hawaiian/Other Pacific Islander	693	135.7	740	141.9	779	146.1	816	149.9	891	160.3
White	275,524	139.5	281,514	142.4	287,329	145.3	293,023	148.1	298,670	150.9
Multiple races	36,187	621.1	36,928	614.6	37,471	605.1	37,813	592.6	37,934	577.3
Transmission category <sup>d</sup>										
Male adult or adolescent										
Male-to-male sexual contact	446,305	_	466,328	_	485,717	_	506,037	_	526,456	_
Injection drug use	79,507	_	78,524	_	77,526	_	76,408	_	75,569	_
Male-to-male sexual contact and injection drug use	53,049	_	53,194	_	53,181	_	53,144	_	53,090	_
Heterosexual contact <sup>e</sup>	69,005	_	70,866	_	72,605	_	74,296	_	76,038	_
Perinatal	4,143	_	4,276	_	4,390	_	4,518	_	4,621	_
Other <sup>f</sup>	3,094	_	3,078	_	3,056	_	3,052	_	3,058	_
Subtotal	655,103	519.0	676,266	530.5	696,475	541.3	717,455	552.4	738,832	563.9

Table 20a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2011–2015—United States (cont)

	20	11	20	12	20	13	20	14	20	15
	No.	Rate <sup>a</sup>								
Female adult or adolescent										
Injection drug use	52,762	_	52,432	_	51,940	_	51,433	_	51,135	_
Heterosexual contact <sup>e</sup>	157,306	_	161,822	_	166,116	_	170,308	_	174,577	_
Perinatal	4,509	_	4,670	_	4,846	_	4,997	_	5,107	_
Other <sup>f</sup>	1,778	_	1,788	_	1,811	_	1,835	_	1,873	_
Subtotal	216,355	163.3	220,713	165.1	224,713	166.7	228,574	168.1	232,692	169.7
Child (<13 yrs at end of year)										
Perinatal	2,439	_	2,297	_	2,129	_	1,991	_	1,872	_
Other <sup>f</sup>	369	_	416	_	460	_	474	_	450	_
Subtotal	2,808	5.3	2,713	5.1	2,589	4.9	2,465	4.7	2,322	4.4
Region of residence <sup>g</sup>										
Northeast	221,710	398.5	225,164	403.3	228,266	407.7	232,424	414.2	234,735	417.8
Midwest	103,565	154.2	106,842	158.7	110,120	163.0	113,041	166.9	115,744	170.6
South	381,602	328.8	395,338	337.0	408,450	344.9	420,852	351.6	434,853	359.3
West	167,389	229.9	172,348	234.4	176,941	238.3	182,177	242.8	188,514	248.6
Total <sup>h</sup>	874,266	280.5	899,692	286.5	923,777	292.1	948,494	297.7	973,846	303.5

a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>d</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>&</sup>lt;sup>g</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

h Includes persons whose race/ethnicity is unknown.

<u><</u>

Table 20b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2011–2015—United States and 6 dependent areas

	20	11	20	12	20	13	20	14	20	15
	No.	Rate <sup>a</sup>	No.	Ratea						
Age at end of year (yr)										
<13	2,847	5.3	2,738	5.1	2,608	4.9	2,482	4.7	2,334	4.4
13–14	1,082	12.9	916	10.9	801	9.4	754	8.9	727	8.7
15–19	6,943	31.6	6,414	29.6	5,790	27.0	5,394	25.3	5,026	23.5
20–24	31,066	138.3	32,323	141.2	32,496	140.6	32,152	138.7	31,208	135.8
25–29	52,266	242.6	54,669	252.6	58,105	266.2	62,288	280.5	66,324	292.8
30–34	71,208	342.5	72,892	344.2	74,117	344.3	75,802	348.5	77,627	355.2
35–39	87,231	439.0	85,713	433.8	85,854	432.0	87,052	432.3	89,729	436.5
40–44	131,837	618.6	125,905	591.0	119,119	563.9	112,718	541.6	105,428	516.7
45–49	170,769	760.7	167,188	760.8	161,657	752.1	154,317	730.9	149,074	708.1
50–54	145,469	637.0	154,565	676.4	163,458	715.9	170,852	749.2	174,372	773.3
55–59	97,150	473.7	106,656	507.2	115,658	539.4	124,374	572.2	133,984	608.6
60–64	53,512	296.4	60,237	333.7	67,244	366.4	75,268	400.9	83,068	431.2
≥65	40,059	95.5	46,716	106.7	54,207	119.6	62,414	133.2	72,388	149.5
Race/ethnicity										
American Indian/Alaska Native	2,425	_	2,547	_	2,637	_	2,764	_	2,905	_
Asian <sup>b</sup>	9,548	_	10,291	_	11,069	_	11,985	_	12,932	_
Black/African American	363,970	_	374,696	_	384,906	_	395,300	_	406,175	_
Hispanic/Latino <sup>c</sup>	201,990	_	209,143	_	215,852	_	223,089	_	230,701	_
Native Hawaiian/Other Pacific Islander	711	_	759	_	797	_	837	_	917	_
White	275,592	_	281,574	_	287,395	_	293,096	_	298,744	_
Multiple races	36,198	_	36,939	_	37,479	_	37,821	_	37,945	_
Transmission category <sup>d</sup>										
Male adult or adolescent										
Male-to-male sexual contact	450,092	_	470,301	_	489,887	_	510,403	_	530,970	_
Injection drug use	83,936	_	82,827	_	81,725	_	80,502	_	79,599	_
Male-to-male sexual contact and injection drug use	53,929	_	54,045	_	54,019	_	53,951	_	53,898	_
Heterosexual contact <sup>e</sup>	71,456	_	73,354	_	75,119	_	76,839	_	78,612	_
Perinatal	4,267	_	4,404	_	4,518	_	4,642	_	4,744	_
Other <sup>f</sup>	3,135	_	3,118	_	3,097	_	3,093	_	3,098	_
Subtotal	666,815	521.6	688,049	533.1	708,365	543.8	729,430	554.9	750,921	566.4

Table 20b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2011–2015—United States and 6 dependent areas (cont)

	20	11	20	12	20	13	20	14	20	15
	No.	Rate <sup>a</sup>								
Female adult or adolescent										
Injection drug use	54,025	_	53,663	_	53,148	_	52,606	_	52,287	_
Heterosexual contact <sup>e</sup>	161,323	_	165,878	_	170,197	_	174,381	_	178,626	_
Perinatal	4,622	_	4,787	_	4,958	_	5,106	_	5,219	_
Other <sup>f</sup>	1,807	_	1,816	_	1,838	_	1,862	_	1,901	_
Subtotal	221,777	165.1	226,145	167.0	230,141	168.5	233,955	169.8	238,034	171.4
Child (<13 yrs at end of year)										
Perinatal	2,474	_	2,321	_	2,148		2,008	_	1,884	
Other <sup>f</sup>	373	_	417	_	460	_	474	_	450	_
Subtotal	2,847	5.3	2,738	5.1	2,608	4.9	2,482	4.7	2,334	4.4
Region of residence <sup>g</sup>										
Northeast	221,710	398.5	225,164	403.3	228,266	407.7	232,424	414.2	234,735	417.8
Midwest	103,565	154.2	106,842	158.7	110,120	163.0	113,041	166.9	115,744	170.6
South	381,602	328.8	395,338	337.0	408,450	344.9	420,852	351.6	434,853	359.3
West	167,389	229.9	172,348	234.4	176,941	238.3	182,177	242.8	188,514	248.6
U.S. dependent areas	17,173	421.7	17,240	428.1	17,337	435.0	17,373	442.4	17,443	451.1
Total <sup>h</sup>	891,439	282.3	916,932	288.3	941,114	293.9	965,867	299.5	991,289	305.2

<sup>&</sup>lt;sup>a</sup> Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>&</sup>lt;sup>b</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>&</sup>lt;sup>g</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

h Includes persons whose race/ethnicity is unknown.

VOI. 28

Table 21a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2011–2015—United States

								-		
	20	11	20	12	20	13	20	14	20	15
	No.	Ratea								
Age at end of year (yr)										
<13	380	0.7	323	0.6	280	0.5	300	0.6	276	0.5
13–14	255	3.1	194	2.3	154	1.8	134	1.6	132	1.6
15–19	2,280	10.5	1,965	9.2	1,702	8	1,305	6.2	972	4.6
20–24	7,997	36.1	8,251	36.5	8,261	36.2	7,519	32.8	6,736	29.7
25–29	16,164	75.9	16,541	77.3	17,393	80.6	17,876	81.4	18,017	80.4
30–34	27,992	136.4	28,294	135.3	28,207	132.6	27,572	128.2	27,258	126.1
35–39	41,870	213.5	40,401	207.1	39,758	202.6	38,920	195.7	38,606	190.1
40–44	72,482	344.4	68,272	324.5	63,609	304.9	58,941	286.7	53,713	266.5
45–49	102,825	463.7	99,837	460.0	95,450	449.6	89,572	429.5	84,744	407.4
50–54	91,647	406.0	96,909	429.0	101,917	451.6	105,686	468.8	106,763	479.0
55–59	62,700	309.4	68,768	330.9	74,289	350.5	79,162	368.4	84,701	389.1
60–64	34,669	194.6	39,001	218.9	43,635	240.8	48,747	262.8	53,541	281.2
≥65	26,142	63.2	30,425	70.5	35,222	78.8	40,485	87.6	46,824	98.1
Race/ethnicity										
American Indian/Alaska Native	1,321	57.7	1,371	59.3	1,404	60.2	1,448	61.6	1,492	63.0
Asian <sup>b</sup>	5,081	33.4	5,381	34.3	5,673	35.1	5,947	35.6	6,211	36.1
Black/African American	197,850	515.3	203,595	525.1	208,803	533.5	211,928	536.4	215,024	539.2
Hispanic/Latino <sup>c</sup>	110,808	213.5	114,036	215.2	116,885	216.2	118,803	215.3	120,770	214.4
Native Hawaiian/Other Pacific Islander	388	76.0	406	77.8	420	78.8	432	79.4	452	81.3
White	150,334	76.1	152,361	77.1	154,318	78.0	155,200	78.4	155,958	78.8
Multiple races	21,574	370.3	21,985	365.9	22,329	360.6	22,416	351.3	22,331	339.9
Transmission category <sup>d</sup>										
Male adult or adolescent										
Male-to-male sexual contact	237,904	_	245,948	_	253,709	_	258,848	_	263,791	_
Injection drug use	53,043	_	52,527	_	51,860	_	51,001	_	50,139	_
Male-to-male sexual contact and injection drug use	34,348	_	34,434	_	34,320	_	33,965	_	33,617	_
Heterosexual contact <sup>e</sup>	41,892	_	43,251	_	44,511	_	45,396	_	46,187	_
Perinatal	2,298	_	2,343	_	2,405	_	2,446	_	2,513	_
Other <sup>f</sup>	2,103	_	2,094	_	2,094	_	2,082	_	2,053	_
Subtotal	371,590	294.4	380,598	298.6	388,899	302.2	393,739	303.1	398,300	304.0

Table 21a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2011–2015—United States (cont)

	20	11	20	12	20	13	20	14	20	15
	No.	Rate <sup>a</sup>								
Female adult or adolescent										
Injection drug use	32,011	_	31,957	_	31,721	_	31,367	_	31,072	
Heterosexual contact <sup>e</sup>	79,857	_	82,668	_	85,232	_	87,002	_	88,777	_
Perinatal	2,466	_	2,538	_	2,650	_	2,710	_	2,759	_
Other <sup>f</sup>	1,099	_	1,097	_	1,095	_	1,100	_	1,099	_
Subtotal	115,433	87.1	118,260	88.5	120,698	89.5	122,180	89.8	123,707	90.2
Child (<13 yrs at end of year)										
Perinatal	358	_	302	_	259	_	269	_	243	_
Other <sup>f</sup>	22	_	21	_	21	_	31	_	33	_
Subtotal	380	0.7	323	0.6	280	0.5	300	0.6	276	0.5
Region of residence <sup>g</sup>										
Northeast	131,321	236.0	132,481	237.3	133,396	238.3	134,082	238.9	133,827	238.2
Midwest	54,467	81.1	55,857	83.0	57,199	84.7	58,110	85.8	58,655	86.5
South	204,202	175.9	211,541	180.3	218,324	184.4	222,083	185.5	226,408	187.1
West	97,413	133.8	99,302	135.0	100,958	136.0	101,944	135.9	103,393	136.3
Total <sup>h</sup>	487,403	156.4	499,181	159.0	509,877	161.2	516,219	162.0	522,283	162.8

<sup>&</sup>lt;sup>a</sup> Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>&</sup>lt;sup>g</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

h Includes persons whose race/ethnicity is unknown.

Vol. 28

Table 21b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2011–2015—United States and 6 dependent areas

	20	11	20	12	20	13	20	14	20	15
	No.	Ratea	No.	Rate <sup>a</sup>	No.	Ratea	No.	Rate <sup>a</sup>	No.	Ratea
Age at end of year (yr)										
<13	386	0.7	328	0.6	283	0.5	303	0.6	278	0.5
13–14	261	3.1	198	2.4	159	1.9	135	1.6	133	1.6
15–19	2,329	10.6	2,009	9.3	1,738	8.1	1,335	6.3	991	4.6
20–24	8,114	36.1	8,363	36.5	8,372	36.2	7,619	32.9	6,827	29.7
25–29	16,370	76.0	16,732	77.3	17,585	80.6	18,077	81.4	18,216	80.4
30–34	28,390	136.6	28,659	135.3	28,553	132.6	27,888	128.2	27,536	126.0
35–39	42,603	214.4	41,083	207.9	40,387	203.2	39,503	196.2	39,144	190.4
40–44	73,790	346.2	69,461	326.1	64,689	306.2	59,941	288.0	54,618	267.7
45–49	104,878	467.2	101,774	463.1	97,259	452.5	91,196	431.9	86,258	409.7
50–54	93,474	409.3	98,805	432.4	103,935	455.2	107,755	472.5	108,778	482.4
55–59	64,015	312.1	70,183	333.8	75,840	353.7	80,763	371.6	86,403	392.5
60–64	35,469	196.5	39,875	220.9	44,552	242.8	49,780	265.1	54,647	283.6
≥65	26,874	64.0	31,264	71.4	36,173	79.8	41,523	88.6	48,013	99.2
Race/ethnicity										
American Indian/Alaska Native	1,322	_	1,372	_	1,405	_	1,449	_	1,493	_
Asian <sup>b</sup>	5,098	_	5,397		5,689	_	5,963	_	6,228	_
Black/African American	198,020	_	203,764		208,973	_	212,097	_	215,195	_
Hispanic/Latino <sup>c</sup>	120,118	_	123,354		126,296	_	128,164	_	130,085	_
Native Hawaiian/Other Pacific Islander	400	_	419		431	_	443	_	466	_
White	150,370	_	152,394		154,355	_	155,239	_	155,996	_
Multiple races	21,578	_	21,988	_	22,331	_	22,418	_	22,334	_
Transmission category <sup>d</sup>										
Male adult or adolescent										
Male-to-male sexual contact	239,905	_	248,006	_	255,845	_	261,019	_	265,977	_
Injection drug use	55,644	_	55,074	_	54,371	_	53,456	_	52,562	_
Male-to-male sexual contact and injection drug use	34,916	_	34,989	_	34,863	_	34,492	_	34,141	_
Heterosexual contact <sup>e</sup>	43,288	_	44,658		45,943	_	46,847	_	47,653	
Perinatal	2,375	_	2,421		2,485	_	2,524	_	2,589	
Other <sup>f</sup>	2,127	_	2,115	_	2,116	_	2,102	_	2,073	_
Subtotal	378,256	295.9	387,263	300.0	395,624	303.7	400,441	304.6	404,995	305.5

Table 21b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2011–2015—United States and 6 dependent areas (cont)

	20	11	20	12	20	13	20	14	20	15
	No.	Rate <sup>a</sup>								
Female adult or adolescent										
Injection drug use	32,748		32,683	_	32,442	_	32,079	_	31,776	_
Heterosexual contact <sup>e</sup>	81,913	_	84,741	_	87,349	_	89,102	_	90,849	
Perinatal	2,541	_	2,613	_	2,721	_	2,782	_	2,833	
Other <sup>f</sup>	1,109	_	1,106	_	1,106	_	1,111	_	1,112	
Subtotal	118,311	88.1	121,143	89.4	123,618	90.5	125,074	90.8	126,569	91.1
Child (<13 yrs at end of year)										
Perinatal	364	_	307	_	262	_	272	_	245	_
Other <sup>f</sup>	22	_	21	_	21	_	31	_	33	
Subtotal	386	0.7	328	0.6	283	0.5	303	0.6	278	0.5
Region of residence <sup>g</sup>										
Northeast	131,321	236.0	132,481	237.3	133,396	238.3	134,082	238.9	133,827	238.2
Midwest	54,467	81.1	55,857	83.0	57,199	84.7	58,110	85.8	58,655	86.5
South	204,202	175.9	211,541	180.3	218,324	184.4	222,083	185.5	226,408	187.1
West	97,413	133.8	99,302	135.0	100,958	136.0	101,944	135.9	103,393	136.3
U.S. dependent areas	9,550	234.5	9,553	237.2	9,648	242.1	9,599	244.4	9,559	247.2
Total <sup>h</sup>	496,953	157.4	508,734	160.0	519,525	162.3	525,818	163.0	531,842	163.8

<sup>&</sup>lt;sup>a</sup> Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>&</sup>lt;sup>b</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>C</sup> Hispanics/Latinos can be of any race.

d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

 $<sup>^{</sup>m g}$  Data are based on address of residence at the end of the specified year (i.e., most recent known address).

h Includes persons whose race/ethnicity is unknown.

Table 22a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2015—United States

		American Indian/ Alaska Native		an <sup>a</sup>		nck/ American	Hispanio	:/Latino <sup>b</sup>	Other	Hawaiian/ · Pacific ander	Wh	iite	Multipl	e races	Tot	tal <sup>c</sup>
	No.	Rate <sup>d</sup>	No.	Rated	No.	Rate <sup>d</sup>	No.	Rated	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>
Age at end of year (yr)																
<13	8	1.8	100	3.9	1,482	20.5	308	2.3	3	2.8	297	1.1	124	5.3	2,322	4.4
13–14	5	7.1	12	3.0	464	40.5	107	5.5	1	6.3	88	2.0	44	15.0	721	8.7
15–19	10	5.5	64	6.3	3,136	105.0	1,005	21.4	4	10.0	515	4.5	219	32.0	4,959	23.5
20–24	117	58.8	397	31.8	17,951	529.1	6,619	138.3	33	71.4	4,369	35.2	1,318	219.7	30,812	135.8
25–29	221	120.6	973	66.6	34,802	1,118.9	14,740	327.1	68	132.5	11,883	94.1	2,846	616.5	65,540	292.6
30–34	284	174.5	1,299	87.4	35,345	1,278.9	19,469	440.2	91	187.9	16,876	136.6	3,285	858.6	76,656	354.6
35–39	314	212.0	1,627	116.7	37,647	1,446.6	23,698	562.7	126	299.9	21,153	182.5	3,631	1,119.7	88,220	434.3
40–44	340	237.3	2,147	154.0	42,577	1,671.6	26,675	683.9	118	318.7	27,570	232.5	4,100	1,470.8	103,583	513.9
45–49	483	328.5	2,099	170.3	56,397	2,184.0	34,333	990.6	131	374.8	46,946	358.6	5,827	2,347.6	146,349	703.6
50–54	469	289.5	1,620	144.1	64,045	2,364.2	34,982	1,158.4	127	366.8	63,042	420.3	6,669	2,766.4	171,172	767.9
55–59	320	209.2	1,110	108.5	52,280	2,047.1	24,592	1,011.4	91	299.1	47,988	312.5	4,847	2,217.3	131,430	603.8
60–64	199	160.8	709	80.7	32,877	1,597.4	14,351	786.0	59	249.3	30,248	216.7	2,852	1,663.6	81,438	427.8
≥65	134	54.6	730	36.7	26,854	638.8	12,857	342.7	39	85.0	27,695	74.5	2,172	632.3	70,644	148.0
Transmission category <sup>e</sup>																
Male adult or adolescent																
Male-to-male sexual contact	1,458	_	8,706	_	162,191	_	120,755	_	632	_	212,143	_	20,096	_	526,456	_
Injection drug use	218	_	429	_	37,008	_	21,226	_	26	_	13,973	_	2,591	_	75,569	_
Male-to-male sexual contact and injection drug use	276	_	364	_	15,835	_	11,393	_	38	_	21,815	_	3,310	_	53,090	_
Heterosexual contact <sup>f</sup>	164	_	904	_	47,832	_	15,307	_	36	_	9,429	_	2,327	_	76,038	_
Perinatal	7	_	25	_	2,631	_	1,174	_	2	_	548	_	224	_	4,621	_
Other <sup>g</sup>	13	_	76	_	880	_	487	_	2	_	1,474	_	119	_	3,058	_
Subtotal	2,136	227.3	10,504	152.6	266,377	1,730.3	170,342	786.9	735	324.5	259,381	309.2	28,667	1,398.0	738,832	563.9

Table 22a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2015—United States (cont)

		American Indian/ Alaska Native		ian <sup>a</sup>		ack/ American	Hispanio	:/Latino <sup>b</sup>	Other	Hawaiian/ Pacific ander	Wh	ite	Multipl	e races	To	tal <sup>c</sup>
	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rated	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>
Female adult or adolescent																
Injection drug use	234	_	175	_	25,812	_	9,827	_	26	_	12,368	_	2,599	_	51,135	_
Heterosexual contact <sup>f</sup>	505	_	2,022	_	108,264	_	31,730	_	125	_	25,542	_	6,224	_	174,577	_
Perinatal	8	_	22	_	3,048	_	1,206	_	1	_	577	_	238	_	5,107	_
Other <sup>g</sup>	13	_	64	_	874	_	323	_	1	_	505	_	82	_	1,873	_
Subtotal	760	77.5	2,283	29.4	137,998	799.5	43,086	202.2	153	68.3	38,992	44.6	9,143	416.0	232,692	169.7
Child (<13 yrs at end of year)																
Perinatal	8	_	69	_	1,206	_	279	_	3	_	198	_	109	_	1,872	_
Other <sup>g</sup>	0	_	31	_	276	_	29	_	0	_	99	_	15	_	450	_
Subtotal	8	1.8	100	3.9	1,482	20.5	308	2.3	3	2.8	297	1.1	124	5.3	2,322	4.4
Region of residence <sup>h</sup>																
Northeast	149	118.2	2,692	74.3	89,132	1408.2	76,531	971.8	58	277.0	53,390	143.1	12,250	1,351.6	234,735	417.8
Midwest	354	87.2	1,261	60.0	50,056	711.3	12,985	251.3	38	122.1	46,261	89.2	4,660	371.5	115,744	170.6
South	721	91.9	2,565	64.3	236,828	1,026.6	65,950	316.4	148	174.8	113,214	161.5	15,246	707.0	434,853	359.3
West	1,680	159.5	6,369	84.8	29,841	867.5	58,270	259.5	647	154.3	85,805	221.7	5,778	256.4	188,514	248.6
Total	2,904	122.6	12,887	74.8	405,857	1,017.8	213,736	379.4	891	160.3	298,670	150.9	37,934	577.3	973,846	303.5

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

b Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Includes persons whose race/ethnicity is unknown.

d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

<sup>&</sup>lt;sup>g</sup> Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

h Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 22b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2015—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian <sup>a</sup>	Black/ African American	Hispanic/Latino <sup>b</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total <sup>c</sup>
	No.	No.	No.	No.	No.	No.	No.	No.
Age at end of year (yr)								
<13	8	100	1,483	317	4	297	125	2,334
13–14	5	12	464	113	1	88	44	727
15–19	10	64	3,139	1,069	4	515	219	5,026
20–24	117	397	17,956	7,008	33	4,369	1,320	31,208
25–29	221	977	34,816	15,498	73	11,885	2,847	66,324
30–34	284	1,301	35,361	20,414	95	16,880	3,285	77,627
35–39	314	1,632	37,667	25,170	130	21,158	3,634	89,729
40–44	340	2,154	42,619	28,461	122	27,574	4,100	105,428
45–49	483	2,108	56,453	36,974	134	46,960	5,829	149,074
50-54	469	1,626	64,085	38,120	127	63,056	6,671	174,372
55–59	321	1,114	52,324	27,083	93	48,000	4,847	133,984
60–64	199	712	32,906	15,938	61	30,256	2,852	83,068
≥65	134	735	26,902	14,536	40	27,706	2,172	72,388
Transmission category <sup>d</sup>								
Male adult or adolescent								
Male-to-male sexual contact	1,458	8,732	162,264	125,101	646	212,190	20,102	530,970
Injection drug use	218	436	37,047	25,202	27	13,978	2,591	79,599
Male-to-male sexual contact and injection drug use	276	364	15,842	12,188	38	21,819	3,311	53,898
Heterosexual contacte	165	906	47,894	17,812	38	9,430	2,327	78,612
Perinatal	7	25	2,634	1,294	2	548	224	4,744
Other <sup>f</sup>	13	76	880	527	2	1,474	119	3,098
Subtotal	2,137	10,540	266,561	182,124	753	259,440	28,674	750,921

Table 22b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2015—United States and 6 dependent areas (cont)

	American Indian/ Alaska Native	Asian <sup>a</sup>	Black/ African American	Hispanic/Latino <sup>b</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	<b>Total</b> <sup>c</sup>
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	234	177	25,827	10,956	26	12,373	2,599	52,288
Heterosexual contacte	505	2,029	108,373	35,644	131	25,552	6,227	178,626
Perinatal	8	22	3,053	1,313	1	577	238	5,219
Other <sup>f</sup>	13	64	878	347	1	505	82	1,901
Subtotal	760	2,292	138,131	48,260	160	39,007	9,146	238,034
Child (<13 yrs at end of year	r)							
Perinatal	8	69	1,207	288	4	198	110	1,884
Other <sup>f</sup>	0	31	276	29	0	99	15	450
Subtotal	8	100	1,483	317	4	297	125	2,334
Region of residence <sup>9</sup>								
Northeast	149	2,692	89,132	76,531	58	53,390	12,250	234,735
/lidwest	354	1,261	50,056	12,985	38	46,261	4,660	115,744
South	721	2,565	236,828	65,950	148	113,214	15,246	434,853
Vest	1,680	6,369	29,841	58,270	647	85,805	5,778	188,514
J.S. dependent areas	1	45	318	16,965	26	74	11	17,443
Гotal	2,905	12,932	406,175	230,701	917	298,744	37,945	991,289

*Note*. Numbers less than 12 should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>b</sup> Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Includes persons whose race/ethnicity is unknown.

d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>&</sup>lt;sup>9</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 23a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2015—United States

		ın Indian/ ı Native	Asi	an <sup>a</sup>		nck/ American	Hispanio	:/Latino <sup>b</sup>	Other	Hawaiian/ Pacific ander	Wh	iite	Multip	le races	To	tal <sup>c</sup>
	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rated	No.	Rated	No.	Rated	No.	Rate <sup>d</sup>	No.	Rated	No.	Rated
Age at end of year (yr)																
<13	0	0.0	5	0.2	179	2.5	45	0.3	1	0.9	27	0.1	19	0.8	276	0.5
13–14	3	4.2	4	1.0	83	7.2	20	1.0	1	6.3	16	0.4	5	1.7	132	1.6
15–19	2	1.1	9	0.9	651	21.8	185	3.9	0	0.0	79	0.7	46	6.7	972	4.6
20–24	23	11.6	52	4.2	4,209	124.1	1,405	29.4	8	17.3	652	5.2	386	64.3	6,736	29.7
25–29	54	29.5	195	13.3	10,358	333.0	4,111	91.2	17	33.1	2,379	18.8	903	195.6	18,017	80.4
30–34	108	66.4	391	26.3	13,410	485.2	7,407	167.5	30	62.0	4,618	37.4	1,294	338.2	27,258	126.1
35–39	129	87.1	628	45.0	17,254	663.0	11,057	262.5	58	138.0	7,669	66.2	1,811	558.5	38,606	190.1
40–44	183	127.7	1,011	72.5	22,820	895.9	14,741	377.9	55	148.5	12,480	105.3	2,421	868.5	53,713	266.5
45–49	277	188.4	1,163	94.4	33,370	1,292.2	21,226	612.5	86	246.0	24,848	189.8	3,768	1,518.1	84,744	407.4
50-54	280	172.9	1,004	89.3	40,004	1,476.7	23,647	783.1	85	245.5	37,071	247.2	4,665	1,935.1	106,763	479.0
55–59	212	138.6	737	72.0	33,605	1,315.9	17,202	707.5	49	161.1	29,459	191.8	3,427	1,567.7	84,701	389.1
60–64	130	105.0	495	56.3	21,502	1,044.7	10,372	568.1	33	139.4	18,962	135.9	2,038	1,188.8	53,541	281.2
≥65	91	37.1	517	26.0	17,579	418.1	9,352	249.3	29	63.2	17,698	47.6	1,548	450.6	46,824	98.1
Transmission category <sup>e</sup>																
Male adult or adolescent																
Male-to-male sexual contact	693	_	4,030	_	77,173	_	62,513	_	323	_	108,207	_	10,825	_	263,791	_
Injection drug use	132	_	253	_	24,267	_	14,787	_	11	_	8,759	_	1,927	_	50,139	_
Male-to-male sexual contact and injection drug use	174	_	224	_	10,435	_	7,524	_	23	_	12,972	_	2,264	-	33,617	_
Heterosexual contact <sup>f</sup>	96	_	561	_	28,239	_	10,242	_	19	_	5,472	_	1,552	_	46,187	_
Perinatal	3	_	11	_	1,445	_	652	_	2	_	274	_	126	_	2,513	_
Other <sup>g</sup>	12	_	56	_	487	_	343	_	1	_	1,072	_	82	_	2,053	_
Subtotal	1,110	118.1	5,135	74.6	142,045	922.7	96,061	443.8	379	167.3	136,756	163.0	16,776	818.1	398,300	304.0

Table 23a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2015—United States (cont)

	American Indian/ Alaska Native		Asian <sup>a</sup>		Black/ African American		Hispanic/Latino <sup>b</sup>		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total <sup>c</sup>	
	No.	Rate <sup>d</sup>	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>	No.	Rate <sup>d</sup>
Female adult or adolescent																
Injection drug use	117	_	91	_	15,960	_	6,448	_	16	_	6,635	_	1,805	_	31,072	_
Heterosexual contact <sup>f</sup>	252	_	929	_	54,701	_	17,331	_	54	_	11,951	_	3,555	_	88,777	_
Perinatal	5	_	9	_	1,661	_	675	_	1	_	274	_	133	_	2,759	_
Other <sup>g</sup>	9	_	42	_	478	_	211	_	1	_	315	_	43	_	1,099	_
Subtotal	382	38.9	1,071	13.8	72,800	421.8	24,664	115.7	72	32.1	19,175	21.9	5,536	251.9	123,707	90.2
Child (<13 yrs at end of year)																
Perinatal	0	_	4	_	160	_	39	_	1	_	22	_	17	_	243	_
Other <sup>g</sup>	0	_	1	_	19	_	6	_	0	_	5	_	2	_	33	_
Subtotal	0	0.0	5	0.2	179	2.5	45	0.3	1	0.9	27	0.1	19	0.8	276	0.5
Region of residence <sup>h</sup>																
Northeast	77	61.1	1,303	35.9	50,697	801.0	45,701	580.3	21	100.3	28,350	76.0	7,652	844.3	133,827	238.2
Midwest	170	41.9	552	26.3	25,015	355.4	7,080	137.0	17	54.6	23,169	44.7	2,651	211.3	58,655	86.5
South	330	42.1	1,084	27.2	123,219	534.1	34,973	167.8	49	57.9	57,941	82.6	8,807	408.4	226,408	187.1
West	915	86.9	3,272	43.6	16,093	467.8	33,016	147.0	365	87.1	46,498	120.1	3,221	142.9	103,393	136.3
Total	1,492	63.0	6,211	36.1	215,024	539.2	120,770	214.4	452	81.3	155,958	78.8	22,331	339.9	522,283	162.8

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>b</sup> Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Includes persons whose race/ethnicity is unknown.

d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

<sup>&</sup>lt;sup>g</sup> Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

h Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 23b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2015—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian <sup>a</sup>	Black/ African American	Hispanic/Latino <sup>b</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	<b>Total</b> <sup>c</sup>
	No.	No.	No.	No.	No.	No.	No.	No.
Age at end of year								
<13	0	5	179	46	2	27	19	278
13–14	3	4	83	21	1	16	5	133
15–19	2	9	653	202	0	79	46	991
20–24	23	52	4,212	1,493	8	652	386	6,827
25–29	54	196	10,361	4,304	19	2,379	903	18,216
30–34	108	391	13,417	7,677	30	4,619	1,294	27,536
35–39	129	629	17,262	11,580	61	7,672	1,811	39,144
40–44	183	1,013	22,840	15,622	57	12,480	2,421	54,618
45–49	277	1,168	33,406	22,692	88	24,852	3,769	86,258
50-54	280	1,007	40,027	25,623	85	37,082	4,667	108,778
55–59	213	738	33,625	18,874	50	29,466	3,427	86,403
60–64	130	497	21,524	11,448	35	18,966	2,038	54,647
≥65	91	519	17,606	10,503	30	17,706	1,548	48,013
Transmission category <sup>d</sup>								
Male adult or adolescent								
Male-to-male sexual contact	693	4,042	77,217	64,607	330	108,234	10,827	265,977
Injection drug use	132	255	24,284	17,188	12	8,761	1,927	52,563
Male-to-male sexual contact and injection drug use	174	224	10,439	8,041	23	12,974	2,264	34,141
Heterosexual contacte	97	561	28,280	11,664	20	5,473	1,552	47,653
Perinatal	3	11	1,447	726	2	274	126	2,589
Other <sup>f</sup>	12	56	487	363	1	1,072	82	2,073
Subtotal	1,111	5,149	142,154	102,589	388	136,788	16,778	404,995

Table 23b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2015—United States and 6 dependent areas (cont)

	American Indian/ Alaska Native	Asian <sup>a</sup>	Black/ African American	Hispanic/Latino <sup>b</sup>	Native Hawaiian/ Other Pacific Islander	White	Multiple races	<b>Total</b> <sup>c</sup>
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent	t							
Injection drug use	117	91	15,968	7,139	17	6,638	1,805	31,776
Heterosexual contact <sup>e</sup>	252	932	54,750	19,344	58	11,954	3,556	90,849
Perinatal	5	9	1,665	745	1	274	133	2,833
Other <sup>f</sup>	9	42	479	222	1	315	43	1,112
Subtotal	382	1,074	72,862	27,450	76	19,181	5,537	126,569
Child (<13 yrs at end of year)								
Perinatal	0	4	160	40	2	22	17	245
Other <sup>f</sup>	0	1	19	6	0	5	2	33
Subtotal	0	5	179	46	2	27	19	278
Region of residence <sup>g</sup>								
lortheast	77	1,303	50,697	45,701	21	28,350	7,652	133,827
lidwest	170	552	25,015	7,080	17	23,169	2,651	58,655
outh	330	1,084	123,219	34,973	49	57,941	8,807	226,408
Vest	915	3,272	16,093	33,016	365	46,498	3,221	103,393
I.S. dependent areas	1	17	171	9,315	14	38	3	9,559
otal	1,493	6,228	215,195	130,085	466	155,996	22,334	531,842

Note. Numbers less than 12 should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>b</sup> Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Includes persons whose race/ethnicity is unknown.

d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>&</sup>lt;sup>e</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>&</sup>lt;sup>9</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 24. Diagnoses of HIV infection, by area of residence, 2015 and 2016—United States and 6 dependent areas

			2	015					20	016		
		ts and scents	Chi	ildren	To	tal		s and scents	Chi	ldren	Ta	otal
Area of residence	No.	Rate <sup>a</sup>	No.	Rate	No.	Rate <sup>a</sup>	No.	Rate <sup>a</sup>	No.	Rate	No.	Rate <sup>a</sup>
Alabama	658	16.2	0	0.0	658	13.6	533	13.1	0	0.0	533	11.0
Alaska	24	4.0	0	0.0	24	3.3	37	6.1	0	0.0	37	5.0
Arizona	695	12.3	4	0.3	699	10.3	778	13.5	1	0.1	779	11.2
Arkansas	271	11.0	0	0.0	271	9.1	314	12.7	1	0.2	315	10.5
California	4,983	15.4	8	0.1	4,991	12.8	4,961	15.2	11	0.2	4,972	12.7
Colorado	378	8.3	1	0.1	379	7.0	423	9.1	0	0.0	423	7.6
Connecticut	273	8.9	2	0.4	275	7.7	251	8.2	2	0.4	253	7.1
Delaware	104	13.0	0	0.0	104	11.0	117	14.5	0	0.0	117	12.3
District of Columbia	364	63.0	1	1.1	365	54.4	326	55.6	1	1.1	327	48.0
Florida	4,672	27.0	15	0.5	4,687	23.2	4,940	28.0	17	0.6	4,957	24.0
Georgia	2,585	30.7	7	0.4	2,592	25.4	2,709	31.8	7	0.4	2,716	26.3
Hawaii	121 40	10.1 3.0	0	0.0 0.3	121 41	8.5 2.5	82 44	6.8 3.2	0	0.0	82 44	5.7 2.6
Idaho Illinois	1,525	3.0 14.2	6	0.3	1,531	2.5 11.9	1,384	12.9	7	0.0	1,391	10.9
Indiana	633	11.5	4	0.3	637	9.6	483	8.8	1	0.3	484	7.3
lowa	124	4.8	0	0.4	124	4.0	133	5.1	4	0.1	137	4.4
Kansas	154	6.5	2	0.0	156	5.4	141	5.9	1	0.0	142	4.9
Kentucky	341	9.2	1	0.1	342	7.7	319	8.6	2	0.3	321	7.2
Louisiana	1,112	28.8	2	0.2	1,114	23.9	1,151	29.7	2	0.2	1,153	24.6
Maine	46	4.0	1	0.6	47	3.5	50	4.3	0	0.0	50	3.8
Maryland	1,193	23.7	1	0.1	1,194	19.9	1,097	21.7	4	0.4	1,101	18.3
Massachusetts	612	10.5	4	0.4	616	9.1	710	12.1	1	0.1	711	10.4
Michigan	726	8.7	1	0.1	727	7.3	747	8.9	1	0.1	748	7.5
Minnesota	294	6.5	2	0.2	296	5.4	286	6.2	3	0.3	289	5.2
Mississippi	507	20.5	1	0.2	508	17.0	424	17.1	1	0.2	425	14.2
Missouri	464	9.1	3	0.3	467	7.7	511	10.0	7	0.7	518	8.5
Montana	19	2.2	0	0.0	19	1.8	17	1.9	1	0.6	18	1.7
Nebraska	81	5.2	0	0.0	81	4.3	76 505	4.9	0	0.0	76 525	4.0
Nevada	480 24	20.0 2.1	2 0	0.4 0.0	482 24	16.7 1.8	525 42	21.4 3.6	0	0.0	525 42	17.9 3.1
New Hampshire New Jersey	1,161	15.4	5	0.0	1,166	13.0	1,143	15.2	3	0.0	1,146	12.8
New Mexico	137	7.9	0	0.4	137	6.6	1,143	7.2	0	0.2	1,140	6.0
New York	3,108	18.6	5	0.0	3,113	15.8	2,875	17.2	2	0.0	2,877	14.6
North Carolina	1,331	15.8	9	0.6	1,340	13.4	1,404	16.5	10	0.6	1,414	13.9
North Dakota	20	3.2	0	0.0	20	2.6	46	7.4	0	0.0	46	6.1
Ohio	931	9.6	6	0.3	937	8.1	969	9.9	4	0.2	973	8.4
Oklahoma	318	9.9	0	0.0	318	8.1	293	9.1	1	0.1	294	7.5
Oregon	218	6.4	0	0.0	218	5.4	221	6.4	1	0.2	222	5.4
Pennsylvania	1,177	10.8	6	0.3	1,183	9.2	1,150	10.6	2	0.1	1,152	9.0
Rhode Island	64	7.0	0	0.0	64	6.1	70	7.7	0	0.0	70	6.6
South Carolina	668	16.2	2	0.3	670	13.7	757	18.1	2	0.3	759	15.3
South Dakota	23	3.3	2	1.3	25	2.9	39	5.5	1	0.6	40	4.6
Tennessee	740	13.4	. 8	0.7	748	11.3	715	12.8	7	0.7	722	10.9
Texas	4,479	20.2	16	0.3	4,495	16.4	4,464	19.8	8	0.2	4,472	16.1
Utah	126	5.4	0	0.0	126	4.2	135	5.7	0	0.0	135	4.4
Vermont	13	2.4	1	1.2 0.1	14	2.2	8	1.5	0 3	0.0 0.2	8	1.3
Virginia Washington	962 450	13.7 7.5	4	0.1	963 454	11.5 6.3	893 432	12.6 7.1	ა 3	0.2	896 435	10.7 6.0
Washington West Virginia	72	4.6	1	0.3	73	4.0	66	4.2	0	0.0	66	3.6
Wisconsin	223	4.6	0	0.4	223	3.9	224	4.6	0	0.0	224	3.9
Wyoming	17	3.5	0	0.0	17	2.9	20	4.1	0	0.0	20	3.4
Subtotal	39,741	14.8	135	0.3	39,876	12.4	39,660	14.7	122	0.2	39,782	12.3
U.S. dependent areas	00,111			0.0	00,0.0		00,000			V. <u> </u>	00,.02	
American Samoa	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Guam	6	4.7	0	0.0	6	3.7	5	3.9	0	0.0	5	3.1
Northern Mariana Islands	3	7.5	0	0.0	3	5.7	0	0.0	0	0.0	0	0.0
Puerto Rico	544	18.3	0	0.0	544	15.7	523	17.8	0	0.0	523	15.3
Republic of Palau	1	5.7	0	0.0	1	4.7	2	11.2	0	0.0	2	9.4
U.S. Virgin Islands	12	13.7	0	0.0	12	11.6	12	13.7	0	0.0	12	11.7
Subtotal	566	17.2	0	0.0	566	14.6	542	16.6	Ö	0.0	542	14.2
Total	40,307	14.8	135	0.3	40,442	12.5	40,202	14.7	122	0.2	40,324	12.3
Note Data are based on addr					most recent k		no) Data for the					no thou are

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address). Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population.

Table 25. Stage 3 (AIDS), by area of residence, 2015, 2016, and cumulative—United States and 6 dependent areas

			20	015					2	016					
		ts and scents	Chi	ldren	To	otal		ts and scents	Chi	ldren	To	otal	<del>-</del>	Cumulative <sup>a</sup>	
Area of residence	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rateb	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	Adults and adolescents	Children	Total
Alabama	346	8.5	0	0.0	346	7.1	268	6.6	1	0.1	269	5.5	12,253	80	12,333
Alaska	17	2.8	0	0.0	17	2.3	20	3.3	0	0.0	20	2.7	850	7	857
Arizona	286	5.1	1	0.1	287	4.2	296	5.1	0	0.0	296	4.3	14,272	49	14,321
Arkansas	130	5.3	1	0.2	131	4.4	110	4.4	0	0.0	110	3.7	5,304	38	5,342
California	1,893	5.8	1	0.0	1,894	4.9	1,943	5.9	5	0.1	1,948	5.0	175,060	712	175,772
Colorado	191	4.2	0	0.0	191	3.5	176	3.8	0	0.0	176	3.2	11,168	34	11,202
Connecticut	139	4.5	0	0.0	139	3.9	135	4.4	0	0.0	135	3.8	16,865	184	17,049
Delaware	61	7.6	0	0.0	61	6.5	70	8.7	0	0.0	70	7.4	4,544	29	4,573
District of Columbia	180	31.1	0	0.0	180	26.9	185	31.6	0	0.0	185	27.2	21,242	194	21,436
Florida	2,193	12.7	4	0.1	2,197	10.9	2,351	13.3	3	0.1	2,354	11.4	135,755	1,569	137,324
Georgia	1,201	14.3	3	0.2	1,204	11.8	1,155	13.6	4	0.2	1,159	11.2	50,074	263	50,337
Hawaii	42	3.5	0	0.0	42	2.9	33	2.7	0	0.0	33	2.3	3,577	18	3,595
Idaho	23	1.7	1	0.3	24	1.5	22	1.6	0	0.0	22	1.3	866	4	870
Illinois	638	5.9	1	0.0	639	5.0	614	5.7	3	0.1	617	4.8	43,530	286	43,816
Indiana	256	4.7	2	0.2	258	3.9	229	4.2	0	0.0	229	3.5	11,295	62	11,357
lowa	68	2.6	0	0.0	68	2.2	62	2.4	1	0.2	63	2.0	2,456	15	2,471
Kansas	59	2.5	1	0.2	60	2.1	59	2.5	0	0.0	59	2.0	3,630	17	3,647
Kentucky	142	3.8	0	0.0	142	3.2	151	4.1	0	0.0	151	3.4	6,586	39	6,625
Louisiana	516	13.4	1	0.1	517	11.1	563	14.5	1	0.1	564	12.0	24,870	147	25,017
Maine	25	2.2	0	0.0	25	1.9	17	1.5	0	0.0	17	1.3	1,417	9	1,426
Maryland	632	12.6	0	0.0	632	10.5	585	11.6	1	0.1	586	9.7	40,172	341	40,513
Massachusetts	275	4.7	2	0.2	277	4.1	243	4.2	0	0.0	243	3.6	24,441	232	24,673
Michigan	352	4.2	1	0.1	353	3.6	375	4.5	1	0.1	376	3.8	19,794	121	19,915
Minnesota	144	3.2	0	0.0	144	2.6	131	2.9	0	0.0	131	2.4	6,813	33	6,846
Mississippi	270	10.9	0	0.0	270	9.0	276	11.2	0	0.0	276	9.2	9,804	58	9,862
Missouri	223	4.4	1	0.1	224	3.7	225	4.4	2	0.2	227	3.7	14,233	68	14,301
Montana	11	1.3	0	0.0	11	1.1	13	1.5	0	0.0	13	1.2	549	3	552
Nebraska	47	3.0	0	0.0	47	2.5	35	2.2	0	0.0	35	1.8	2,080	12	2,092
Nevada	206	8.6	0	0.0	206	7.1	239	9.8	0	0.0	239	8.1	8,114	29	8,143
New Hampshire	15	1.3	0	0.0	15	1.1	21	1.8	0	0.0	21	1.6	1,348	10	1,358
New Jersey	639	8.5	4	0.3	643	7.2	518	6.9	1	0.1	519	5.8	58,447	810	59,257
New Mexico	55	3.2	0	0.0	55	2.6	60	3.5	1	0.3	61	2.9	3,494	10	3,504
New York	1,544	9.2	2	0.1	1,546	7.8	1,572	9.4	3	0.1	1,575	8.0	201,388	2,430	203,818
North Carolina	726	8.6	2	0.1	728	7.3	591	6.9	1	0.1	592	5.8	24,539	143	24,682
North Dakota	14	2.2	0	0.0	14	1.8	15	2.4	0	0.0	15	2.0	236	2	238

Table 25. Stage 3 (AIDS), by area of residence, 2015, 2016, and cumulative—United States and 6 dependent areas (cont)

			20	15					2	016					
-		ts and scents	Chil	dren	То	otal		s and scents	Chi	ldren	То	otal		Cumulative	a
Area of residence	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	Adults and adolescents	Children	Total
Ohio	404	4.1	2	0.1	406	3.5	484	5.0	1	0.1	485	4.2	20,856	154	21,010
Oklahoma	153	4.8	0	0.0	153	3.9	148	4.6	1	0.1	149	3.8	6,539	27	6,566
Oregon	122	3.6	0	0.0	122	3.0	94	2.7	0	0.0	94	2.3	7,647	19	7,666
Pennsylvania	612	5.6	2	0.1	614	4.8	538	4.9	1	0.1	539	4.2	42,470	374	42,844
Rhode Island	33	3.6	0	0.0	33	3.1	30	3.3	0	0.0	30	2.8	3,194	29	3,223
South Carolina	385	9.4	1	0.1	386	7.9	368	8.8	1	0.1	369	7.4	18,799	120	18,919
South Dakota	14	2.0	0	0.0	14	1.6	21	3.0	0	0.0	21	2.4	401	7	408
Tennessee	336	6.1	3	0.3	339	5.1	297	5.3	0	0.0	297	4.5	17,452	70	17,522
Texas	2,047	9.2	2	0.0	2,049	7.5	2,073	9.2	4	0.1	2,077	7.5	95,506	411	95,917
Utah	54	2.3	0	0.0	54	1.8	42	1.8	0	0.0	42	1.4	2,924	21	2,945
Vermont	11	2.0	0	0.0	11	1.8	9	1.7	0	0.0	9	1.4	575	6	581
Virginia	372	5.3	1	0.1	373	4.5	332	4.7	1	0.1	333	4.0	22,317	192	22,509
Washington	197	3.3	0	0.0	197	2.8	174	2.9	1	0.1	175	2.4	14,672	34	14,706
West Virginia	34	2.2	0	0.0	34	1.8	43	2.7	0	0.0	43	2.3	2,035	11	2,046
Wisconsin	101	2.1	1	0.1	102	1.8	101	2.1	0	0.0	101	1.7	5,977	38	6,015
Wyoming	6	1.2	0	0.0	6	1.0	10	2.1	0	0.0	10	1.7	343	2	345
Subtotal	18,440	6.9	40	0.1	18,480	5.8	18,122	6.7	38	0.1	18,160	5.6	1,222,773	9,573	1,232,346
U.S. dependent areas															
American Samoa	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0	1
Guam	2	1.6	0	0.0	2	1.2	5	3.9	0	0.0	5	3.1	91	2	93
Northern Mariana Islands	2	5.0	0	0.0	2	3.8	0	0.0	0	0.0	0	0.0	5	0	5
Puerto Rico	244	8.2	0	0.0	244	7.0	236	8.0	0	0.0	236	6.9	34,919	404	35,323
Republic of Palau	0	0.0	0	0.0	0	0.0	1	5.6	0	0.0	1	4.7	6	0	6
U.S. Virgin Islands	10	11.4	0	0.0	10	9.7	6	6.8	1	6.5	7	6.8	800	21	821
Subtotal	258	7.8	0	0.0	258	6.7	248	7.6	1	0.2	249	6.5	35,822	427	36,249
Total	18,698	6.9	40	0.1	18,738	5.8	18,370	6.7	39	0.1	18,409	5.6	1,258,595	10,000	1,268,595

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address). Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> From the beginning of the epidemic through 2016.

b Rates are per 100,000 population.

Table 26. Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2015—United States and 6 dependent areas

		an Indian/ a Native	As	ian <sup>a</sup>		African rican	Hispani	c/Latino <sup>b</sup>	Other	Hawaiian/ · Pacific ander	Wh	ite	Multip	e races	То	otal <sup>c</sup>
Area of residence	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rated
Alabama	5	21.3	32	58.9	7,883	747.4	370	267.7	5	270.1	3,391	123.1	584	1,317.5	12,316	302.4
Alaska	156	190.6	19	50.9	87	430.2	62	167.7	3	44.7	294	76.0	36	115.9	657	109.3
Arizona	579	267.3	178	99.7	1,880	825.3	4,492	284.0	21	205.6	7,660	228.6	406	471.5	15,261	270.0
Arkansas	5	27.3	16	44.0	2,326	631.3	337	224.6	5	92.2	2,366	127.3	249	743.5	5,308	214.8
California	331	235.1	4,726	100.1	20,804	1,106.7	43,727	374.8	245	205.7	48,798	370.0	3,437	480.5	122,079	376.4
Colorado	61	205.9	118	85.1	1,672	947.9	2,462	282.9	13	220.8	6,914	213.3	226	289.1	11,519	253.6
Connecticut	11	179.8	92	69.1	3,391	1,140.8	3,514	829.9	4	377.0	3,140	145.4	207	536.6	10,360	338.7
Delaware	3	116.4	7	23.0	1,877	1,133.4	274	446.3	1	362.3	954	181.8	114	910.6	3,230	404.9
District of Columbia	13	1,018.8	73	306.7	10,853	4,113.7	1,107	1,954.1	8	2,730.4	2,431	1,098.5	480	4,411.4	14,972	2,590.2
Florida	58	126.7	480	102.4	49,338	1,929.8	24,209	595.2	40	375.6	30,134	302.4	2,322	1,112.7	106,585	615.2
Georgia	20	100.9	210	64.0	33,946	1,323.5	3,318	488.8	14	282.6	9,556	203.0	2,387	2,219.3	49,463	588.0
Hawaii	9	330.0	413	87.9	162	719.4	322	315.4	250	228.6	1,369	480.3	263	128.6	2,788	233.1
Idaho	11	73.5	7	37.9	88	1,036.6	162	113.4	0	0.0	768	67.7	26	126.9	1,062	79.2
Illinois	33	199.8	436	76.1	16,508	1,101.9	6,629	405.7	21	727.7	9,963	144.6	1,849	1,527.8	35,441	330.1
Indiana	5	38.5	169	148.0	3,817	780.6	960	306.6	0	0.0	5,410	120.5	380	564.2	10,741	195.7
Iowa	4	54.9	58	96.0	458	574.0	224	180.6	0	0.0	1,565	68.2	118	423.9	2,427	93.5
Kansas	8	40.9	34	50.2	704	519.5	487	205.8	1	55.3	1,441	76.6	152	346.3	2,830	118.6
Kentucky	6	74.6	41	81.7	2,173	753.0	422	399.9	1	50.3	3,745	117.0	254	586.4	6,644	179.6
Louisiana	31	126.2	67	98.4	13,302	1,107.4	875	500.0	6	367.9	4,876	207.3	331	845.3	19,492	504.7
Maine	6	84.9	6	44.9	194	1,458.4	97	625.4	1	314.5	1,129	103.9	44	316.9	1,478	128.5
Maryland	18	144.8	205	64.3	24,240	1,645.9	2,160	511.7	4	161.0	4,424	163.1	2,020	2,340.3	33,072	657.8
Massachusetts	24	233.3	379	103.4	5,690	1,474.1	5,221	899.8	4	175.7	7,980	181.8	364	480.8	19,665	338.4
Michigan	26	55.3	109	45.0	8,294	736.4	811	230.6	2	94.1	4,869	75.3	500	378.2	14,615	174.6
Minnesota	104	232.0	141	69.1	2,710	1,141.7	778	392.4	5	255.2	3,812	100.3	248	362.3	7,803	171.3
Mississippi	11	96.3	17	66.3	6,726	750.8	295	451.7	1	114.9	1,778	122.5	374	1,985.8	9,236	374.0
Missouri	14	63.8	72	74.0	5,202	913.8	636	361.9	5	91.1	5,615	135.7	341	456.6	11,887	234.0
Montana	26	55.5	1	14.9	18	431.1	35	132.4	2	322.6	462	60.3	30	180.2	574	66.1
Nebraska	22	186.5	31	88.4	569	836.7	306	223.7	1	108.5	1,059	82.8	51	269.8	2,040	131.6
Nevada	50	238.1	271	132.0	2,118	1,068.0	2,200	359.3	33	231.5	3,968	307.7	264	441.2	8,906	371.0
New Hampshire	0	0.0	11	38.6	143	1,089.5	165	485.0	0	0.0	871	82.4	45	351.1	1,236	107.6
New Jersey	11	103.0	310	44.0	16,134	1,674.2	9,939	723.6	9	372.1	6,927	158.0	2,248	2,665.6	35,636	473.7
New Mexico	242	167.6	14	53.7	189	597.1	1,522	193.3	1	87.6	1,154	162.1	92	434.0	3,215	186.5
New York	59	122.1	1,584	110.5	46,171	1,908.8	51,196	1,731.1	16	224.8	21,438	222.0	7,752	3,576.5	128,681	768.8
North Carolina	178	188.8	149	67.2	18,596	1,045.7	2,285	360.4	10	199.0	7,498	134.9	1,090	996.3	29,814	354.9
North Dakota	11	39.1	3	33.9	107	752.6	20	109.6	0	0.0	180	32.9	13	153.6	334	53.4

Table 26. Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2015—United States and 6 dependent areas (cont)

		n Indian/ Native	As	ian <sup>a</sup>		African rican	Hispanio	c/Latino <sup>b</sup>	Other	Hawaiian/ Pacific Inder	Wh	ite	Multip	e races	To	tal <sup>c</sup>
Area of residence	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rated
Ohio	17	88.4	94	46.9	9,072	783.1	1,255	422.0	2	61.7	9,357	118.0	801	584.1	20,709	212.5
Oklahoma	293	114.3	67	97.3	1,350	578.2	547	199.9	8	198.0	3,204	143.7	305	212.9	5,774	179.9
Oregon	47	124.6	123	84.2	453	761.6	869	236.1	19	151.5	4,885	181.2	202	234.0	6,598	193.7
Pennsylvania	31	203.1	250	71.1	16,545	1,474.8	5,616	870.6	22	707.9	10,278	119.1	1,487	1,224.2	34,233	314.4
Rhode Island	7	189.9	38	126.1	548	1,100.8	627	540.9	1	174.5	1,077	155.1	59	424.0	2,357	259.5
South Carolina	12	78.0	35	56.3	11,165	1,024.2	752	393.3	3	135.6	3,886	143.7	361	790.3	16,224	394.6
South Dakota	78	150.7	4	42.1	116	1,017.3	30	146.2	0	0.0	274	45.8	12	119.0	514	73.3
Tennessee	10	64.1	65	69.8	9,141	1,016.3	820	353.4	7	260.2	5,872	139.3	507	782.0	16,425	297.4
Texas	41	53.4	810	78.8	30,207	1,150.2	26,087	324.3	25	139.5	21,626	212.8	3,069	1,279.1	81,873	368.9
Utah	23	100.8	56	95.4	241	1,028.3	583	201.1	5	23.7	1,734	92.7	57	164.7	2,702	116.4
Vermont	0	0.0	9	103.2	62	1,068.4	55	604.5	1	609.8	519	101.9	25	337.0	671	123.7
Virginia	16	83.5	258	58.2	12,597	949.6	1,902	338.0	8	160.7	6,147	135.5	645	498.7	21,607	307.7
Washington	128	167.9	412	82.5	1,911	878.3	1,711	273.8	54	143.4	7,540	173.2	719	389.8	12,484	208.3
West Virginia	1	29.5	7	54.8	396	729.2	81	391.4	0	0.0	1,197	81.9	95	541.4	1,781	113.3
Wisconsin	31	76.6	78	63.9	2,177	772.0	817	304.6	1	67.1	2,648	64.9	163	305.4	5,916	122.0
Wyoming	10	107.2	2	44.4	24	417.3	57	134.2	0	0.0	190	45.8	6	96.5	289	59.7
Subtotal	2,896	150.8	12,787	87.3	404,375	1,238.3	213,428	496.8	888	197.1	298,373	174.2	37,810	890.0	971,524	362.3
U.S. dependent areas <sup>e</sup>																
American Samoa	0	_	0	_	0	_	0	_	1	_	0	_	1	_	2	4.7
Guam	0	_	39	_	3	_	2	_	17	_	11	_	3	_	75	59.3
Northern Mariana Islands	0	_	1	_	0	_	0	_	2	_	2	_	1	_	6	14.9
Puerto Rico	1	_	1	_	3	_	16,757	_	1	_	19	_	1	_	16,783	564
Republic of Palau	0	_	2	_	0	_	1	_	4	_	0	_	0	_	7	39.6
U.S. Virgin Islands	0	_	2	_	311	_	196	_	0	_	42	_	4	_	558	635.5
Subtotal	1	_	45	_	317	_	16,956	_	25	_	74	_	10	_	17,431	529.7
Total	2,897	_	12,832	_	404,692	_	230,384	_	913	_	298,447	_	37,820	_	988,955	364.3

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address). Numbers less than 12, and rates based on these numbers, should be interpreted with caution

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

b Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Includes persons whose race/ethnicity is unknown.

d Rates are per 100,000 population.

<sup>&</sup>lt;sup>e</sup> Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

Table 27. Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2015—United States and 6 dependent areas

		an Indian/ a Native	As	ian <sup>a</sup>		African rican	Hispani	c/Latino <sup>b</sup>	Other	Hawaiian/ Pacific ander	Wh	iite	Multipl	e races	To	otal <sup>c</sup>
Area of residence	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rate <sup>d</sup>	No.	Rated	No.	Rated	No.	Rated
Alabama	0	0.0	12	22.1	3,579	339.3	195	141.1	3	162.1	1,466	53.2	296	667.8	5,551	136.3
Alaska	92	112.4	15	40.2	37	182.9	38	102.8	2	29.8	165	42.7	19	61.2	368	61.2
Arizona	305	140.8	70	39.2	830	364.4	2,235	141.3	11	107.7	3,851	114.9	210	243.9	7,513	132.9
Arkansas	2	10.9	6	16.5	1,007	273.3	172	114.6	3	55.3	1,117	60.1	135	403.1	2,442	98.8
California	174	123.6	2,470	52.3	11,778	626.5	25,350	217.3	127	106.6	27,546	208.8	1,893	264.7	69,345	213.8
Colorado	30	101.2	49	35.3	761	431.4	1,267	145.6	5	84.9	2,880	88.8	133	170.2	5,125	112.9
Connecticut	7	114.4	46	34.6	2,118	712.6	2,264	534.7	3	282.8	1,910	88.5	133	344.8	6,481	211.9
Delaware	2	77.6	5	16.4	1,188	717.3	166	270.4	1	362.3	555	105.7	64	511.2	1,981	248.3
District of Columbia	7	548.6	33	138.7	6,138	2,326.6	551	972.7	2	682.6	1,056	477.2	267	2,453.8	8,055	1,393.6
Florida	25	54.6	207	44.2	28,269	1,105.7	12,389	304.6	12	112.7	16,300	163.5	1,444	692.0	58,647	338.5
Georgia	7	35.3	85	25.9	17,652	688.2	1,812	266.9	4	80.7	4,877	103.6	1,406	1,307.2	25,843	307.2
Hawaii	4	146.7	244	51.9	88	390.8	191	187.1	156	142.7	793	278.2	148	72.4	1,624	135.8
Idaho	4	26.7	1	5.4	36	424.1	88	61.6	0	0.0	383	33.8	17	83.0	529	39.4
Illinois	10	60.6	203	35.4	8,443	563.5	3,633	222.3	10	346.5	4,869	70.7	1,062	877.5	18,230	169.8
Indiana	3	23.1	75	65.7	1,856	379.5	521	166.4	0	0.0	2,797	62.3	216	320.7	5,468	99.6
lowa	3	41.2	24	39.7	245	307.1	137	110.5	0	0.0	899	39.2	60	215.5	1,368	52.7
Kansas	2	10.2	13	19.2	335	247.2	281	118.8	0	0.0	783	41.6	89	202.8	1,503	63.0
Kentucky	3	37.3	13	25.9	1,044	361.8	259	245.5	0	0.0	1,912	59.7	154	355.5	3,385	91.5
Louisiana	14	57.0	28	41.1	6,951	578.7	473	270.3	2	122.6	2,563	108.9	180	459.7	10,212	264.4
Maine	3	42.5	4	30.0	77	578.9	49	315.9	0	0.0	615	56.6	26	187.2	774	67.3
Maryland	4	32.2	85	26.6	13,186	895.3	1,231	291.6	2	80.5	2,211	81.5	1,211	1,403.0	17,930	356.6
Massachusetts	14	136.1	199	54.3	3,376	874.6	3,071	529.2	1	43.9	4,364	99.4	206	272.1	11,233	193.3
Michigan	11	23.4	43	17.7	4,331	384.5	438	124.5	2	94.1	2,565	39.7	288	217.8	7,678	91.7
Minnesota	54	120.5	73	35.8	1,304	549.4	431	217.4	1	51.0	1,711	45.0	137	200.2	3,711	81.5
Mississippi	2	17.5	8	31.2	3,222	359.6	164	251.1	0	0.0	868	59.8	222	1,178.7	4,486	181.6
Missouri	9	41.0	33	33.9	2,782	488.7	352	200.3	3	54.6	2,947	71.2	215	287.9	6,341	124.8
Montana	18	38.4	0	0.0	12	287.4	16	60.5	1	161.3	270	35.2	22	132.2	339	39.0
Nebraska	9	76.3	16	45.6	301	442.6	170	124.3	1	108.5	539	42.2	33	174.6	1,069	69.0
Nevada	27	128.6	120	58.4	1,049	529.0	1,108	181.0	17	119.3	1,940	150.5	138	230.6	4,399	183.3
New Hampshire	0	0.0	8	28.1	72	548.6	101	296.9	0	0.0	440	41.6	29	226.2	650	56.6
New Jersey	6	56.2	146	20.7	8,431	874.9	5,284	384.7	2	82.7	3,492	79.7	1,396	1,655.3	18,759	249.4
New Mexico	128	88.7	6	23.0	92	290.6	844	107.2	1	87.6	718	100.8	54	254.7	1,843	106.9
New York	32	66.2	752	52.5	27,006	1,116.5	31,366	1,060.6	4	56.2	11,049	114.4	4,929	2,274.0	75,160	449.0
North Carolina	76	80.6	45	20.3	8,377	471.0	1,097	173.0	2	39.8	3,251	58.5	562	513.7	13,410	159.6
North Dakota	8	28.5	3	33.9	47	330.6	13	71.3	0	0.0	86	15.7	9	106.3	166	26.5

Table 27. Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2015—United States and 6 dependent areas (cont)

		n Indian/ Native	As	ian <sup>a</sup>	Black/ <i>A</i> Amei		Hispanio	c/Latino <sup>b</sup>	Other	Hawaiian/ Pacific ander	Wh	iite	Multiple	e races	To	tal <sup>c</sup>
Area of residence	No.	Rated	No.	Rated	No.	Rated	No.	Rated	No.	Rate <sup>d</sup>	No.	Rated	No.	Rated	No.	Rated
Ohio	8	41.6	34	17.0	4,248	366.7	626	210.5	0	0.0	4,516	57.0	433	315.8	9,866	101.2
Oklahoma	149	58.1	28	40.7	627	268.5	277	101.2	3	74.2	1,583	71.0	157	109.6	2,824	88.0
Oregon	32	84.9	56	38.4	247	415.2	511	138.9	10	79.7	2,850	105.7	104	120.5	3,810	111.9
Pennsylvania	12	78.6	122	34.7	9,226	822.4	3,127	484.7	9	289.6	5,600	64.9	892	734.3	18,988	174.4
Rhode Island	3	81.4	23	76.3	331	664.9	397	342.5	1	174.5	612	88.2	23	165.3	1,390	153.0
South Carolina	5	32.5	19	30.6	6,186	567.4	418	218.6	2	90.4	1,987	73.5	239	523.2	8,856	215.4
South Dakota	39	75.3	1	10.5	47	412.2	17	82.9	0	0.0	109	18.2	7	69.4	220	31.4
Tennessee	5	32.0	31	33.3	4,433	492.9	436	187.9	2	74.3	3,044	72.2	321	495.1	8,272	149.8
Texas	21	27.3	353	34.3	15,257	580.9	14,302	177.8	7	39.1	11,538	113.5	1,736	723.5	43,215	194.7
Utah	13	57.0	26	44.3	118	503.5	342	118.0	3	14.2	921	49.2	28	80.9	1,451	62.5
Vermont	0	0.0	3	34.4	32	551.4	33	362.7	1	609.8	266	52.2	14	188.7	349	64.3
Virginia	8	41.8	124	28.0	5,798	437.1	976	173.4	4	80.3	2,913	64.2	346	267.5	10,170	144.8
Washington	80	104.9	213	42.6	1,021	469.2	976	156.2	31	82.3	4,074	93.6	448	242.9	6,848	114.3
West Virginia	0	0.0	2	15.6	208	383.0	43	207.8	0	0.0	686	46.9	63	359.0	1,002	63.8
Wisconsin	14	34.6	30	24.6	1,037	367.8	454	169.3	0	0.0	1,344	32.9	94	176.1	2,973	61.3
Wyoming	8	85.8	1	22.2	9	156.5	33	77.7	0	0.0	100	24.1	4	64.3	155	32.0
Subtotal	1,492	77.7	6,206	42.4	214,845	657.9	120,725	281.0	451	100.1	155,931	91.0	22,312	525.2	522,007	194.7
U.S. dependent areas <sup>e</sup>																
American Samoa	0	_	0	_	0	_	0	_	1	_	0	_	0	_	1	2.3
Guam	0	_	14	_	1	_	0	_	7	_	5	_	2	_	29	22.9
Northern Mariana Islands	0	_	1	_	0	_	0	_	2	_	0	_	0	_	3	7.5
Puerto Rico	1	_	0	_	1	_	9,202	_	0	_	7	_	0	_	9,211	309.5
Republic of Palau	0	_	1	_	0	_	0	_	3	_	0	_	0	_	4	22.6
U.S. Virgin Islands	0	_	1	_	169	_	112	_	0	_	26	_	1	_	309	351.9
Subtotal	1	_	17	_	171	_	9,314	_	13	_	38	_	3	_	9,557	290.4
Total	1,493	_	6,223	_	215,016	_	130,039	_	464	_	155,969	_	22,315	_	531,564	195.8

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address). Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

<sup>&</sup>lt;sup>a</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>&</sup>lt;sup>b</sup> Hispanics/Latinos can be of any race.

<sup>&</sup>lt;sup>C</sup> Includes persons whose race/ethnicity is unknown.

d Rates are per 100,000 population.

<sup>&</sup>lt;sup>e</sup> Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

Table 28. Diagnoses of HIV infection, 2016, and persons living with diagnosed HIV infection (prevalence), yearend 2015, by metropolitan statistical area of residence—United States and Puerto Rico

	Di	agnosis, 20	16 <sup>a</sup>	Prevalence of infection, year	
MSA of residence	No.	Rate <sup>c</sup>	Rank <sup>d</sup>	No.	Rate <sup>c</sup>
Akron, OH	62	8.8	66	896	127.4
Albany–Schenectady–Troy, NY	58	6.6	83	1,864	211.6
Albuquerque, NM	57	6.3	85	1,614	178.3
Allentown–Bethlehem–Easton, PA–NJ	50	6.0	89	1,450	174.1
Atlanta–Sandy Springs–Roswell, GA	1,701	29.4	4	30,884	541.9
Augusta–Richmond County, GA–SC	94	15.8	27	2,197	372.3
Austin–Round Rock, TX	308	15.0	30	5,625	281.5
Bakersfield, CA	112	12.7	41	1,531	174.1
Baltimore–Columbia–Towson, MD	531	19.0	14	17,896	640.6
Baton Rouge, LA	252	30.2	3	4,990	601.4
Birmingham–Hoover, AL	112	9.8	62	3,950	345.0
_	17	2.5	106	3,930	48.1
Boise City, ID					
Boston–Cambridge–Newton, MA–NH <sup>e</sup>	510	10.6	55	13,660	286.6
Boston Division	269	13.5	_	7,917	399.6
Cambridge Division	233	9.8		5,425	230.2
Bridgeport–Stamford–Norwalk, CT	73	7.7	73	2,590	274.2
Buffalo-Cheektowaga-Niagara Falls, NY	92	8.1	69	2,393	210.7
Cape Coral–Fort Myers, FL	103	14.3	36	2,039	291.2
Charleston–North Charleston, SC	116	15.2	29	2,496	335.2
Charlotte-Concord-Gastonia, NC-SC	404	16.3	24	7,750	319.6
Chattanooga, TN–GA	59	10.7	54	1,059	193.6
Chicago-Naperville-Elgin, IL-IN-WI	1,263	13.3	37	29,459	309.0
Chicago Division	1,125	15.4	_	26,962	368.1
Elgin Division	36	5.7	_	383	60.4
Gary Division	60	8.6	_	1,155	164.3
Lake County Division	42	4.8	_	959	110.0
Cincinnati, OH–KY–IN	209	9.7	63	3,793	176.0
Cleveland-Elyria, OH	228	11.1	47	4,992	242.3
Colorado Springs, CO	40	5.6	95	805	115.4
Columbia, SC	177	21.7	11	3,854	475.9
Columbus, OH	236	11.6	46	5,301	262.4
Dallas–Fort Worth–Arlington, TX	1,348	18.6	15	25,024	353.0
Dallas Division	1,025	21.4	_	19,650	418.5
Fort Worth Division	323	13.2	_	5,374	224.5
Dayton, OH	64	8.0	70	1,490	186.3
Deltona–Daytona Beach–Ormond Beach, FL	94	14.7	32	1,774	284.6
Denver-Aurora-Lakewood, CO	303	10.6	56	8,831	314.4
Des Moines-West Des Moines, IA	38	6.0	88	776	124.6
Detroit-Warren-Dearborn, MI	509	11.8	43	9,574	222.8
Detroit Division	341	19.5	_	6,606	376.0
Warren Division	168	6.6	_	2,968	116.8
Durham-Chapel Hill, NC	103	18.4	18	2,154	390.8
El Paso, TX	101	12.0	42	2,026	242.0
Fayetteville–Springdale–Rogers, AR–MO	29	5.5	96	598	116.5
Fresno, CA	128	13.1	39	1,659	170.7
Grand Rapids–Wyoming, MI	49	4.7	101	1,100	105.9
Greensboro–High Point, NC	159	21.0	12	2,540	337.9
Greenville-Anderson-Mauldin, SC	95	10.7	52	1,871	214.3
Harrisburg–Carlisle, PA	61	10.7	52 51	1,207	213.6
-		6.0			
Hartford–West Hartford–East Hartford, CT	72 62	6.0 6.2	90 86	3,213	265.5
Honolulu (Urban), HI	02	0.2	86	1,736	174.8

Table 28. Diagnoses of HIV infection, 2016, and persons living with diagnosed HIV infection (prevalence), year-end 2015, by metropolitan statistical area of residence—United States and Puerto Rico *(cont)* 

	Di	agnosis, 20	 16 <sup>a</sup>	Prevalence of infection, ye	diagnosed HI\ ar-end 2015 <sup>b</sup>
MSA of residence	No.	Rate <sup>c</sup>	Rank <sup>d</sup>	No.	Rate <sup>c</sup>
Houston–The Woodlands–Sugar Land, TX	1,475	21.8	10	27,639	415.8
ndianapolis–Carmel–Anderson, IN	236	11.8	44	5,293	266.4
Jackson, MS	145	25.0	6	3,322	574.1
Jacksonville, FL	339	22.9	8	6,629	457.8
Kansas City, MO–KS	216	10.3	59	4,447	213.3
Knoxville, TN	64	7.4	78	1,084	125.9
_akeland–Winter Haven, FL	124	18.6	16	2,165	333.4
Lancaster, PA	39	7.2	79	715	133.3
Las Vegas–Henderson–Paradise, NV	470	21.8	9	7,436	352.5
_exington–Fayette, KY	53	10.5	57	1,055	210.7
Little Rock–North Little Rock–Conway, AR	144	19.6	13	2,032	277.8
Los Angeles–Long Beach–Anaheim, CA	2,198	16.5	23	54,386	409.9
Anaheim Division	353	11.1		6,185	195.9
Los Angeles Division	1,845	18.2	_	48,201	476.7
Louisville/Jefferson County, KY-IN	187	14.6	34	2,437	190.8
Madison, WI	26	4.0	103	702	109.6
McAllen–Edinburg–Mission, TX	83	9.8	61	1,131	134.8
Memphis, TN-MS-AR	308	22.9	7	6,600	491.8
Miami–Fort Lauderdale–West Palm Beach, FL	2,346	38.7	1	52,727	878.5
Fort Lauderdale Division	766	40.1		18,890	1,000.9
Miami Division	1,275	47.0		25,984	965.0
West Palm Beach Division	305	21.1	_	7,853	552.3
Milwaukee–Waukesha–West Allis, WI	121	7.7	— 75	3,040	193.1
Minneapolis–St. Paul–Bloomington, MN–WI	248	7.7 7.0	73 80	6,527	185.5
wiimeapolis–St. Faui–віоопітуtоп, win–vvi Modesto, CA	240	3.9	104	561	104.8
Nashville–Davidson–Murfreesboro–Franklin, TN	194	3.9 10.4	58	4,769	260.7
	81	9.5	64		369.4
New Haven-Milford, CT				3,173	
New Orleans–Metairie, LA	422	33.3 16.9	2 22	7,459	591.0
New York–Newark–Jersey City, NY–NJ–PA <sup>e</sup>	3,397		22	138,360	687.7
Nassau County Division New York Division	216	7.6	_	5,913	206.9
	2,707	18.8	_	117,506	818.2
Newark Division	451	18.0		13,826	552.1
North Port–Sarasota–Bradenton, FL	61	7.7	72	1,920	250.0
Ogden–Clearfield, UT	11	1.7	108	351	54.6
Oklahoma City, OK	149	10.9	50	2,628	193.7
Omaha–Council Bluffs, NE–IA	53	5.7	93	590	64.5
Orlando–Kissimmee–Sanford, FL	668	27.4	5	10,984	461.1
Oxnard–Thousand Oaks–Ventura, CA	45	5.3	97	923	108.9
Palm Bay–Melbourne–Titusville, FL	64	11.1	48	1,451	255.5
Philadelphia–Camden–Wilmington, PA–NJ–DE–MD	790	13.0	40	24,857	410.0
Camden Division	103	8.2	_	2,977	237.8
Montgomery County Division	69	3.5	_	1,524	77.7
Philadelphia Division	536	25.1	_	17,969	844.3
Wilmington Division	82	11.3	_	2,387	330.8
Phoenix–Mesa–Scottsdale, AZ	612	13.1	38	11,370	248.9
Pittsburgh, PA	146	6.2	87	3,238	137.7
Portland–South Portland, ME	19	3.6	105	800	151.9
Portland–Vancouver–Hillsboro, OR–WA	164	6.8	82	5,235	219.5
Providence–Warwick, RI–MA	106	6.6	84	3,537	219.3
Provo-Orem, UT	13	2.2	107	186	31.8
Raleigh, NC	191	14.7	33	3,649	287.0

Table 28. Diagnoses of HIV infection, 2016, and persons living with diagnosed HIV infection (prevalence), yearend 2015, by metropolitan statistical area of residence—United States and Puerto Rico *(cont)* 

	Di	agnosis, 20′	16 <sup>a</sup>	Prevalence of cinfection, year	
MSA of residence	No.	Rate <sup>c</sup>	Rank <sup>d</sup>	No.	Rate <sup>c</sup>
Richmond, VA	184	14.4	35	4,431	348.8
Riverside–San Bernardino–Ontario, CA	486	10.7	53	7,662	171.2
Rochester, NY	61	5.7	94	2,902	268.4
Sacramento-Roseville-Arden-Arcade, CA	229	10.0	60	4,081	180.0
St. Louis, MO-IL	308	11.0	49	6,815	242.7
Salt Lake City, UT	101	8.5	67	1,894	162.2
San Antonio–New Braunfels, TX	390	16.1	25	6,216	261.0
San Diego-Carlsbad, CA	494	14.9	31	11,336	344.5
San Francisco–Oakland–Hayward, CA <sup>e</sup>	741	15.8	26	23,216	500.1
Oakland Division	398	14.3	_	7,429	269.6
San Francisco Division	315	19.3	_	14,983	921.9
San Jose–Sunnyvale–Santa Clara, CA	137	6.9	81	2,986	151.7
San Juan–Carolina–Caguas, PR	397	18.4	19	9,235	420.6
Santa Rosa, CA	24	4.8	100	1,210	241.3
Scranton–Wilkes-Barre–Hazelton, PA	28	5.0	99	628	112.6
Seattle-Tacoma-Bellevue, WA	315	8.3	68	8,762	235.1
Seattle Division	266	9.1	_	7,431	257.6
Tacoma Division	49	5.7	_	1,331	157.9
Spokane–Spokane Valley, WA	24	4.3	102	579	105.8
Springfield, MA	73	11.6	45	2,085	330.9
Stockton–Lodi, CA	55	7.5	76	1,296	179.1
Syracuse, NY	38	5.8	91	1,230	186.4
Tampa–St. Petersburg–Clearwater, FL	560	18.5	17	11,937	401.8
Toledo, OH	47	7.8	71	971	160.3
Tucson, AZ	90	8.9	65	2,368	234.9
Tulsa, OK	76	7.7	74	1,802	183.8
Virginia Beach–Norfolk–Newport News, VA–NC	297	17.2	21	5,473	317.6
Washington–Arlington–Alexandria, DC–VA–MD–WV	1,122	18.3	20	21,522	354.1
Silver Spring Division	195	15.1	_	4,067	317.3
Washington Division	927	19.2	_	17,455	363.9
Wichita, KS	37	5.7	92	866	134.7
Winston-Salem, NC	101	15.3	28	1,791	272.3
Worcester, MA–CT	70	7.5	77	1,944	208.1
Youngstown–Warren–Boardman, OH–PA	28	5.1	98	767	139.6
Subtotal for MSAs (population of ≥500,000)	32,621	14.7	_	780,399	354.6
Metropolitan areas (population of 50,000–499,999)	4,891	8.4	_	98,716	170.1
Nonmetropolitan areas	2,344	5.1	_	54,278	117.4
Total <sup>f</sup>	40,305	12.3	_	990,637	305.4

Abbreviation: MSA, metropolitan statistical area.

Note. Because of the lack of U.S. census information for all U.S. dependent areas, table includes data for only the United States and Puerto Rico. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

MSA definitions for this report can be found at http://www.census.gov/programs-surveys/metro-micro.html.

<sup>&</sup>lt;sup>a</sup> Data are based on residence at time of diagnosis of HIV infection.

<sup>&</sup>lt;sup>b</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>&</sup>lt;sup>C</sup> Rates are per 100,000 population.

<sup>&</sup>lt;sup>d</sup> Based on rate.

e Counts of diagnoses of HIV infection for the metropolitan divisions do not sum to the MSA total. MSA total includes data from 1 metropolitan division with population of <500,000.

Includes persons whose county of residence is unknown.

Table 29. Stage 3 (AIDS), 2016 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2015, by metropolitan statistical area of residence—United States and Puerto Rico

				Diag	nosis, cumulativ	∕e <sup>a,b</sup>		
	Dia	agnosis, 20	16 <sup>b</sup>	Adults or adolescents	Children	Total	Prevalence (AIDS), year	
MSA of residence	No.	Rated	Rank <sup>e</sup>	No.	No.	No.	No.	Rated
Akron, OH	21	3.0	84	964	1	965	399	56.7
Albany–Schenectady–Troy, NY	22	2.5	90	2,679	28	2,707	1,073	121.8
Albuquerque, NM	28	3.1	81	1,855	4	1,859	945	104.4
Allentown-Bethlehem-Easton, PA-NJ	19	2.3	95	1,777	19	1,796	823	98.8
Atlanta–Sandy Springs–Roswell, GA	695	12.0	7	34,229	151	34,380	16,414	288.0
Augusta-Richmond County, GA-SC	48	8.1	19	2,682	23	2,705	1,101	186.6
Austin-Round Rock, TX	101	4.9	49	6,376	26	6,402	3,032	151.7
Bakersfield, CA	29	3.3	79	2,129	9	2,138	854	97.1
Baltimore–Columbia–Towson, MD	315	11.3	8	26,080	229	26,309	9,922	355.1
Baton Rouge, LA	150	18.0	1	5,795	24	5,819	2,641	318.3
Birmingham-Hoover, AL	61	5.3	42	3,567	25	3,592	1,684	147.1
Boise City, ID	13	1.9	105	440	0	440	115	17.0
Boston–Cambridge–Newton, MA–NH <sup>f</sup>	174	3.6	69	17,128	162	17,290	7,656	160.6
Boston Division	90	4.5	_	10,579	97	10,676	4,500	227.1
Cambridge Division	79	3.3	_	6,162	64	6,226	2,999	127.2
Bridgeport–Stamford–Norwalk, CT	34	3.6	72	4,314	57	4,371	1,554	164.5
Buffalo-Cheektowaga-Niagara Falls, NY	40	3.5	74	3,089	20	3,109	1,265	111.4
Cape Coral–Fort Myers, FL	57	7.9	20	2,307	25	2,332	1,177	168.1
Charleston–North Charleston, SC	51	6.7	26	2,795	25	2,820	1,315	176.6
Charlotte-Concord-Gastonia, NC-SC	175	7.1	23	6,164	30	6,194	3,402	140.3
Chattanooga, TN–GA	20	3.6	70	1,338	3	1,341	563	102.9
Chicago-Naperville-Elgin, IL-IN-WI	534	5.6	38	38,962	263	39,225	15,014	157.5
Chicago Division	482	6.6	_	35,663	241	35,904	13,705	187.1
Elgin Division	14	2.2	_	813	8	821	206	32.5
Gary Division	23	3.3	_	1,441	9	1,450	568	80.8
Lake County Division	15	1.7	_	1,045	5	1,050	535	61.4
Cincinnati, OH–KY–IN	89	4.1	65	3,928	21	3,949	1,888	87.6
Cleveland–Elyria, OH	120	5.8	34	5,387	49	5,436	2,359	114.5
Colorado Springs, CO	17	2.4	94	758	5	763	369	52.9
Columbia, SC	103	12.6	6	4,635	26	4,661	2,112	260.8
Columbus, OH	131	6.4	28	4,879	24	4,903	2,386	118.1

Table 29. Stage 3 (AIDS), 2016 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2015, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence				Diag				
	Diagnosis, 2016 <sup>b</sup>			Adults or adolescents	Children	Total	Prevalence of stage 3 (AIDS), year-end 2015	
	No.	Rated	Rank <sup>e</sup>	No.	No.	No.	No.	Rated
Dallas–Fort Worth–Arlington, TX	656	9.1	15	27,764	66	27,830	12,975	183.0
Dallas Division	525	11.0	_	21,925	39	21,964	10,154	216.2
Fort Worth Division	131	5.4	_	5,839	27	5,866	2,821	117.8
Dayton, OH	32	4.0	66	1,647	14	1,661	758	94.8
Deltona-Daytona Beach-Ormond Beach, FL	53	8.3	17	2,131	19	2,150	1,047	168.0
Denver-Aurora-Lakewood, CO	124	4.3	60	8,702	24	8,726	3,805	135.5
Des Moines-West Des Moines, IA	23	3.6	71	780	4	784	421	67.6
Detroit-Warren-Dearborn, MI	273	6.4	29	13,711	79	13,790	5,060	117.7
Detroit Division	179	10.2	_	10,708	62	10,770	3,594	204.5
Warren Division	94	3.7	_	3,003	17	3,020	1,466	57.7
Durham-Chapel Hill, NC	38	6.8	24	1,685	10	1,695	890	161.5
El Paso, TX	44	5.2	43	2,162	10	2,172	1,142	136.4
Fayetteville–Springdale–Rogers, AR–MO	13	2.5	93	530	6	536	309	60.2
Fresno, CA	55	5.6	39	2,203	11	2,214	959	98.6
Grand Rapids-Wyoming, MI	20	1.9	103	1,231	6	1,237	573	55.2
Greensboro-High Point, NC	33	4.4	59	1,831	19	1,850	949	126.2
Greenville-Anderson-Mauldin, SC	43	4.9	51	2,090	6	2,096	1,030	118.0
Harrisburg–Carlisle, PA	33	5.8	35	1,661	9	1,670	648	114.7
Hartford–West Hartford–East Hartford, CT	52	4.3	62	5,927	46	5,973	2,014	166.5
Honolulu (Urban), HI	22	2.2	96	2,431	13	2,444	981	98.8
Houston–The Woodlands–Sugar Land, TX	719	10.6	11	35,053	183	35,236	14,713	221.3
Indianapolis-Carmel-Anderson, IN	107	5.3	41	5,470	26	5,496	2,676	134.7
Jackson, MS	99	17.1	2	3,641	31	3,672	1,632	282.0
Jacksonville, FL	194	13.1	5	8,424	79	8,503	3,755	259.3
Kansas City, MO–KS	94	4.5	56	6,050	17	6,067	2,504	120.1
Knoxville, TN	22	2.5	89	1,345	8	1,353	566	65.7
Lakeland–Winter Haven, FL	68	10.2	12	2,593	22	2,615	1,288	198.3
Lancaster, PA	20	3.7	68	913	22	935	353	65.8
Las Vegas–Henderson–Paradise, NV	217	10.1	13	6,710	28	6,738	3,636	172.4
Lexington–Fayette, KY	32	6.3	31	1,033	1	1,034	534	106.7
Little Rock–North Little Rock–Conway, AR	55	7.5	22	1,941	15	1,956	866	118.4

Table 29. Stage 3 (AIDS), 2016 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2015, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

				Diag				
	Dia	agnosis, 20	<b>16</b> <sup>b</sup>	Adults or adolescents	Children	Total	Prevalence (AIDS), year	
MSA of residence	No.	Rated	Rank <sup>e</sup>	No.	No.	No.	No.	Rated
Los Angeles–Long Beach–Anaheim, CA	828	6.2	33	72,381	309	72,690	29,798	224.6
Anaheim Division	120	3.8	_	8,544	45	8,589	3,317	105.1
Los Angeles Division	708	7.0	_	63,837	264	64,101	26,481	261.9
Louisville/Jefferson County, KY–IN	63	4.9	50	3,300	30	3,330	1,028	80.5
Madison, WI	13	2.0	101	685	5	690	340	53.1
McAllen-Edinburg-Mission, TX	44	5.2	45	1,128	13	1,141	643	76.6
Memphis, TN-MS-AR	143	10.6	10	7,461	23	7,484	3,189	237.6
Miami–Fort Lauderdale–West Palm Beach, FL	1,029	17.0	3	70,082	1,009	71,091	28,000	466.5
Fort Lauderdale Division	360	18.9	_	21,521	266	21,787	10,142	537.4
Miami Division	512	18.9	_	36,617	514	37,131	13,157	488.6
West Palm Beach Division	157	10.9	_	11,944	229	12,173	4,701	330.6
Milwaukee–Waukesha–West Allis, WI	56	3.6	73	3,316	19	3,335	1,501	95.3
Minneapolis-St. Paul-Bloomington, MN-WI	107	3.0	83	5,977	24	6,001	3,006	85.4
Modesto, CA	19	3.5	75	898	6	904	357	66.7
Nashville-Davidson-Murfreesboro-Franklin, TN	81	4.3	61	5,245	25	5,270	2,391	130.7
New Haven-Milford, CT	39	4.6	55	5,177	74	5,251	2,063	240.1
New Orleans-Metairie, LA	179	14.1	4	11,414	80	11,494	3,968	314.4
New York–Newark–Jersey City, NY–NJ–PA <sup>f</sup>	1,779	8.8	16	228,870	3,018	231,888	79,546	395.4
Nassau County Division	105	3.7	_	9,523	117	9,640	3,476	121.6
New York Division	1,476	10.3	_	192,849	2,519	195,368	68,207	474.9
Newark Division	192	7.7	_	24,528	369	24,897	7,181	286.8
North Port–Sarasota–Bradenton, FL	40	5.1	46	2,505	29	2,534	1,094	142.4
Ogden–Clearfield, UT	3	0.5	107	334	4	338	190	29.6
Oklahoma City, OK	69	5.0	48	3,074	4	3,078	1,260	92.9
Omaha–Council Bluffs, NE–IA	18	1.9	102	1,440	5	1,445	296	32.4
Orlando-Kissimmee-Sanford, FL	273	11.2	9	12,128	95	12,223	5,859	246.0
Oxnard–Thousand Oaks–Ventura, CA	18	2.1	100	1,277	5	1,282	512	60.4
Palm Bay–Melbourne–Titusville, FL	28	4.8	52	1,869	13	1,882	868	152.8

Table 29. Stage 3 (AIDS), 2016 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2015, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

				Diagnosis, cumulative <sup>a,b</sup>				
MSA of residence	Diagnosis, 2016 <sup>b</sup>			Adults or adolescents	Children	Total	Prevalence of stage 3 (AIDS), year-end 2015	
	No.	Rated	Rank <sup>e</sup>	No.	No.	No.	No.	Rated
Philadelphia–Camden–Wilmington, PA–NJ–DE–MD	381	6.3	32	35,436	319	35,755	13,728	226.4
Camden Division	42	3.4	_	3,959	43	4,002	1,492	119.2
Montgomery County Division	42	2.1	_	2,918	12	2,930	775	39.5
Philadelphia Division	249	11.7	_	24,801	240	25,041	10,026	471.1
Wilmington Division	48	6.6	_	3,758	24	3,782	1,435	198.9
Phoenix–Mesa–Scottsdale, AZ	236	5.1	47	10,403	31	10,434	5,444	119.2
Pittsburgh, PA	66	2.8	85	4,107	22	4,129	1,697	72.2
Portland–South Portland, ME	10	1.9	104	749	1	750	403	76.5
Portland-Vancouver-Hillsboro, OR-WA	67	2.8	86	6,090	9	6,099	2,942	123.4
Providence–Warwick, RI–MA	40	2.5	92	4,836	45	4,881	2,085	129.3
Provo-Orem, UT	1	0.2	108	160	3	163	94	16.1
Raleigh, NC	75	5.8	36	3,144	19	3,163	1,720	135.3
Richmond, VA	70	5.5	40	4,508	35	4,543	1,968	154.9
Riverside–San Bernardino–Ontario, CA	212	4.7	53	11,244	63	11,307	4,327	96.7
Rochester, NY	35	3.2	80	3,749	17	3,766	1,641	151.8
Sacramento-Roseville-Arden-Arcade, CA	97	4.2	64	5,131	30	5,161	2,184	96.3
St. Louis, MO–IL	131	4.7	54	7,866	45	7,911	3,443	122.6
Salt Lake City, UT	32	2.7	88	2,071	9	2,080	999	85.6
San Antonio-New Braunfels, TX	165	6.8	25	7,036	32	7,068	3,292	138.2
San Diego-Carlsbad, CA	189	5.7	37	15,858	71	15,929	6,222	189.1
San Francisco–Oakland–Hayward, CA <sup>f</sup>	243	5.2	44	46,313	102	46,415	13,812	297.5
Oakland Division	119	4.3	_	12,116	53	12,169	4,521	164.0
San Francisco Division	114	7.0	_	32,477	44	32,521	8,786	540.6
San Jose–Sunnyvale–Santa Clara, CA	68	3.4	77	4,869	17	4,886	1,880	95.5
San Juan–Carolina–Caguas, PR	162	7.5	21	24,995	278	25,273	4,678	213.0
Santa Rosa, CA	5	1.0	106	2,164	8	2,172	789	157.3
Scranton-Wilkes-Barre-Hazelton, PA	15	2.7	87	743	7	750	327	58.6
Seattle-Tacoma-Bellevue, WA	125	3.3	78	11,214	28	11,242	4,663	125.1
Seattle Division	99	3.4	_	9,884	18	9,902	3,957	137.2
Tacoma Division	26	3.0	_	1,330	10	1,340	706	83.8
Spokane–Spokane Valley, WA	12	2.2	97	677	1	678	338	61.7
• • • • • • • • • • • • • • • • • • • •								

Vol. 28

Table 29. Stage 3 (AIDS), 2016 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2015, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

				Diag				
MSA of residence	Diagnosis, 2016 <sup>b</sup>			Adults or adolescents	Children	Total	Prevalence of stage (AIDS), year-end 2015	
	No.	Rated	Rank <sup>e</sup>	No.	No.	No.	No.	Rated
Springfield, MA	28	4.4	58	2,576	28	2,604	1,194	189.5
Stockton-Lodi, CA	29	4.0	67	1,509	15	1,524	712	98.4
Syracuse, NY	28	4.3	63	1,632	10	1,642	706	107.0
Tampa–St. Petersburg–Clearwater, FL	291	9.6	14	14,927	116	15,043	6,734	226.7
Toledo, OH	13	2.1	98	1,052	15	1,067	462	76.3
Tucson, AZ	31	3.1	82	2,538	12	2,550	1,233	122.3
Tulsa, OK	44	4.5	57	2,037	11	2,048	920	93.8
Virginia Beach-Norfolk-Newport News, VA-NC	114	6.6	27	6,310	66	6,376	2,199	127.6
Washington–Arlington–Alexandria, DC–VA–MD–WV	506	8.3	18	40,298	336	40,634	11,034	181.5
Silver Spring Division	83	6.4	_	4,091	28	4,119	2,084	162.6
Washington Division	423	8.7	_	36,207	308	36,515	8,950	186.6
Wichita, KS	16	2.5	91	1,060	2	1,062	451	70.1
Winston-Salem, NC	42	6.3	30	1,414	11	1,425	751	114.2
Worcester, MA-CT	20	2.1	99	2,555	22	2,577	1,221	130.7
Youngstown–Warren–Boardman, OH–PA	19	3.5	76	765	0	765	358	65.2
Subtotal for MSAs (population of ≥500,000)	14,635	6.6	_	1,064,513	8,649	1,073,162	418,707	190.2
Metropolitan areas (population of 50,000–499,999)	2,334	4.0	_	121,714	844	122,558	52,272	90.1
Nonmetropolitan areas	1,258	2.7	_	66,018	439	66,457	29,381	63.6
Total <sup>g</sup>	18,396	5.6	_	1,257,692	9,977	1,267,669	531,495	163.9

Abbreviation: MSA, metropolitan statistical area.

Note. Because of the lack of U.S. census information for all U.S. dependent areas, table includes data for only the United States and Puerto Rico. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

MSA definitions for this report can be found at http://www.census.gov/programs-surveys/metro-micro.html.

<sup>&</sup>lt;sup>a</sup> From the beginning of the epidemic through 2016.

<sup>&</sup>lt;sup>b</sup> Data are based on residence at time of diagnosis of HIV infection.

<sup>&</sup>lt;sup>C</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>&</sup>lt;sup>d</sup> Rates are per 100,000 population.

e Based on rate.

f Counts of stage 3 (AIDS) classifications for the metropolitan divisions do not sum to the MSA total. MSA total includes data from 1 metropolitan division with population of <500,000.

g Includes persons whose county of residence is unknown.

## Web Addresses for Reports of State and Local HIV Surveillance

Alabama http://www.adph.org/aids/Default.asp?id=984

Alaska http://epibulletins.dhss.alaska.gov/Bulletin/DisplayClassificationBulletins/46
Arizona http://www.azdhs.gov/phs/edc/odis/hiv-epidemiology/reports/index.php?pg=annual

Arkansas http://www.healthy.arkansas.gov/programs-services/topics/hiv-prevention California http://www.cdph.ca.gov/Programs/CID/DOA/Pages/OAsre.aspx

Chicago http://www.cityofchicago.org/city/en/depts/cdph/provdrs/data\_reports\_and\_administration/svcs/get\_sti\_hiv\_datainchicago.html

Colorado https://www.colorado.gov/pacific/cdphe/stihiv-data-and-trends
Connecticut http://www.ct.gov/dph/cwp/view.asp?a=3135&q=393048
Delaware http://www.dhss.delaware.gov/dhss/dph/epi/disstatshiv.html
District of Columbia http://doh.dc.gov/service/hiv-reports-and-publications

Florida http://www.floridahealth.gov/diseases-and-conditions/aids/surveillance/index.html Georgia http://dph.georgia.gov/georgias-hivaids-epidemiology-surveillance-section

Guam http://dphss.guam.gov/content/hiv-surveillance-program

Hawaii http://health.hawaii.gov/harmreduction/hiv-aids/data-and-statistics/

Houston http://www.houstontx.gov/health/HIV-STD/

Idaho http://healthandwelfare.idaho.gov/Health/FamilyPlanningSTDHIV/STDStatistics/tabid/393/Default.aspx

Illinois http://www.idph.state.il.us/aids/stats.htm
Indiana http://www.in.gov/isdh/23266.htm
Iowa http://idph.iowa.gov/hivstdhep/hiv/data
Kansas http://www.kdheks.gov/sti\_hiv/epi\_profiles.htm
Kentucky http://chfs.ky.gov/dph/epi/hivaids/surveillance.htm
Los Angeles http://publichealth.lacounty.gov/dhsp/Reports.htm

Louisiana http://new.dhh.louisiana.gov/index.cfm/newsroom/category/63

Maine http://www.maine.gov/dhhs/mecdc/infectious-disease/hiv-std/data/hiv.shtml
Maryland http://phpa.health.maryland.gov/OIDEOR/CHSE/Pages/statistics.aspx

Massachusetts http://www.mass.gov/eohhs/gov/departments/dph/programs/id/hiv-aids/epi-profile/ http://www.michigan.gov/mdhhs/0,5885,7-339-71550\_2955\_2982\_46000\_46003---,00.html

Minnesota http://www.health.state.mn.us/divs/idepc/diseases/hiv/stats/index.html Mississippi http://www.msdh.state.ms.us/msdhsite/index.cfm/14,0,150,134,html

Missouri http://health.mo.gov/data/hivstdaids/data.php Montana http://dphhs.mt.gov/publichealth/hivstd

Nebraska http://dhhs.ne.gov/publichealth/Pages/dpc\_hiv.aspx

Nevada http://dpbh.nv.gov/Programs/HIV-OPHIE/dta/Publications/HIV/AIDS\_Surveillance\_Program\_(HIV-OPHIE)\_-\_Publications/

New Hampshire http://www.dhhs.nh.gov/data/index.htm

New Jersey http://www.nj.gov/health/hivstdtb/hiv-aids/statmap.shtml

New Mexico http://nmhealth.org/data/infectious/20/

New York http://www.health.ny.gov/diseases/aids/general/statistics/index.htm

New York City http://www1.nyc.gov/site/doh/data/data-sets/hiv-aids-surveillance-and-epidemiology-reports.pagel

North Carolina http://epi.publichealth.nc.gov/cd/stds/figures.html

North Dakota http://www.ndhealth.gov/hiv/Data/

Ohio http://www.odh.ohio.gov/healthstats/disease/hivdata/hivcov.aspx

Oklahoma http://www.ok.gov/health/Disease,\_Prevention,\_Preparedness/HIV\_STD\_Service/Fact\_Sheets\_-\_OK\_Data/index.html
Oregon http://public.health.oregon.gov/DiseasesConditions/CommunicableDisease/DiseaseSurveillanceData/HIVData/Pages/index.aspx

Pennsylvania http://www.health.pa.gov/My%20Health/Diseases%20and%20Conditions/E-H/HIV%20And%20AIDS%20Epidemiology/Pages/default.aspx#.Wd5C0miPJPZ

Philadelphia http://www.phila.gov/health/AACO/AACODataResearch.html

Puerto Rico http://www.salud.gov.pr/Estadisticas-Registros-y-Publicaciones/Estadisticas%20VIH/Forms/AllItems.aspx

Republic of Palau http://www.palauhealth.org/files/MOH%20Annual%20Report%202014.pdf

Rhode Island http://health.ri.gov/publications/bytopic.php?parm=HIV San Francisco http://www.sfdph.org/dph/files/reports/default.asp

South Carolina http://www.dhec.sc.gov/Health/DiseasesandConditions/InfectiousDiseases/HIVandSTDs/DataandReports/

South Dakota http://doh.sd.gov/diseases/infectious/HIV-AIDS/Prevention.aspx

Tennessee http://tn.gov/health/topic/STD-surveillance

Texas http://www.dshs.texas.gov/hivstd/reports/default.shtm
U.S. Virgin Islands http://doh.vi.gov/programs/communicable-disease/index.html
http://health.utah.gov/epi/diseases/hivaids/surveillance/index.html

Vermont http://www.healthvermont.gov/immunizations-infectious-disease/hiv/surveillance

Virginia http://www.vdh.virginia.gov/disease-prevention/sexually-transmitted-diseases-std-surveillance-operations-data-administration/hiv-data-statistics/

Washington http://www.doh.wa.gov/DataandStatisticalReports/DiseasesandChronicConditions/HIVAIDSData.aspx

West Virginia http://www.dhhr.wv.gov/oeps/std-hiv-hep/HIV\_AIDS/Pages/HIVSurveillance.aspx

Wisconsin http://www.dhs.wisconsin.gov/aids-hiv/data.htm

Wyoming http://health.wyo.gov/publichealth/communicable-disease-unit/hivaids-surveillance-program/

Note. Electronic reports are not available for the following areas: American Samoa and the Northern Mariana Islands.

HIV Surveillance Report 125 Vol. 28